Deciphering the Details of RNA Aminoglycoside Interactions: From Atomistic Models to Biotechnological Applications by Ilgu, Muslum
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2012
Deciphering the Details of RNA Aminoglycoside
Interactions: From Atomistic Models to
Biotechnological Applications
Muslum Ilgu
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Biochemistry Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Ilgu, Muslum, "Deciphering the Details of RNA Aminoglycoside Interactions: From Atomistic Models to Biotechnological
Applications" (2012). Graduate Theses and Dissertations. 12750.
https://lib.dr.iastate.edu/etd/12750
Deciphering the details of RNA aminoglycoside interactions:  
from atomistic models to biotechnological applications 
 
by 
 
 
Muslum Ilgu 
 
 
 
 
 
A dissertation submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
Major:  Biochemistry 
 
Program of Study Committee: 
Marit Nilsen-Hamilton, Major Professor 
W. Allen Miller 
Gustavo MacIntosh 
Ted W. Huiatt 
Thomas A. Bobik 
 
 
 
 
 
 
Iowa State University 
 
Ames, Iowa 
 
2012 
 
Copyright © Muslum Ilgu, 2012.  All rights reserved. 
 
  
 
i 
 
 
 
 
 
 
 
 
To my daughter Devrim Ilgaz  
 
  
 
ii 
TABLE OF CONTENTS 
CHAPTER 1. GENERAL INTRODUCTION........................................................................ 1 
DISSERTATION ORGANIZATION ................................................................................. 1 
RESEARCH AIMS AND SIGNIFICANCE....................................................................... 5 
THE PRINCIPLE OF THE IMAGEtags REPORTER SYSTEM ...................................... 7 
THE PRINCIPLE OF THE DRAGINs SYSTEM .............................................................. 7 
CHAPTER 2.  LITERATURE REVIEW............................................................................... 9 
APTAMERS .................................................................................................................... 9 
Applications of Nucleic Acid Aptamers ...................................................................... 16 
Aptamers as Signaling Probes................................................................................... 16 
Aptamers as Analytical Tools..................................................................................... 18 
Aptamers as Drug Delivery Agents............................................................................ 19 
Aptamers as Therapeutics ......................................................................................... 19 
Multifunctional Aptamers............................................................................................ 21 
Functional Intracellular Aptamers .............................................................................. 23 
Aptamers to Control Transcription and Translation ................................................... 24 
Aptamers to Inhibit Viral Infections ............................................................................ 25 
Aptamers to Induce Cell Death .................................................................................. 27 
Aptamers to give Aminoglycoside Resistance to Bacteria......................................... 28 
MOLECULAR MODELING OF NUCLEIC ACIDS AND APTAMERS .......................... 30 
RIBOSWITCHES........................................................................................................... 36 
Natural Riboswitches ................................................................................................. 36 
Mechanisms of Riboswitches..................................................................................... 37 
  
 
iii 
Specific Examples of Riboswitches ........................................................................... 38 
Engineered Riboswitches .......................................................................................... 40 
Future Perspectives ................................................................................................... 42 
IMAGING TECHNOLOGIES AND RNA DETECTION.................................................. 44 
Reporter Genes in Imaging........................................................................................ 45 
RNA Detection ........................................................................................................... 48 
DRUG DEVELOPMENT AND RESISTANCE............................................................... 54 
Drug Development ..................................................................................................... 54 
Drug Resistance ........................................................................................................ 55 
Physiological Functions of Efflux Pumps ................................................................... 60 
Multidrug Resistance in Cancer Therapy................................................................... 61 
Inhibitors of Efflux Pumps .......................................................................................... 66 
MECHANISMS OF RESISTANCE TO AMINOGLYCOSIDES ..................................... 71 
Ribosome Alteration................................................................................................... 71 
Decreased Permeability and Active Extrusion ........................................................... 72 
Inactivation of aminoglycosides ................................................................................. 73 
APPROACHES TO PREVENT DRUG RESISTANCE ................................................. 79 
Simultaneous Use of Multiple Drugs.......................................................................... 79 
Reducing Antibiotic Use............................................................................................. 79 
Alternative Ways to Combat Bacterial Infections ....................................................... 80 
Bacterial interference ................................................................................................. 80 
Bacteriophage Therapy.............................................................................................. 80 
Bacterial vaccines ...................................................................................................... 81 
Cationic peptides ....................................................................................................... 81 
  
 
iv 
Cyclic D,L-α-peptides................................................................................................. 81 
AMINOGLYCOSIDES AS INTRACELLULAR RNA APTAMER TARGETS................ 83 
TABLES AND FIGURES .............................................................................................. 86 
REFERENCES .............................................................................................................. 92 
CHAPTER 3.................................................................................................................... 128 
Factors that Influence Selectivity of the Neomycin-B RNA Aptamer....................... 128 
Abstract ...................................................................................................................... 129 
INTRODUCTION ......................................................................................................... 130 
MATERIALS AND METHODS.................................................................................... 133 
Chemicals and RNAs............................................................................................... 133 
Isothermal titration calorimetry (ITC)........................................................................ 133 
Molecular docking of aminoglycosides to the neomycin RNA aptamer via DOCK .. 134 
Preparation of the RNA ........................................................................................ 134 
Preparation of aminoglycoside antibiotics ............................................................ 134 
Active site identification and molecular docking ................................................... 135 
Post-docking analysis : Use of Ligplot to map the RNA-aminoglycoside  
interactions ........................................................................................................... 135 
Measurement of 2-aminopurine (2AP) fluorescence intensity.............................. 136 
Molecular dynamics simulations using GROMACS ................................................. 136 
Preparing Neomycin-B for MD simulations .......................................................... 137 
RESULTS.................................................................................................................... 138 
Broad aminoglycoside specificity of the neomycin-B aptamer................................. 138 
Molecular docking and MD simulations predict a hydrophobic interaction between 
A16 and the sugar and a flexible pentaloop ................................................................ 138 
  
 
v 
Experimental analysis of an aptamer with 2-aminopurine in position 16 identifies a 
shift in the environment of A16 with ligand binding...................................................... 139 
Effects of buffer components on the aptamer-aminoglycoside specificity ............... 140 
The role of the A16 in establishing specificity of aminoglycoside binding................ 141 
DISCUSSION .............................................................................................................. 142 
ACKNOWLEDGEMENTS ........................................................................................... 145 
REFERENCES ............................................................................................................ 146 
FIGURE LEGENDS..................................................................................................... 149 
FIGURES AND TABLES ............................................................................................ 152 
SUPPORTING INFORMATION .................................................................................. 157 
CHAPTER 4.................................................................................................................... 162 
DRAGINs: Drug Binding Aptamers For Growing Intracellular Numbers ................. 162 
Abstract ...................................................................................................................... 163 
INTRODUCTION ......................................................................................................... 164 
Mechanism of action of the aminoglycosides .......................................................... 166 
Possible RNAs to use as DRAGINs that interact with aminoglycosides.................. 167 
MATERIALS AND METHODS.................................................................................... 168 
Bacterial growth analysis ......................................................................................... 169 
Analysis of binding interaction by isothermal titration calorimetry (ITC) .................. 169 
Determination of IC50 values for aminoglycosides.................................................. 170 
Cloning of aptamer sequences ................................................................................ 170 
RESULTS AND DISCUSSION.................................................................................... 171 
Decrease in IC50 for several different aminoglycosides was observed in cells 
expressing aptamers compared with controls ............................................................. 171 
  
 
vi 
Mathematical prediction I: Increase in drug concentration....................................... 172 
Measure extracellular drug concentrations .............................................................. 172 
Mathematical Prediction II: Mobility affects the aptamer action ............................... 173 
FIGURE LEGENDS..................................................................................................... 174 
FIGURES AND TABLES ............................................................................................ 176 
REFERENCES ............................................................................................................ 185 
CHAPTER 5. GENERAL CONCLUSIONS..................................................................... 189 
THE SPECIFICITY OF AN RNA APTAMER IS HIGHLY DEPENDENT ON THE  
IONIC ENVIRONMENT ............................................................................................... 189 
APTAMER-TARGET INTERACTIONS CAN BE UTILIZED FOR IN VIVO 
APPLICATIONS.............................................................................................................. 191 
MATHEMATICAL MODELING OF APTAMER EXPRESSION MAY CHALLENGE  
US TO IMPROVE THE DRAGINs SYSTEM............................................................... 191 
UNDERSTANDING RNA-AMINOGLYCOSIDE INTERACTIONS MAY HELP TO 
DEVELOP BETTER ANTIBIOTICS................................................................................ 192 
RNA-AMINOGLYCOSIDE INTERACTIONS MAY HELP US DEVELOP 
RIBOSWITCHES ............................................................................................................ 192 
FUTURE PERSPECTIVE............................................................................................ 193 
REFERENCES ............................................................................................................ 195 
APPENDIX I. CONTRIBUTION to the DEVELOPMENT of IMAGEtags 
(INTRACELLULAR MULTIAPTAMER GENETIC tags) for DETECTING PROMOTER 
ACTIVITY IN LIVING CELLS ............................................................................................. 196 
FRET Image Acquisition .......................................................................................... 197 
Test to check the stability of IMAGEtags ................................................................. 198 
  
 
vii 
TABLES and FIGURES.............................................................................................. 199 
FIGURE LEGENDS..................................................................................................... 201 
FIGURES..................................................................................................................... 202 
REFERENCES ............................................................................................................ 205 
APPENDIX II. NUCLEAR MAGNETIC RESONANCE (NMR) STUDY OF THE 
NEOMYCIN-B RNA APTAMER TO DETERMINE THE CONFORMATION OF A16  
UPON AMINOGLYCOSIDE BINDING ........................................................................... 206 
FIGURE LEGENDS..................................................................................................... 208 
APPENDIX III. EQUILIBRIUM BINDING ANALYSIS OF RIBOSWITCHES THAT  
BIND TO NEOMYCIN-B ................................................................................................. 210 
FIGURE LEGENDS..................................................................................................... 211 
FIGURES..................................................................................................................... 212 
REFERENCE .............................................................................................................. 213 
ACKNOWLEDGEMENTS............................................................................................... 214	  
  
1 
CHAPTER 1. GENERAL INTRODUCTION 
DISSERTATION ORGANIZATION 
This dissertation contains five chapters and three appendices.   
Chapter 1 is a general introduction to the dissertation organization and the research 
significance of the studies included in this dissertation.  
 The second chapter is a literature review that discusses the aptamers and their 
comparison with antibodies (summarized in Table 1).  Functional intracellular aptamers are 
then discussed to introduce the abilities of aptamers, which are strikingly different than those 
of antibodies.  Following aptamers, multifunctional aptamers that are developed to increase 
potency and carry out multiple functions are discussed with some examples.  Then, current 
imaging technologies and methods for RNA imaging are discussed to show their 
advantages and disadvantages.  After the imaging technologies section, drug development 
is briefly introduced and followed by a drug development and resistance section in which 
mechanisms of drug resistance are discussed, mainly focusing on the efflux pumps.  Also, 
mechanisms of resistance to aminoglycosides and approaches to prevent drug resistance 
are included in chapter 2.  Then, aminoglycoside antibiotics are discussed as intracellular 
aptamer targets, how they can be utilized as ligands for the expressed RNA aptamers in a 
cell.  Before the final section molecular modeling of nucleic acids, especially aptamers, is 
discussed.  In the final section, riboswitches, which are RNA-based control units for gene 
expressions, are detailed.  All together the literature review section aims to cover the related 
research that help guide the development of the studies carried out and presented in this 
dissertation.   
Chapter 3 covers a detailed study of the neomycin-B RNA aptamer for determining 
its selectivity and binding ability to both neomycin– and kanamycin-class aminoglycosides.  
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This manuscript is in preparation for submission to Nucleic Acids Research.  
Aminoglycosides are positively charged biomolecules, which make them very effective RNA 
targeting agents.  Although they primarily target the 16S rRNA decoding region (or A-site) 
and cause misreading of the genetic code, they have been found to interact with several 
other natural and artificial small RNAs.  Our focus of study was a 23mer neomycin-B RNA 
aptamer.  Previous analyses of the interaction of neomycin-B and paromomycin showed that 
the aptamer is highly neomycin-B specific (>100-fold higher affinity for neomycin-B than for 
paromomycin).  However, our observations showed that paromomycin binds with only about 
5-fold less affinity when the equilibrium was analyzed in solution by isothermal titration 
calorimetry (ITC).  Therefore, we have re-evaluated the interactions of aminoglycosides with 
the neomycin-B RNA aptamer.  Our data suggest a pattern for aminoglycoside binding as: 
neomycin-B > ribostamycin ≥ kanamycin-B > paromomycin > tobramycin > sisomicin > 
geneticin > kanamycin-A > amikacin ≥ netilmicin.  In parallel, this observation was supported 
by the docking results obtained using the NMR-resolved structure of the aptamer.  The only 
outlier in the comparison was ribostamycin and so we further studied ribostamycin binding.  
After docking, the Ligplot analyses gave pictorial representations for each of the RNA-
aminoglycoside interaction with the residues in H-bond and hydrophobic contacts.  During 
docking, the RNA was treated as a rigid moiety, which limited our ability to simulate the 
atomic details of the interactions between the aptamer and aminoglycosides.  Therefore, we 
performed molecular dynamics (MD) simulations to get more detailed information about the 
motion of each atom in the aptamer with and without neomycin-B.  MD simulations showed 
that the adenine nucleotide at the 16th position (according to the NMR numbering) changes 
its environment upon binding.  The same residue was also found, as in the docking results, 
with a hydrophobic interaction between the aptamer and sugar.  By contrast, it was found to 
have hydrogen bonds in the NMR structure.  We experimentally validated this observation of 
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change in microenvironment of A16 by performing fluorescence assays using 2AP-labeled 
aptamer at the 16th position.  Our results revealed that the A16 moves from a stacked 
position to more hydrophobic environment so that it gives more fluorescence upon 
aminoglycoside binding.  Also, the increases in 2AP fluorescence differed for neomycin-B, 
ribostamycin and paromomycin suggesting that the A16 interacts with these ligands or with 
other moieties in the RNA differently depending on the ligand.  Therefore, we tested the 
binding ability of A16 variants to the neomycin-family aminoglycosides and discovered that 
removing it or replacing it with other bases (uracil, cytosine or guanine) changed its 
aminoglycoside selectivity without affecting the neomycin-B binding.  Finally, we found that 
the discrepancy in the selectivity of the aptamer was primarily due to a difference in the 
buffer environment from that which was used in the previous studies.  To understand the 
impacts of individual buffer constituents on the specificity of the aptamer, we tested the 
binding interactions under five different buffer conditions, including the original buffer and 
the NMR buffer.  Both the selectivity and affinity of the aptamer are highly buffer dependent.  
The aptamer becomes highly selective in cacodylate buffer that was used in the original 
study and binds poorly to paromomycin and ribostamycin.  Finally, we have found that 
magnesium ions facilitate the aptamer adopting the proper 3D conformation for 
aminoglycoside binding and their presence decreases the entropic cost of the folding. 
The contributions of the authors for the chapter 3 are described as follows. Muslum 
Ilgu designed the experiments, collected and analyzed data and wrote the manuscript.  
Molecular docking was carried out in collaboration with Taner Z. Sen, Raghu Yennamalli 
and Megan N. Kleckler.  Raghu Yennamalli performed the docking and with Megan N. 
Kleckler they analyzed the results.  MD simulations were carried out in collaboration with 
Monica H. Lamm and Megan N. Kleckler.  Marit Nilsen-Hamilton worked with Muslum Ilgu to 
design the experiments, analyze the data and write the manuscript. 
  
4 
In chapter 4, a novel method to increase drug concentrations in cells for more 
efficiently killing is described.  To test the method, a bacterial model system was adopted 
and several small RNA molecules interacting with aminoglycosides were cloned 
downstream of T7 RNA polymerase promoter in an expression vector.  Then, the growth 
analysis of E. coli expressing aptamers was observed for 12-hour period.  Our analysis 
indicated that aptamers helped to increase the intracellular concentration of 
aminoglycosides thereby increasing their efficacy. 
The research work presented in chapter 4 is in preparation and the authors for it are 
described as follows.  Muslum Ilgu designed experiments, collected and analyzed data and 
wrote the manuscript.  Robert Feldges collected data, Supipi Liyamali Auwardt designed 
experiments, collected and analyzed data.  Marit Nilsen-Hamilton worked with Muslum Ilgu 
to design experiments, analyze the data and write the manuscript. 
Chapter 5 is the general conclusion of the studies addressed in chapters 3 and 4.  
This chapter summarizes the importance of binding studies of aminoglycosides with small 
RNA molecules for deciphering the residues responsible for these interactions.  Other topics 
of discussion in chapter 5 are future directions and potential applications of the insights 
achieved in chapter 3 and chapter 4.  Finally, a perspective of aptamer research in general 
is discussed. 
Appendix I describes Muslum Ilgu’s results for developing an RNA-based imaging 
technique for visualization of gene expression in vivo and in real time.  This work has been 
submitted to Nature Methods, and the development of IMAGEtags (Intracellular 
MultiUptamer GEnetic tags) for visualizing gene expression in mammalian cell cultures.  For 
this purpose, the collaboration continues with Ilchung Shin, Judhajeet Ray and Samir 
Mehanovic from Marit Nilsen-Hamilton’s lab, Jonathan Beasley from George Kraus’s lab at 
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Iowa State University in the Department of Chemistry and Ming Zhao and Leilei Peng at 
University of Arizona in Optical Sciences.   
Appendix II describes the preliminary NMR results that were performed to 
understand the conformation of 16th residue upon aminoglycoside binding.  This work is in 
progress and once the assignments are completed in collaboration with Bruce Fulton, NMR 
facility director at Iowa State University in BBMB department, it will be included in chapter 3 
to complete the manuscript.  1H, NOESY and TOCSY NMR experiments have been 
performed so far and the results are presented in Appendix II. 
Appendix III describes Muslum Ilgu’s results from experiments designed with the 
purpose of understanding the aminoglycoside selectivity of three different neomycin-B 
riboswitches that are used to regulate gene expression.  The results indicated that these 
neomycin riboswitches are also able to interact with a variety of aminoglycosides.  Future 
work will involve testing them in vivo with more than neomycin-B to determine if they are 
responsive to other aminoglycosides.   
RESEARCH AIMS AND SIGNIFICANCE 
Aminoglycosides are natural antibiotics used for many years to combat bacterial 
infections.  Because new strains of bacteria with antibiotic resistance emerge each year, the 
antibiotics currently in the market are expected to eventually lose their effectiveness. 
Therefore, new antibiotics or other ways of combating pathogens are needed to solve this 
antibiotic resistance problem.  Combining new approaches to understand the details of 
RNA-aminoglycoside interactions can help us develop new more effective antibiotics.  
The higher order structures and flexibility of the aptamers allow them to interact with 
more than one type of a target such as with a variety of aminoglycosides as discussed in 
chapter 3.  Better understanding of the regulation of aptamer structure and dynamics 
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through MD simulations is essential for more rapidly and effectively developing aptamer 
applications as well as improving their features like target specificity and affinity.  This was 
achieved by determining the binding affinities and the dynamics of the RNA-aminoglycoside 
complex, then testing the predictions with wet-lab experiments.  These findings and the 
experimental approaches taken to obtain data can help researchers to modify the present 
drugs to enhance their effectiveness. 
An alternative way to developing new drugs is to discover new techniques to 
increase the efficacy of present antibiotics.  Development of such methods is necessary due 
to the emergence of drug resistant strains.  A challenge in cancer treatment is to maintain a 
high enough intracellular drug concentration to kill the cancer cells.  This is because cancer 
cells upregulate the expression of multi-drug transporters that leads to the need for higher 
extracellular concentrations of drugs to compensate for a counter balancing activity that 
promotes cellular entry of the drugs for effective cell killing.  Modern drug synthesis research 
has addressed this issue by many means, mainly based on “push mechanisms”. However, 
the extent to which the extracellular drug concentration and the cell permeability to the drug 
can be increased is limited.  Another way to increase intracellular drug concentrations is for 
the cells to express short RNA aptamers that can bind to their drug target.  Aptamers 
behave like antibodies but have more dynamic structures and can function in a cell.  We 
have named these aptamers DRAGINs (Drug Binding Aptamers for Growing Intracellular 
Numbers).  To test this hypothesis experimentally, we used bacteria that are sensitive to 
killing by aminoglycosides (the drugs) and aminoglycoside aptamers (DRAGINs) to increase 
cellular sensitivity to the drugs.  These features were utilized as described in chapter 4 in 
detail to increase aminoglycoside concentrations in E. coli as a proof of principle.  The same 
concept can later be applied into the cancer cells. 
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RNA aptamers can be utilized for other applications in vivo.  One way is to use them 
as real time imaging platforms.  This may lead us to understand the real time dynamics of 
gene expression at the promoter level.  The development of this method involves the 
labeling of aptamer targets, aminoglycosides, which can go through the cellular membrane 
and bind to aptamers once they are expressed.  In addition, increasing the number of 
expressed aptamers in a string can increase the signal/noise.  Adding the use of 
fluorescence resonance energy transfer (FRET), which occurs if the donor and acceptor 
dyes are brought close to each other with expressed IMAGEtag aptamer, can increase the 
validity of the signal.  This method is still under development using several different 
aptamers and their labeled targets.  The progress of this project is explained in the Appendix 
I. 
THE PRINCIPLE OF THE IMAGETAGS REPORTER SYSTEM 
 The IMAGEtag (intracellular multi aptamer genetic tag) consists of a string of 
multiple tandem aptamers that can be expressed in the cells as RNA. The IMAGEtag does 
not encode a protein, but could be part of a fusion construct with endogenous mRNAs so 
that these can be localized and tracked in the cell. Detection of the IMAGEtags relies on the 
aptamers’ binding to a ligand molecule that is labeled with a fluorescent moiety or 
radioactive element, which would be added to the cells before analysis. To increase the 
binding capacity and the potential signal of such tags, constructs with several aptamers 
have been created by employing a cloning technique based on methods previously used for 
creating repetitive polypeptide units. 
THE PRINCIPLE OF THE DRAGINS SYSTEM 
The test of a new approach based on a “pull mechanism” by expressing molecules 
that can bind drugs inside the cells and increase their intracellular concentrations was 
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achieved in DRAGINs system.  The expressed aptamers selected for tight and specific 
binding to their drug targets are aminoglycoside-binding RNAs.  It was predicted that the 
presence of mobile aptamers inside the cells would increase the intracellular concentration 
of the target drug compared to in the absence of aptamers by mathematical modeling.  In 
this context, the intracellularly expressed aptamers are referred to as DRAGINs (Drug 
Binding Aptamers for Growing Intracellular Numbers).  To test this hypothesis 
experimentally, we used bacteria that are sensitive to killing by aminoglycosides (the drugs) 
and aminoglycoside-binding RNA aptamers to increase cellular sensitivity to the drugs.   E. 
coli BL21 strain was transformed with aptamer-expressing plasmids and incubated with 
different concentrations of aminoglycosides to determine the effect of aptamer expression 
on efficacy of cell killing.  
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CHAPTER 2.  LITERATURE REVIEW 
APTAMERS 
Ribonucleic acid (RNA) molecules contain only four types of bases; adenine (A), 
cytosine (C), guanine (G) and uracil (U).  Despite their simple composition, RNAs have 
diverse biological functions. It has long been believed that RNA is mainly a genetic 
information carrier in the cell as in the form of mRNA, and/or tRNA.  However, in recent 
years, some complex roles of RNA molecules have been clearly demonstrated [1].  Many 
RNAs provide structural support for molecular machineries.  Also, in the early 1980s the 
discovery of RNA’s catalytic capability led to the speculation of an “RNA world” that 
preceded the advent of DNA and protein [2, 3].  Likewise, small RNAs have been shown to 
be very critical in regulating gene expression via modulation of translation initiation and 
mRNA stability [4].  However, until the end of 20th century, very little was known about the 
principles underlying higher order RNA structures and their interactions with other molecules.   
‘Aptamer’ (from the Latin, aptus, meaning ‘to fit’) is a single stranded nucleic acid 
(DNA or RNA) molecule that can bind to its target with high specificity and affinity.  Although 
the term has also more recently been applied to peptides with similar characteristics that are 
called peptide aptamers, this study focuses on nucleic acid aptamers as they are utilized to 
develop new biotechnological tools.  In 1990, two laboratories independently developed the 
technique of aptamer selection: the Gold lab used the term ‘SELEX’ (Systemic Evolution of 
Ligands by EXponential enrichment) for their process of selecting RNA ligands against 
T4 DNA polymerase [5] and the Szostak lab coined the term ‘in vitro selection’ for selecting 
RNA ligands that could bind to various organic dyes [6]. 
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Since the discovery of the aptamer selection process, various uses of aptamers have 
been documented in the literature.  Researchers have identified numerous high affinity 
aptamers that target a broad range of molecules.  Many aptamers have been selected in 
vitro and optimized to bind to various molecular targets such as small molecules, proteins, 
nucleic acids, even cells, and tissues.  Some of these RNAs have found their way for both in 
vitro and in vivo applications [7-11].  In 2006, an aptamer handbook was published to 
describe various aspects of aptamer research, development and application [12].  Also, an 
aptamer database has been created to collect various aptamers selected in vitro through 
SELEX (http://aptamer.icmb.utexas.edu/) [13]. 
Nucleic acid aptamers are expected to be very helpful tools in the fields of 
therapeutics, drug development, target validation and diagnostics as they offer molecular 
recognition properties that rival that of the commonly used biomolecules, antibodies.  An 
aptamer can discriminate a single chemical group difference between two molecules or 
even the same molecules with different conformations [14-16].  In addition to their 
discriminatory recognition, aptamers offer advantages over antibodies as they are lower cost 
and possess desirable storage properties.  Furthermore, they elicit little or 
no immunogenicity in therapeutic applications [17-21]; whereas antibodies, even humanized 
ones, can induce immunogenicity [22].  Another advantage of using SELEX is that aptamers 
can be selected against toxic compounds, which would be otherwise hard to target.   
The SELEX process usually takes about 8 weeks for the selection but the additional 
optimization required for many aptamers results in it taking more time to develop an aptamer 
than to obtain an antibody.  However, the main disadvantage of antibody selection is that it 
needs animals for antibody production and each time a new batch of antibody is produced it 
must be optimized for its applications.  In contrast, one can get aptamers, in the test tube, 
with binding equilibrium constants in the pM to µM range, which often compares favorably to 
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the binding strength of many antigen–antibody complexes [23].  In addition to their potential 
use as pharmaceutical and diagnostic agents, another advantage of aptamers is that they 
function both inside and outside cells [24-28].  Whereas, antibodies must be added 
extracellularly, aptamers can be produced intracellularly.  For these reasons, aptamers are 
competitive with or even superior to antibodies in many respects as summarized in Table 1.  
SELEX is an iterative process of adsorption, recovery and re-amplification.    It 
begins with a large synthetic pool (library) of single-stranded nucleic acids, which is 
challenged to bind either to a purified protein, or a small peptide, a small molecule, a nucleic 
acid or a whole cell.  The starting SELEX population has fixed ends for PCR primer-
annealing.  One of the ends contains T7 RNA polymerase promoter for in vitro transcription 
by which RNA aptamers can be enriched in SELEX.  Between these fixed ends, 
combinatorial libraries often contain 30 to 40 nucleotide-long contiguous random sequences 
otherwise known as sequence space.  The theoretical diversity of such a combinatorial 
library can potentially encompass 430 (1018) or 440 (1024) individual sequences available for 
partitioning.  However, this number often exceeds, by many orders of magnitude, the 
number of molecules that can be handled in practice.  So, convenience and cost generally 
restrict the starting pool to a sample of no more than 1012–1015 randomly chosen 
oligonucleotides, each of which is presumed to contain a unique base sequence.  However, 
it has been claimed that even less diverse combinatorial libraries will yield useful aptamers 
[29, 30].  
The desired property of an aptamer is, typically, the ability to bind to a given ligand 
with high affinity and selectivity.  Thus, for a successful SELEX experiment, it is crucial to 
identify an effective method for partitioning.  By mixing the solution-phase library under 
defined conditions with the target molecule and subsequently retrieving the target and 
removing the unbound or loosely bound nucleic acids, the few nucleic acids that have bound 
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to the target can be recovered from the library.  To achieve this partitioning, nitro-cellulose 
filter binding, affinity chromatography, size fractionation on columns, flow cytometry, surface 
plasmon resonance (SPR), electrophoresis on native polyacrylamide gels (PAGE) or 
capillary electrophoresis (CE) can be used. 
To select the highest affinity binding molecules, low binding-affinity molecules need 
to be selected against by sequential rounds of selection.  At each round, the selected 
nucleic acid molecules are subsequently amplified as DNA.  If the single-stranded library is 
of RNA or RNA analogs, it is first copied into complementary DNA (cDNA) by reverse 
transcriptase (RT).  These single-stranded DNA molecules are amplified directly by PCR.  
The DNA population is subsequently used to generate a new library of single-stranded 
molecules (in vitro transcription for RNA or strand separation for DNA), which is subjected to 
another round of selection procedure.  This process is repeated until a population of high-
affinity single-stranded molecules is selected.  Because the affinity-based partitioning 
methods are imperfect, the cycle of partitioning and amplification is normally repeated 6 to 
12 times or more, until molecules of the desired property predominate in the population of 
nucleic acids.  In the final step, the binders are cloned and sequenced for further analysis 
and characterization.   
The process of SELEX achieves a reduction in sequence diversity from the initial 
sample of sequence space to a population that is typically dominated by about 10 distinct 
sequences with appreciable binding to the desired target.  In addition, the error-prone nature 
of the enzymes used to amplify the selected sequences combined with high concentrations 
of dNTPs and Mg+2 favor the introduction of random mutations that effectively allow the 
procedure to sample a greater proportion of the sequence space than was initially sampled.  
A process very similar to Darwinian evolution by natural selection and survival of the fittest is 
the explanation for the appearance of clearly related, but evolutionarily divergent, 
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sequences in the final aptamer population [31].  Overall, the combination of PCR, in vitro 
transcription, and isolation of the bound sequences in each round usually takes several days; 
therefore, high-affinity aptamers can be enriched and successfully isolated in 8 to 10 weeks 
through conventional SELEX. 
During the SELEX process, depending on the anticipated application, the desired 
binding properties can be adjusted to be a fast association rate, slow dissociation rate, high 
affinity, low affinity to closely related molecules, or a combination of all.  In order to get 
higher selectivity, negative selection can be deployed against the partitioning matrix, or a 
structural analog of the target by which non-specific binders are eliminated.  Also, for high 
affinity, the target concentration can be limited at the beginning of the SELEX and gradually 
decreased in the later rounds.  As a result, at the end of the SELEX process, the enriched 
population of aptamer sequences can have both high specificity and high selectivity to the 
desired target. 
Aptamer-target interaction is mainly determined by the tertiary structure of the folded 
nucleic acid aptamers.  The three-dimensional structure of an aptamer is uniquely 
determined by the sequence of its bases.  When an aptamer is bound to its ligand, there will 
possibly be van der Waals surface contacts, hydrogen bonds, stacking interactions and 
other noncovalent bonds that make the interaction highly specific and functional.  This very 
high specificity was exemplified with the theophylline aptamer [14].  Initially, five rounds of 
regular selection were performed by capturing the RNAs on a sepharose column derivatized 
with 1-carboxypropyl theophylline.  This initial selection was followed by another three 
rounds of counter-selections performed against caffeine, structurally differs from 
theophylline with an additional methyl group.  The resulting pool contained 15 conserved 
bases and out of this pool, a 42 nucleotide aptamer (TCT8-4) was found to have high affinity 
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for theophylline with a dissociation constant of 0.32 µM, which was shown 10000-fold higher 
than for caffeine (Jenison et al., 1994). 
On the other hand, for some targets the aptamer’s specificity can be broad 
depending on the nature of the chemical interactions that dominate the interaction of these 
aptamers with their targets.  For example, different aminoglycoside antibiotics were 
demonstrated to bind the lividomycin and kanamycin-B RNA aptamers.  In the case of the 
former, most of the aptamers originally selected to bind to lividomycin were found to be able 
to interact with both neomycin-B and paromomycin, as well [32].  Similarly, kanamycin-B 
aptamers initially selected to recognize kanamycin-B were later found to be able to even 
better interact with tobramycin than kanamycin-B [33].  This lack of specificity was probably 
due to the predominance of electrostatic interactions between the aminoglycosides and the 
RNA aptamers.  In fact, it was clearly demonstrated for neomycin-B RNA aptamer that 
electrostatic interactions and hydrogen bonding dominate the interactions between 
neomycin-B and its aptamer and are mainly due to the positively-charged nature of 
neomycin-B [34].   
The omnipresence of degrading enzymes in virtually all biological fluids is a potential 
problem due to aptamers consisting of biopolymers of natural origin.  Nucleic acids are 
degraded by nucleases in blood within seconds to a few minutes [35, 36].  Therefore, 
aptamers that are utilized in biological fluids need chemical modifications in order to make 
them more stable.  Several strategies have been developed by which the potential targets 
for the degrading enzymes are modified for enhancing aptamer stability.  The first examples 
included the use of nucleotides with 2’-OH position of the ribose modified with 2’-deoxy, 2’-
amines (2’-NH2) and 2’-fluorines (2’-F) [37] and later with (2’-OME) [38].  RNA aptamers with 
2’-NH2 and 2’-F have increased stability and enhanced biological half lives [39-41].  RNAs 
can also be modified by covalently linking the 2’O and 4’C with a methylene group and 
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obtaining so called ‘locked nucleic acids’ (LNA).  Thermostability, tumor uptake, blood 
retention and plasma stability of tenascin-C binding aptamer were increased with the LNA 
modification [42]. 
Another way to get nuclease-resistant aptamers is the use of L-nucleic acids which 
cannot be recognized by endonucleases.  Thus, researchers have obtained nuclease-
resistant and plasma-stable ‘spiegelmers’ (from the German word Spiegel, mirror) with L-
nucleic acids in place of natural D-nucleic acids [43-45].  Nevertheless, chemical synthesis 
of the mirror-image targets limits the number of available spiegelmers.  The 4’-thio (-S) 
modification is another way to give nuclease resistance to aptamers.  By utilizing 4’-thioCTP 
and 4’-thioUTP during SELEX to select a human α-thrombin aptamer the half life was 
enhanced from 22 min to 19.5 h in the presence of 50 pg/µl RNase A [46].   
Replacing one or two of the nonbridging oxygens on the phosphodiester backbone 
with thiol (-S) groups was also shown to provide nuclease resistance for aptamers.  The half 
life of the thio-aptamer against NF-IL6 was increased four-fold in the presence of 0.12 pg/ml 
DNase I when compared to the unmodified NF-IL6 aptamer [47].  By the same token, 
capping the 5’ and 3’-termini of aptamers enhances nuclease resistance because the 
degradation of aptamers in human blood is largely due to 3’→5’ exonucleases.  An inverted 
thymidine (3’-idT) is commonly used to cap the 3’ end which creates an oligonucleotide with 
an two 5’-ends and no 3’-end.  Combined with the previously-mentioned 2’-F and 2’-OME 
ribose modifications, 3’-idT increased the half-life of a platelet-derived growth factor (PDGF) 
DNA aptamer from 0.6h to 8h in 85% rat serum [48].  Short phosphorothioate caps were 
also used at the 5’ and 3’ ends to improve aptamer stability [49].  Also, researchers obtained 
multivalent circular DNA aptamers with both thrombin and L-selectin aptamers by 
connecting the 5’ and 3’ ends [50].  The circular RNA aptamer for streptavidin was 
generated both in vitro [51] and in vivo [52] through self-ligating permutated intron-exon 
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sequence.  These modifications helped the successful development of aptamer applications 
for use in human fluids. 
Applications of Nucleic Acid Aptamers 
The versatility of nucleic acids is due to their ability to display distinct and stable 
tertiary structures.  Thus, they are able to form binding pockets and catalytically active 
centers.  The SELEX procedure is now generally recognized as a powerful tool for selecting 
high-specificity and high-affinity nucleic acid aptamers for almost any target molecule.  
Aptamers have been used for a wide range of in vitro and in vivo applications [8, 10, 11, 53-
60].  Target molecules in the SELEX range from small molecules like ATP [30, 61], 
sulforhodamine B [62], theophylline [14], amino acids [15, 63, 64], carbohydrates [65], 
aminoglycoside antibiotics [33, 66, 67], citrulline [68] and vitamins [69] to all kinds of proteins 
including enzymes [70, 71], transcription factors [72-74], viral proteins [75-80], cell adhesion 
proteins [81-83], growth factors [84-86] and cytokines [87]..       
Aptamers as Signaling Probes 
Fluorescent modification before or after during SELEX has been used to obtain 
signaling aptamers.  One type of signaling aptamer is called a ‘aptamer beacon’, which is 
modified with a quencher and a fluorophore at the 5’ and 3’ ends respectively.  Interaction of 
ligand with the aptamer causes conformational changes that result in the fluorophore and 
quencher changing their relative positioning, thereby changing fluorescence.  An anti-
thrombin aptamer was engineered into an aptamer beacon by adding nucleotides to the 5'-
end, which are complementary to nucleotides at the 3'-end of the aptamer, to form a duplex 
so that the attached fluorophores did not affect the thrombin binding site [88].  Upon 
thrombin binding, the conformational change was followed by an increase in fluorescence.  
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This exemplifies the aptamer beacon as a sensitive tool for detecting proteins through 
changes in fluorescence. 
Simpler fluorescent aptamers have only one fluorophore, which changes its 
fluorescence intensity due to the structural changes of aptamers upon their ligand binding 
[59].  Blank et al used a FITC-18C-conjugated DNA aptamer, selectively binding to tumor 
micro-vessels but not normal blood vessels, to visualize a rat brain tumor by fluorescence 
microscopy [89].   
Another type of signaling aptamer is the ‘structure-switching signaling aptamer’ [90].  
In this case, the duplex is formed between a fluorophore-labeled aptamer and a small 
oligonucleotide modified with quencher, which hybridizes with the binding site of the 
aptamer.  When the ligand binds, the hybridized oligonucleotide with quencher is released 
and the fluorophore emission can be detected.   
In addition, some aptamers were designed to generate signals based on 
fluorescence resonance energy transfer (FRET) [88, 91].  In the recent article, a sensitive 
method for rapid angiogenin detection based on FRET has been described.  A dual-labeled 
angiogenin aptamer probe was constructed by labeling the 5′ with 6-
carboxyfluorescein (FAM) and 3′ with 6-carboxy-tetramethylrhodamine (TMR) as donor and 
acceptor, respectively.  By monitoring the fluorescence intensity of donor and acceptor on 
this aptamer, the quantitative detection limit was 200 pM angiogenin and the linear range 
was between 500 pM to 40 nM angiogenin [91]. 
Finally, aptamers are functionalized with gold nanoparticles (GNPs) that can be used 
for computed tomography (CT) imaging [92].  Compared with nanoparticles, small iodinated 
molecules normally used in CT have the following limitations; a lack of targeted molecular 
imaging, short imaging time, and renal toxicity.  However, by functionalizing the surface of 
gold nanoparticles with an RNA aptamer specific to prostate-specific membrane antigen 
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(PSMA), these limitations were eliminated.  At the same time, a targeted molecular CT 
imaging system was enabled capable of specifically imaging prostate cancer cells that 
express the PSMA protein.  Their results indicated that PSMA aptamer-conjugated GNP has 
more than 4-fold greater CT intensity for a targeted LNCaP cell than that of a nontargeted 
PC3 cell [92]. 
Aptamers as Analytical Tools 
Aptamers also hold great potential as analytical tools in separation and molecular 
recognition technologies [57, 93].  For example, the thyroid transcription factor 1 (TTFI) 
aptamer was biotinylated and attached to streptavidin magnetic beads to purify TTFI [94].  
The affinity chromatography purification assay on protein mixtures from bacteria lysates 
showed good specificity for TTFI.  In another example, thrombin was specifically detected 
through MALDI-TOF-MS when the thrombin aptamer was immobilized to the matrix surface 
[95].  In the proximity-dependent DNA ligation assay, a long single stranded DNA (ssDNA) 
attached to the platelet-derived growth factor (PDGF) was ligated when the aptamers were 
brought close together on the PDGF dimer and then amplified to detect zeptomolar 
concentrations of the PDGF dimer [96]. 
Modular aptameric sensors have been developed utilizing the fluorescence increase 
from malachite green (MG) after it is bound by its RNA aptamer [97]. Using rational design, 
the ATP RNA aptamer, theophylline RNA aptamer or flavine mononucleotide (FMN) RNA 
aptamer, separately were fused with the truncated MG RNA aptamer. The presence of 
adenosine, theophylline or flavine mononucleotide (FMN) could be detected by an increase 
in the fluorescence of malachite green.  In another sensor, the cocaine aptamer was used 
as part of a colorimetric probe for cocaine using the dye, diethylthiotricarbocyanine iodide.  
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Cocaine displaced the dye from the aptamer, which resulted in its decreased absorbance, 
possibly due to its precipitation [98].  
Aptamers as Drug Delivery Agents 
Aptamers can also be used as delivery vehicles for drugs or signaling molecules 
either when they are linked covalently or indirectly through a hybridized oligonucleotide to 
the drugs.  For example, an irreversible inhibitor of neutrophil elastase, valine phosphonate 
(ValP), was linked to an oligonucleotide hybridized to a random DNA/RNA library.  In vitro 
selection generated an aptamer-ValP complex with increased potency by three to four 
orders of magnitude and with better specificity compared to ValP alone [99, 100].  A weak 
inhibitor of human neutrophil elastase (hNE), a tetrapeptide Ala-Ala-Pro-Val, was covalently 
linked to the 3’-end of a hNE aptamer with three 18-carbon linkers through post-SELEX 
modification.  By this way, the aptamer could deliver the tetrapeptide to the active site of 
hNE and increase the drug potency by 105 times compared to the drug alone [101].   
Aptamers were also functionalized with gold nanoparticles (GNPs) for combined 
computed tomography (CT) imaging and prostate cancer therapy as explained earlier.  In 
the same report, Kim et. al. showed that the PSMA aptamer-conjugated GNPs were 
significantly more potent against targeted LNCaP cells than against nontargeted PC3 cells 
after loading of doxorubicin [92].  By this means, they successfully delivered the anti-cancer 
drug, doxorubicin, specifically to the targeted cells. 
Aptamers as Therapeutics 
The idea of using aptamers as therapeutic agents is now more than 20 years old and 
noticeable progress has been made over time.  Aptamers have been developed as anti-
cancer, anti-microbials, anti-coagulation, anti-inflammation, anti-angiogenesis, anti-
proliferation and immune therapy [7, 10].  For example, there are aptamers developed as 
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anti-viral therapeutics using the selected aptamers against HIV-1 Rev [102], HIV-1 integrase 
[103] and HIV-1 reverse transcriptase [104].  These anti-HIV aptamers are discussed in the 
functional intracellular aptamers section.  In this section, anti-cancer, anti-angiogenesis and 
anti-coagulation aptamers are discussed as therapeutic applications of aptamers.    
Aptamers can be used in cancer therapy with inclusion of boron neutron capture 
therapy.  Boron (10B) can capture neutrons to form 11B, which can then split into 4He and 7Li 
and kills cells within a distance of 5-9 µm.  Therefore, aptamers consisting of boronated 
nucleotides will gain new functionalities for cancer therapy if the aptamers are targeted to 
cancer-cell markers.  Aptamers against ATP have been selected using either 5’-(α-P-
borano)-UTP or 5’-(α-P-borano)-GTP during SELEX.  The selected aptamers showed novel 
folding and the bU and bG were essential for aptamer function [105]. 
Aptamers were also developed as anti-coagulation agents.  Thrombin, a serine 
protease converted from pro-thrombin by the action of factor Xa, is a key regulatory enzyme 
in the coagulation pathway by converting fibrinogen into fibrin [106].  2′-fluoro-modified RNA 
molecules were exposed to a mixture of human and porcine α-thrombin in round 1 and then 
toggled between human and porcine thrombin in alternate rounds of selection [107].  An 
aptamer named Toggle-25 was identified that bound to human thrombin with an affinity of 
2.8 nM and to porcine thrombin with ~ 83 pM affinity.  An aptamer that recognized both 
human and porcine thrombin could be developed further in a porcine model system before 
being tested in human clinical trials. Further characterization showed that the aptamer could 
increase the thrombin life-time by 2-fold in human plasma and by 4-fold in porcine plasma.  
Also, the aptamer inhibited thrombin-dependent platelet activation in a dose-dependent 
manner in both human and porcine platelets [107]. 
At the end of 2004, there was a breakthrough in the therapeutics application of 
aptamers when the Food and Drug Administration (FDA) approved the first aptamer drug 
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called Macugen by OSI Pharmaceuticals or pegaptanib sodium by Pfizer and Eyetech.  This 
drug was developed as a potent angiogenesis inhibitor to recognize vascular endothelial 
growth factor (VEGF) and is used to treat wet age-related macular degeneration (AMD) [86, 
108].  The 27 nucleotide aptamer includes 2'F pyrimidine, 2'OME purine, 5'-end PEG and 
also a 3'-end dT modifications to protect it from endonucleases.  These modifications 
stabilize the aptamer in vivo and provide for better pharmacological kinetic properties and 
more effective treatment of AMD in humans [109].  After all these development efforts by 
researchers at Nexstar Pharmaceuticals, optimally-stabilized and formulated aptamers were 
marketed as intravenous or subcutaneous injectables with biological half-lives of up to 12 
hours [110, 111].  According to a recent review 8 other aptamers are currently undergoing 
clinical evaluation for various haematology, oncology, ocular and inflammatory indications 
[7]. 
Multifunctional Aptamers 
In practice, aptamers are usually selected one at a time as monomers against a 
single target.  As explained in the previous sections, they are also functionalized as 
monomeric units.  However, they may even become more valuable biotechnological tools if 
the same- or different types of aptamers can be combined in the same molecule.  
Multifunctional aptamers have been generated to increase potency, to carry out multiple 
tasks or for allosteric regulation with potential applications in catalysis, therapy and 
biosensors.   
Besides being linked to ribozymes to regulate catalytic activity, molecules consisting 
of multiple single-type or multi-type aptamers can have improved potency, activity, 
functionality and modality.  Bifunctional aptamers can be obtained from the modified in vitro 
selection method called ‘chimeric SELEX’.  Applying this protocol, the pools of 
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chloramphenicol and coenzyme-A (CoA) aptamers were linked together at two ends through 
a homologous sequence in the middle.  This linked pool was then reselected for its ability to 
bind both chloramphenicol and CoA.  After five rounds of selection, bifunctional aptamers 
were generated with higher affinities for both ligands than the original linked aptamer pool.  
The enriched bifunctional aptamers bound to both CoA and chloramphenicol with as good 
affinities as the original CoA and chloramphenicol individual aptamers [112].     
 Rational design has also been used to generate multifunctional aptamers.  For 
example, a thrombin aptamer, an L-selectin aptamer and a DNA element conjugated to 
biotin or fluorescein were linked together through duplex linkers or three way junctions.  The 
resulting multivalent aptamers had multiple functions including anticoagulation activity and 
application as biosensors [50, 113].  Another bifunctional aptamer was obtained by linking 
the AMP and cocaine aptamers was and then hydridized to a complementary length of DNA.  
Release of the hybridized sequence by either AMP or cocaine was detected by colorimetric 
or electrical signals [114].   
Once generated, multiple units of aptamers have also been used to knock down 
several protein functions more efficiently.  Twelve units of the B52 aptamer was expressed 
in cells and in Drosophila melanogaster that showed a 10-fold increase in affinity compared 
to the monovalent aptamer.  Also, its stable expression inhibited B52 functions and reversed 
the Drosophila phenotypes caused by overexpression of B52 [28].  In addition, an aptamer 
was selected for CTLA-4, the T-cell receptor with a negative signal for T-cell activation that 
exists as a dimer cross-linked by a pair of B7-1 proteins.  A tetramer of the CTLA-4 aptamer 
was found to better inhibit CTLA-4 function than its monovalent form and thus enhance T-
cell immunity against tumors [115].  Similarly, a multi-thrombin aptamer showed stronger 
anticoagulant activity than its monomer [113].  Finally, a divalent aptamer against 4-1BB, a 
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cell surface receptor on CD8+ T cells, stimulate CD8+ T-cell activation whereas the 
monovalent 4-1BB aptamer was shown to be inactive [116]. 
Simply, the potency of monomeric aptamers can be increased due to multiaptamers 
ability to capture more ligands.  In 1998, it was reported that both one and three units of 
tobramycin and kanamycin aptamers, once expressed in E. coli, resulted in drug-resistance 
which was better with the three of tandem aptamers.  In addition, when inserted into the 5’-
UTR, multi-tobramycin and -kanamycin aptamers inhibited translation in the presence of 
tobramycin and kanamycin-A [27].   
Another purpose of constructing dimer aptamers is to increase the signal and the 
resolution in imaging.  A divalent human neutrophil elastase (hNE) aptamer showed about 
20 fold increase in affinity and higher fluorescence compared to its monovalent form [117].  
A molecule with multivalent malachite green aptamers was also found to bind more 
malachite green per molecule and emit a stronger fluorescence than a single malachite 
green aptamer [118].  Another example is the multivalent MS2 coat protein aptamers which 
were inserted into the 3’ end of lacZ mRNA.  They could interact with the coexpressed MS2-
GFP fusion proteins thereby lacZ mRNA movement imaged inside a cell [119].  However, 
the results showed that the sensitivity was such that individual lacZ mRNA movement could 
be observed with 24 linked MS2 aptamers as part of the mRNA, whereas only the 
movement of multiple lacZ mRNAs could be observed with 6 and 12 units of MS2 aptamers 
fused with the mRNA [119]. 
Functional Intracellular Aptamers  
The ability to construct expression systems with aptamers to function inside a cell 
gives a lot of advantages to aptamers over antibodies and RNA-based therapy.  For 
example, this advantageous property has eliminated the problems of low transfection 
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efficiency, and the lysosomal and nuclear localization of the RNAs used in therapies.  
Therefore, a variety of expression systems that involve aptamer sequences integrated either 
by themselves or as decoys has been developed.  These engineered vectors make the use 
of aptamers 1) to control transcription and translation, 2) to inhibit HIV-1 infection, 3) to 
induce cell death and 4) to give aminoglycoside resistance to the bacteria.  In our studies, 
we have utilized some of these RNA aptamers and their secondary structures obtained via 
RNAStructure4.6 are shown in Figure 1. 
Aptamers to Control Transcription and Translation 
In nature, there have been identified natural riboswitches located in the 5' or 3' UTR 
of mRNA transcripts to regulate transcription or translation processes by small metabolites 
[120].  By mimicking the functions of these riboswitches, in vitro selected aptamers can 
regulate transcription or translation once inserted into the 5' or 3' UTR of the desired genes.  
In fact, the first-reported intracellular application of aptamers was intended to control gene 
expression via small molecules.  This was achieved by inserting three copies of tobramycin 
or kanamycin-A aptamers into the 5' UTR of reporter gene, the expression of which was 
regulated by the aptamer's target.  In the presence of 60 µM target molecule, more than 90% 
of reporter expression was inhibited compared to the controls [27].  In the same report, three 
copies of an aminoglycoside aptamer was replaced by three copies of an aptamer selected 
to bind two related Hoechst dyes, H33258 and H333342, with which ligand dependent 
translational regulation was observed in both wheat germ extracts and in Chinese hamster 
ovary (CHO) cells transfected with DNA encoding the lacZ gene [27].  These first examples 
of intracellular applications of aptamers encourage other researchers to utilize a variety of 
aptamers inside cells. 
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The malachite green (MG) RNA aptamer has been used to control translation of 
cyclin.  The aptamer, selected for use in RNA chromophore-assisted laser inactivation [121], 
was inserted right before the start codon (AUG) of a cyclin transcript in Saccharomyces 
cerevisiae (S. cerevisiae).  By this way, translation of a modified cyclin transcript was 
regulated by a structural analog of MG, tetramethylrosamine (TMR) [122].  They observed 
that in the presence of TMR, the MG RNA aptamer-ligand complex in the 5'UTR of cyclin 
transcripts was stable enough to inhibit translation of cyclin by more than 90%.  In another 
example, the MG RNA aptamer was engineered through in vivo (in S. cerevisiae) selection 
as a TMR-dependent transcription activator [123].  In this study, transcriptional activity of the 
engineered RNA molecule increased about 10 fold in the presence of TMR.  
In a more recent article, researchers described a different route to express aptamers 
in yeast to inhibit a transcription factor called heat shock factor 1 (HSF1) [124].  They utilized 
the intron homing process that is induced by Pol I transcription.  In this way, they effectively 
integrated self-splicing introns containing the aptamer sequences into hundreds of rRNA 
genes.  An aptamer against HSF1, a conserved transcription factor responsible for 
mobilizing specific genomic expression programs in response to elevated temperature, was 
expressed.  As a result, a temperature sensitive growth defective phenotype and decreased 
level of heat shock gene expression were observed.  In addition, they showed that the 
aptamer can bind yeast HSF1 and its mammalian ortholog with equal affinity,  They claimed 
that successful inhibition would also be possible in mammals because HSF1 enables and 
promotes malignant growth and metastasis in mammals[124]. 
Aptamers to Inhibit Viral Infections 
Defeating viruses has been a challenge for decades, especially, after the emergence 
of human immunodeficiency virus (HIV).  Although there have been anti-HIV drugs for 
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decades, both prevention and cure remain elusive due to severe side effects and resistant 
mutants of the virus.  However, to control HIV infections in vitro selected aptamers against 
viral proteins have been developed as chemical antivirals.  Aptamers have been selected 
against HIV-1 reverse transcriptase (RT) [104], HIV-1 Rev [102] and HIV-1 integrase [103] 
as mentioned earlier.  These aptamers were shown to inhibit viral replication in several 
studies. 
  Among all, the most obvious target was the HIV-1 RT to develop a way for HIV 
therapy.  In fact, the RNA aptamers selected for HIV-1 RT were shown to be functional to 
inhibit RT’s activity in Escherichia coli (E. coli).  To validate this, researchers have utilized 
the requirement of a base pairing interaction between the Shine-Dalgarno (SD) sequence 
and 16S rRNA in ribosomes for bacterial translational initiation.  The coding sequence for 
the RT RNA aptamer was cloned into a position adjacent to the SD sequence of the lacZ 
gene in E. coli to target HIV RT protein expressed in E. coli.  As a result, in the presence of 
the HIV RT, the aptamer bound to the expressed RT protein and blocked the access of 30S 
ribosomal subunit to the SD sequence of lacZ gene by steric hindrance.  Whereas, without 
the HIV RT, the expression of lacZ was not affected this proves the successful effect of the 
aptamers. [125-127]   
Aptamers can also be used intracellularly as decoys to interact with the disease-
related RNA-binding proteins.  For example, RT aptamers were used to inhibit type I human 
immunodeficiency virus (HIV-1) infection as aptamer decoys.  An oligonucleotide encoding a 
33 nucleotide pseudoknot RNA aptamer targeting HIV-1 RT was cloned into a retroviral 
vector between mutant tRNA gene and an RNA polymerase Ill termination signal [128].  The 
tRNA-aptamer transcripts generated by the RNA polymerase Ill were found in the cytoplasm 
after being transiently expressed in several human cell lines.  In the human 293T cell line, 
co-transfected with a pro-viral HIV-1 DNA, inhibition of HIV particle release was reduced by 
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more than 75 %.  Then, the viral particles derived from 293T cells were used to infect 
human T-lymphoid C8166 cells expressing chimeric tRNA-aptamer and successfully 
inhibited the subsequent viral production again by more than 75 % compared to the controls 
[128]. 
In a similar study, aptamers against HIV-1 reverse transcriptase were combined with 
small hairpin RNAs (shRNAs) to inhibit HIV replication as in the form of alternative aptamer 
decoys.  The shRNA and the aptamer were inserted downstream of a U6 promoter, utilized 
by RNA polymerase Ill, in the MMP-eGFP retroviral vector for blocking endogenous HIV-1 
replication [129].  In addition, combining the aptamer with a self cleaving ribozyme at both 5' 
and 3' ends made it possible to produce the exact sequence of the desired aptamer after its 
intracellular transcription [129].  CEMX 174 cells transfected with the retroviral vector 
containing aptamer decoy were challenged by the HIV.  The results showed that the 
aptamer decreased the levels of the early RT products up to 96 % at 2 hours post infection, 
whereas the shRNA-aptamer decoy had as much as 62 % inhibition of the same early RT 
products.  Even, aptamers were able to inhibit two consecutive rounds of reverse 
transcription of HIV-1 genome by their ability to get encapsidated into the virion particles.  
Finally, in the same study, they found that about 85% of aptamer RNAs and shRNAs were 
present in the cytoplasm with an RNase protection assay [129]. 
Aptamers to Induce Cell Death  
RNA aptamers can be used to target endogenous proteins to induce cell death as 
well.  In 2006, five RNA aptamers targeting the Bcl-2 homolog CED-9 were selected and two 
of these RNA aptamers were used to induce cell death in Caenorhabditis elegans (C. 
elegans) [130].  Over-expression of either of the two aptamers in six touch receptor neurons 
in C. elegans induced efficient apoptosis of these neurons.  This clearly exemplifies that 
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RNA aptamers can be used to modulate programmed cell death in vivo and can potentially 
be used to develop antagonist drugs to treat human diseases caused by abnormal 
apoptosis.   
Furthermore, aptamers targeting nucleophosmin (NPM), which is a multifunctional 
protein involved in both proliferation and apoptosis, were used in vivo [131].  Because NPM 
negatively regulates p53 and is frequently over-expressed in a wide variety of cancers, 
targeting NPM with aptamers would cause apoptosis.  In fact, expression of the selected 
RNA aptamers had series of effects one of which was to inhibit oligomerization of NPM.  
This inhibition results in mislocalization of NPM in the nucleoplasm rather than in the 
nucleolus.  Moreover, p14ARF is mislocalized in the nucleoplasm and p53 is upregulated in 
cells expressing NPM aptamers.  Finally, cancer cells expressing NPM aptamers not only 
underwent apoptosis on their own, but were found more susceptible to apoptosis induced by 
DNA-damaging agents as well [131]. All together these examples clearly demonstrated that 
aptamers can be used as anti-cancer agents. 
Aptamers to give Aminoglycoside Resistance to Bacteria 
Antibiotic antibiotics have been used extensively to kill bacteria for decades.  They 
are positively-charged chemicals produced by fungi as secondary metabolites and due to 
their positive electrostatic potential; they can target RNAs with high affinity.  In fact, their 
primary target is the A-site embedded in 30S ribosomal small subunit [132, 133].  Once 
aminoglycosides bind to the A-site, misreading of genetic information occurs and bacteria 
eventually die.  However, researchers showed that this event can be prevented by 
expressing RNA aptamers that were selected for aminoglycosides; kanamycin and 
tobramycin [27].  They cloned one and three copies of kanamycin or tobramycin aptamers 
and expressed with T7 RNA polymerase promoter.  Once induced with IPTG, these RNAs 
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captured aminoglycosides and prevented the aminoglycoside binding to ribosomes thereby 
bacteria could grow in the presence of aminoglycosides.  As a result, bacteria were able to 
grow in the presence of 10 and 20 µM kanamycin or tobramycin [27].  These successful 
implementations have indicated that aptamers can be functionally used inside cells.  
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MOLECULAR MODELING OF NUCLEIC ACIDS AND APTAMERS 
Biological macromolecules function by way of their specific tertiary and quaternary 
structures that highly depend, in a complicated way, on their composition (primary 
structures).  This structure-function relationship has led structural biologists to investigate 
the molecular structures of many biologically-significant molecules, specifically proteins and 
nucleic acids.  These studies pinpoint how these biomacromolecules are shaped and how 
small changes in their structures affect their function.   
Structural biologists use various experimental techniques to accurately determine the 
structures of a variety of molecules, including X-ray crystallography, nuclear magnetic 
resonance (NMR), cryo-electron microscopy (cryo-EM), circular dichroism (CD), small angle 
X-ray scattering (SAXS), multiangle light scattering, ultra-fast laser spectroscopy and dual 
polarisation interferometry.  These methods involve simultaneous measurements on a 
population of unique molecules.  Most methods can only define an average static state of 
the molecular structures in the molecular population that usually represents a snapshot of 
highly dynamic processes.  In contrast, molecular dynamics (MD) simulations make it 
possible to obtain highly accurate physiochemical molecular models that can complement 
the work of structural biologists and expand our understanding of the dynamics of molecular 
structure.   
In a typical MD experiment, each atom (or point charge with an associated mass) is 
properly defined where the chemical bonds between neighboring atoms are defined as 
spring-like interactions.  In this system, van der Waals forces are described as Lennard-
Jones potential while electrostatic interactions are computed based on Coulomb's law.  
Equilibrium bond lengths, bond angles, partial charges, force constants and van der Waals 
parameters are all together described as a force field.  Using all these force field parameters, 
atoms are assigned with velocities, related to the temperature of the system and atomic 
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trajectories in space and time, that are integrated based on Newton's laws of motion (F=ma).  
Then, the molecule is free to vibrate, rotate, and translate into favored conformations in 
response to intra- and intermolecular forces acting upon it.  In this way, MD simulations can 
inform researchers about the possible behavior of dynamic processes as a function of time 
with the intrinsic inclusion of temperature effects. 
So far, several MD simulation programs have been developed, which are based on 
energy minimization for the analysis of proteins, nucleic acids and lipids.  These MD 
simulations can be carried out either in vacuum (described as gas-phase simulations), in 
solution (described as explicit solvent simulations) or in crystal environments to study the 
behavior of molecules.  MD simulations can be applied to understanding the mechanisms of 
enzyme catalysis, protein folding and stability as well as molecular recognition of 
proteins, DNA, RNA and membrane complexes. 
As a result of recent findings about RNA’s ability to control vital cellular events and 
the growing number of diseases linked to RNA malfunction, RNA manipulation has gained 
more attention.  However, to get control over RNA, it is essential to understand the network 
of interactions that help an RNA to assume its ensemble of conformations.  RNA molecules 
do not have static structures as are often presented from crystallographic data.  To the 
contrary, RNA is a very flexible molecule that can change its conformation/s in response to 
cellular signals.  Therefore, it can control cellular events like turning specific genes on or off 
by interacting with other biomolecules [134].  In some cases, an RNA can adopt so many 
possible conformations under different conditions that it cannot be defined as having a 
single structure [134].  The details of the network of interactions that help form the complex 
tertiary and quaternary structures of RNAs, obtained through MD simulations for a variety of 
RNA molecules, have also uncovered some unexpected characteristics of RNAs as 
discussed below, 
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One of the very first examples of MD simulations of an RNA includes the modeling of 
solvated yeast tRNAAsp over 500-ps [135].  This study showed the anticodon loop and the 
acceptor stem as the most flexible regions of the L-shaped tRNA molecule.  5’-U1 and 3’-
CCA terminal residues and the apical G34 wobble nucleotide were also found extremely 
flexible.  In addition to the flexibility of the molecule, Mg+2 ions were located in the core of 
the tRNA that help stabilize the four-base triples [135].  This simulation encouraged the 
other researchers to study other RNA molecules. 
These early simulations of yeast tRNAAsp, were followed by another MD simulation 
study that identified two water-mediated uracil-cytosine (UC) base-pairs that switch between 
different conformations in an RNA duplex [136].  One of these conformations included a 
water molecule that behaved as a hydrogen donor and acceptor. In the second 
conformation, the oxygen of a water molecule was found in close proximity to the two-base 
donor sites.  The latter conformation was also observed in 23S rRNA sarcin-ricin domain 
where it was located in one of the minor groove surfaces [137]. These MD simulations with 
an RNA duplex revealed for the first time that the dynamic behavior of the water-mediated 
UC base-pairs differed from the Watson-Crick and non-canonical guanine-uracil base-pairs 
[136].  As a result, one further step of complexity has been added to the conformational 
flexibility of the RNA duplexes, which could be attributed to water-mediated UC base-pairs. 
Another important group of RNA elements are loop-loop interaction motifs that play a 
role in encapsidation of the viral genomes [138].  They form structurally and biochemically 
significant complexes such as in the retroviral RNA genome dimers of HIV-1 and Moloney 
murine leukemia virus [138].  MD simulations of RNAs with kissing-loop motifs helped 
understand their structural dynamics and formation of cation-binding pockets [139].  Relaxed 
intermolecular G-C base pairs and a cation binding pocket formed by the core region of the 
kissing complexes were first noticed in these MD simulations.  In addition, the binding 
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pocket was observed as a very flexible region that could effect fluctuations in the 
asymmetrical bending of the whole molecule.  However, different types of kissing loops 
behaved differently in terms of their cation binding.  For example, two hexa-coordinated 
magnesium ions and one sodium ion were critical for the stabilization of subtype A whereas 
the pocket of a subtype B kissing loop contains three delocalized sodium ions [139].  With 
the help of MD simulations, the kissing complexes were found to be more flexible entities 
than canonical A-form RNA duplexes. 
Kink-turns (K-turns) were examined in another study.  Some of these K-turns were 
previously shown to contain flexible elements that could mediate large-scale ribosomal 
motions [140].  For example, three of these K-turns exhibited hinge-like motions in ribosomal 
RNA that play critical roles in translation [140].  Solution biochemical analysis indicated that 
X-ray geometries of K-turns were rather unstable; although, from their X-ray geometries it 
was not expected that these K-turns would be very flexibility.  In MD simulations, K-turns 
motions were observed as flexible loops controlling two rigid helical stems in hinge-like 
motions.  In sum, this study along with X-ray and in solution biochemical studies has helped 
a detailed understanding of the K-turns, revealing how molecular interactions can modulate 
the shape and flexibility of molecules [140]. 
Discovery of the ribozymes led to the RNA world hypothesis late in the 20th century 
[141].  RNA molecules were proposed to be one evolutionary step prior to protein-based 
enzymes in catalyzing chemical reactions.  Conformational rearrangements were found to 
be involved in catalysis by the hepatitis delta virus (HDV) ribozyme.   This self-cleaving RNA 
enzyme that plays a role in the replication of the human HDV was simulated by MD [142].  
Crystallographic studies had shown that cytidine at 75 position (C75) was situated in close 
proximity to the cleavage site both in the reaction precursor and at 3’ of the genomic HDV 
ribozyme.  It was confirmed by the MD simulations that site-specific self-cleavage required 
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the dynamic binding of C75 in the catalytic pocket.  This binding facilitated the H-bond 
formation between U1 and C75.  Surprisingly a distant RNA tertiary interaction involving a 
protonated cytidine (C41) was found to stabilize the C75 interaction [142].  Later, from 
another MD simulation study, the same group showed that a previously unnoticed U-turn 
motif was utilized by the genomic HDV ribozyme for fast catalysis [143]. 
Studies of an in vitro selected aptamer led to the discovery of a very interesting 
phenomenon.  The malachite green aptamer (MGA) itself had an unusual property that once 
it binds to malachite green (MG), it enhances the MG fluorescence [118].  However, in 
solution, MG alone is rapidly bleached.  Experimental studies supported by computational 
analysis demonstrated that the MGA could inhibit the bleaching of MG by preventing the 
hydroxylation of MG at the central carbon [144].  The mechanism of action was in a 
concentration-dependent manner with a stoichiometry, which suggested steric hindrance 
and exclusion of the hydroxyl ion.  This steric exclusion of an hydroxyl ion was 
demonstrated by computational cavity analysis of the NMR structure as well as being 
confirmed experimentally [144].  With this study, a nucleic acid aptamer was shown to 
control access to specific chemical groups on small molecules by steric hindrance.  
The structures of RNA molecules share a lot of common features with the anatomy 
of the human body.  As anatomical features of our joints define the range of motion of our 
arms and legs, RNA junctions is directly affect the motion of RNA helices.  A research group 
from the University of Michigan lead by Hashim Al-Hashimi used molecular dynamics and 
NMR to investigate the flexibility of transactivation region (TAR) of HIV-1 RNA and the 
conformational changes that occur upon aminoglycoside binding in this model system [145].  
Shown in Figure 4, the chemical structures of aminoglycosides differ from one another in 
charge, size and other chemical properties.  This study revealed that larger aminoglycosides 
froze RNA in more bent positions whereas smaller ones favored straighter RNA structures.  
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Also, further analysis indicated that, when positioned between two helices, the 
aminoglycoside acts like a wedge, pushing the helices apart [134].  This study along with 
many others has clearly demonstrated that MD simulations are very helpful to investigate 
the complex network of interactions in RNA structures as well as to increase our 
understanding of the structures refined from X-ray and NMR structural data. 
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RIBOSWITCHES 
Cells have evolved a variety of complex control mechanisms to efficiently use their 
energy resources.  The degree of complexity of control mechanisms at different levels gives 
them an opportunity to spatiotemporally regulate cellular events essential for their survival.  
At the gene expression level, most of the control has previously been believed to be 
maintained by DNA binding proteins. However, recently it was shown that one type of 
control mechanism involves metabolite-sensing mRNA units called riboswitches (earlier 
called “regulons” [146].  They are highly selective and can even discriminate against closely 
related analogs of their targets.  Cells use riboswitches as cis-acting RNA-based sensors to 
rapidly adapt to their microenvironment. Through the riboswitches cells can link changes in 
metabolite levels due to changes in flux through metabolic pathways to changes in 
transcription and translation of relevant enzymes [147, 148].  These metabolite-sensing 
RNA units are in general located in the non-coding portions of mRNAs where they serve as 
receptors of specific metabolites to regulate gene expression [149, 150].  For riboswitch 
regulation, the helical stability, dynamic sampling and conformational selection of the RNA 
units are important [151].  Their mechanisms of action directly depend on ligand binding that, 
in turn, results in conformational changes in the three-dimensional structures of the 
riboswitches.  These structural rearrangements influence RNA binding or translocation by 
the ribosome, which affects the efficiency of translation initiation [152]. 
Natural Riboswitches 
Riboswitches have a wide range of targets or effector molecules and can be divided 
into two groups of natural and engineered riboswitches.  Natural riboswitches recognize 
amino acids like lysine [153] and glycine [154]; amino acid derivatives like S-
adenosylmethionine (SAM) [155-157] and S-adenosylhomocysteine (SAH) [158]; 
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coenzymes like flavin mononucleotide (FMN) [159], thiamin pyrophosphate (TPP) [159], 
coenzyme B12 [160]; simple sugars like glucosamine 6-phosphate (Glcn6P) [161]; purines 
like guanine, cyclic di-GMP, adenine and pre-queuosine (preQ1) [162, 163]; and tRNA [164].  
Also, they can sense metal ions like molybdenum cofactor and magnesium ions [164, 165]. 
Riboswitches can even sense temperature and pH that are the determinant physico-
chemical factors for bacterial survival [166, 167]. 
Naturally occurring riboswitches have very complex three-dimensional structures, 
which provides them with the ability to achieve a very specific and targeted regulation of 
gene expression.  Their structure is composed of an aptamer portion and an expression 
platform.  The aptamer recognizes its cognate small effector molecule and this interaction 
leads to global structural changes in the expression platform, which functions as the 
regulator of gene expression.  The size of nucleotide binding aptamer domains ranges from 
40 nt to 300 nt [150].  
Mechanisms of Riboswitches 
Riboswitches typically turn off gene expression in response to the binding of their 
effectors, but some turn it on.  They can target transcription, translation initiation or mRNA 
stability.  Prokaryotic riboswitches that regulate transcription by an “off” mechanism promote 
the formation of rho-independent transcription termination hairpins, which consist of a GC-
rich stem followed by a poly-U tail and leads to premature transcriptional termination.  The 
structural rearrangement that occurs as a result of the riboswitch binding its effector results 
in the arrest of transcriptional elongation due to the destabilization of the RNA-RNA 
polymerase complex.  Inhibition of translational initiation by prokaryotic riboswitches is 
achieved by their folding so as to sequester ribosome-binding sites like the Shine-Dalgarno 
box or the start codon (AUG).  Finally, the stability of the mRNA is affected by a ribozyme in 
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the glmS riboswitch.  The riboswitch cleaves itself when it binds glucose 6-phosphate and 
this interaction leads to rapid mRNA degradation [168].  
Another type of regulation by riboswitches involves alternative splicing.  For example, 
a TPP riboswitch in plants modifies splicing and alternative 3'-end processing [169, 170].  In 
Neurospora crassa, a TPP riboswitch produces an upstream Open Reading Frame (uORF), 
which in turn affects the expression of downstream genes  [171].  
A very rare example of regulation of gene expression by riboswitches involves an 
RNA element, such as the Gcv element, that activates gene expression.    Glycine binding 
to the gcv element promotes a structural rearrangement of the riboswitch that involves 
formation of an anti-terminator structure, which competes with the terminator helix in mRNA. 
The structural change shifts the transcription into an active state [172].  
Specific Examples of Riboswitches 
Riboswitches control genes that encode proteins involved either in their ligand 
synthesis pathway or as transporters of their ligands. In-line probing, which was developed 
to detect conformational changes in mRNA, was used to identify the riboswitch in btuB gene 
that is regulated by coenzyme B12 (AdoCbl) [160]. The genes controlled by the cobalamin 
riboswitch include a membrane protein for the transportation of coenzyme B12 and essential 
genes for its metabolites. The following examples summarize the types of riboswitches 
identified so far. 
The RFN-element or FMN riboswitch recognizes flavin mononucleotide (FMN) and 
regulates riboflavin biosynthesis and transport [159, 173].  The THI-box or alternatively TPP 
riboswitch found in the 3’ UTR of plant genes bind thiamin pyrophosphate (TPP) to 
regulate thiamin biosynthesis and transport, as well as transport of similar metabolites. It is 
one of the few riboswitches found so far in eukaryotes [159, 174]. 
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Two types of amino acid binding riboswitches have been identified: 1) the glycine 
riboswitch that binds glycine and regulates genes in glycine metabolism, including the use of 
glycine as an energy source, and 2) the lysine riboswitch (or L-box) binds lysine to regulate 
lysine biosynthesis, catabolism and transport [153]. So far, the glycine riboswitch is the only 
known natural RNA with cooperative binding to its effector, which is accomplished by two 
adjacent aptamer domains located in the same mRNA [172].   
Amino acid derivative-binding riboswitches are the SAH and SAM types.  SAH 
riboswitches bind S-adenosylhomocysteine to regulate genes involved in recycling the SAH 
metabolite that is produced when used in methylation reactions.  To regulate 
methionine and S-adenosylmethionine (SAM) biosynthesis and transport, three distinct SAM 
riboswitches have been identified as SAM-I (originally called S-box) [157], SAM-II [175] and 
the SMK box [176].  Although they all switch off gene expression in response to SAM binding, 
no sequence or structural similarities have been observed between these riboswitches.  
They differ in structural arrangements of their aptamer regions, phylogenetic distributions 
and mechanisms of regulation.  SAM-I riboswitches typically function through transcription 
terminator formation whereas SAM-II riboswitches inhibit translation via ligand-dependent 
sequestration of the ribosome-binding sequence. 
Purine riboswitches regulate purine metabolism and transport.  The specificity for 
either guanine or adenine depends completely upon Watson-Crick interactions with a 
single pyrimidine in the riboswitch at position Y74 [172]. In the guanine riboswitch this 
residue is always a cytosine (i.e. C74), in the adenine residue it is always a uracil (i.e. U74). 
Deoxyguanosine is recognized by homologous purine riboswitches that are more 
significantly different from each other than a single nucleotide mutation observed the 
guanine riboswitches.  Also, preQ1 riboswitches bind pre-queuosine and regulate genes 
involved in the synthesis or transport of this precursor to queuosine. Two entirely distinct 
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classes of PreQ1 riboswitches are known: PreQ1-I riboswitches and PreQ1-II riboswitches. 
The binding domain of PreQ1-I riboswitches is unusually small among naturally occurring 
riboswitches. PreQ1-II riboswitches, which are only found in certain species in the genera 
Streptococcus and Lactococcus, have a completely different structure, and are larger than 
pre-Q1-1 riboswitches [162, 163].  Two classes of cyclic di-GMP riboswitches are also 
known: cyclic di-GMP-I riboswitches and cyclic di-GMP-II riboswitches. They bind the 
signaling molecule cyclic di-GMP in order to regulate a variety of genes controlled by this 
second messenger [163]. 
Finally, the T-box RNA is interacts with both charged and uncharged tRNAs, by 
which it monitors the substrate to product ratio rather than the absolute amount of its 
substrate.  In this system, binding of uncharged tRNA is competitively inhibited by 
aminoacylated tRNA [177].  
Engineered Riboswitches 
The power of controlling gene expression patterns has motivated researchers to 
discover new riboswitches that could be applied in therapy.   We can divide these into three 
types based on their content.  The first type consists of self-cleaving ribozymes, the second 
utilizes cis or trans-expressed antisense RNAs and the final one has only the aptamer 
sequence that can respond to an external effector. 
Several riboswitches have been engineered using ribozymes that can be regulated 
by an external effector [178, 179].  In these studies, self-cleaving ribozymes were utilized to 
control gene expression in mammalian cells.   The regulation was obtained by inhibiting 
ribozyme activity through the external addition of toyocamycin or 5-fluorouridine (5FU).  The 
authors utilized the luciferase gene as a reporter and detected ~365-fold and 110-fold 
enhancement in luciferase expression with respective effectors [179].  
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In 2004, Isaacs et al. demonstrated both trans and cis repression of gene expression 
in prokaryotic cells using an engineered riboswitch [180].  They placed an internally 
complementary sequence directly upstream of the ribosome-binding site that forms a stem-
loop structure, which interferes with ribosome binding.  Also, they targeted this stem loop by 
expressing a small non-coding RNA in trans that reversed the effect of the riboswitch and 
increased gene expression [180].  In a similar vein, anti-switches were developed as 
translational ribo-regulators in the form of trans-acting RNAs that could respond to small 
molecules by creating hybrid riboswitches.  In this system, the binding of theopylline to its 
cognate aptamer was able to open up the structure of a sequestered sequence for an 
antisense to bind and thereby prevent GFP expression [181].  
The third class of synthetic riboswitch solely depends on small molecule binding 
aptamers that are inserted into the 5’ UTR of an mRNA [27, 182, 183].  The small molecule 
binding to these RNA aptamers alters their structures to affect translation of the downstream 
coding regions.  In this context, either the binding of the eukaryotic ribosomal subunit to the 
cap-structure or its scanning along the mRNA is interfered with by the aptamer–ligand 
complex [184].  So far, only a few small molecule-binding aptamers have been described as 
functional riboswitches [27, 122, 182, 183, 185].  These aptamers are targeted by 
theophylline, tetracycline, neomycin-B, or Hoechst 33342.  For these riboswitches the 
presence of the cognate ligand results in structural rearrangement of the aptamer to prevent 
translation.  A neomycin-B binding riboswitch, controlled by extracellular neomycin-B, was 
selected with the aid of a GFP reporter system [183].  Other RNAs known to bind neomycin-
B were also tested with the GFP reporter construct, including the naturally occurring 16S 
rRNA A-site region [186] and other previously selected neomycin-B aptamers [187].  
However, only the neomycin aptamer specifically selected with riboswitch functionality was 
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found responsive to neomycin-B.  This result suggests that the ability to behave as a 
riboswitch requires structural features beyond those that result in tight effector binding.   
Future Perspectives 
The role of RNA elements as riboswitches in prokaryotic gene regulation was not 
widely recognized until the beginning of the 21st century.  As of 2012, there are currently 
about 700 articles in the PubMed database for the term “riboswitch”.  In addition to these, 
there is an extensive literature for the RNAs playing a role in regulation of bacterial gene 
expression that predates the use of the term.  Also, recent findings that have identified the 
first few riboswitch elements in eukaryotic systems imply that these RNA-based regulatory 
mechanisms are used even more widely than is currently known. 
The ability to modulate gene expression with an extracellular binding partner would 
enable researchers to control the level of a particular gene with riboswitches.  These newly 
developed biotechnological tools then can be utilized in therapy as gene expression control 
units.  Bacteria develop drug resistance through many alternative routes, one of which is to 
use riboswitches to control expression of certain genes targeted by the drugs.  In addition, 
the emergence of drug-resistant organisms that utilize riboswitches suggests that it is 
possible to discover novel drugs and new therapeutics by targeting these riboswitches [188].  
The growing dataset of genomic sequences and bioinformatics techniques provide 
the knowledge that is necessary for developing tools for the identification of riboswitches.  
However, we still need to understand the relationship between ligand-bound and unbound 
states of riboswitches in order to fully understand their mechanistic and structural features 
and their physiological roles in the cell.  The ability to predict the means by which a 
particular RNA aptamer can be modified to provide it with riboswitch activity will allow for a 
rapid increase in the number of RNA switches available for application in synthetic biology.  
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Understanding riboswitch function from a structural basis will also speed the development of 
new antimicrobial drugs that can target riboswitches.  These results will be the outcome of 
multi-disciplinary studies that are likely to be an area of active research for the next 
generation of researchers.  
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IMAGING TECHNOLOGIES AND RNA DETECTION 
Molecular imaging covers noninvasive as well as invasive methods used to 
investigate the molecular events inside organisms.  The ability to image molecular events 
brings a number of exciting possibilities for medical applications from basic pharmaceutical 
developments to early detection and treatment of diseases.  Potential reporter systems have 
been explored using various imaging modalities including radioactivity, bioluminescence and 
fluorescence [189]. 
Radiotracer methods have been widely used for imaging living subjects 
noninvasively.  Two of these methods are single photon emission computed tomography 
(SPECT) and positron emission tomography (PET) which are used to detect isotopes 
emitting gamma rays and positrons respectively.  Each of these methods has its own 
advantages and disadvantages.  For example, gamma (γ) rays, penetrating through tissues, 
can be detected directly by gamma cameras, which can produce three dimensional 
tomographic images when rotated around the subject for SPECT [190].  In contrast, 
positrons emitted in PET cannot penetrate through a tissue, but instead collide with 
electrons and undergo annihilation, which causes two gamma rays to be emitted at close to 
180 degrees that are detected for imaging.  Although different isotopes cannot be 
distinguished in PET because the gamma rays created from positron annihilations have the 
same energy (511 keV), PET offers over ten times the sensitivity of SPECT.  Gamma rays 
emitted directly from atomic nuclei can have a range of energies; thus, dual-isotope SPECT 
can be used to image several isotopes simultaneously provided that the energies of their 
gamma rays are sufficiently different [191].  One of the commonly used SPECT tracers in 
cancer biology is 18F-deoxyglucose (FDG), which is immediately modified to FDG-phosphate 
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by the high level of expression of hexokinase in cancer cells [192].  By this means growing 
tumors can easily be detected by FGD in vivo. 
Gene expression levels change in many diseases and at different developmental 
stages.  The development of noninvasive means of detecting changes in gene expression 
levels is the critical step for monitoring progression of diseases and normal developmental 
events in order to understand them more fully and for effective diagnosis and treatment, in 
the case of disease.  So far, several gene reporter systems have been developed to 
determine the level of gene expression as well as the location of the reporter.  A vector can 
be engineered with the promoter placed upstream of the reporter gene to control its 
expression.  Then, the reporter gene products can be detected and quantified from which 
the transcriptional activity of the promoter can be estimated. 
Reporter Genes in Imaging  
Early reporter genes include mainly enzymes like chloramphenicol acetyltransferase 
(CAT), thymidine kinase, alkaline phosphatase, luciferase and β-galactosidase [193].  
Luciferase and β-galactosidase can also be analyzed in situ, to identify specific cells that 
express these enzymes [194].  These two assays require the external addition of the ligands, 
luciferin and o-nitrophenyl-β-galactoside (ONPG).  Luciferase from the firefly (Photinus 
pyralis) catalyzes the ATP driven oxidative decarboxylation of luciferin, resulting in the 
emission of a photon of light that can be detected with a luminometer.  It has gained 
popularity because the luciferase assay is simple and is up to 1000-fold higher more 
sensitive than the CAT assay [194, 195]; its bioluminescence is sufficient to detect the 
enzyme in fewer than a hundred cells.  The availability of the luciferase and β-galactosidase 
genes has simplified the efforts to quantify the activity of transcriptional regulatory elements.  
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Also, the efficiency of gene delivery methods like transient transfection can be determined 
with the use of these reporter genes.  
The improvements in the detection devices increased the sensitivity of the 
measurements.  For example, limited penetration of light through tissues was a challenge 
for detection of excitation and emission.  However, detection of bioluminescence in vivo is 
significantly improved by the use of charge coupled device (CCD) cameras that are cooled 
to -120°C.  With increased sensitivity and signal-to-noise ratio of CCD cameras, it is 
possible to detect luciferase activity in deeper tissues [196].  Although bioluminescent 
imaging does not provide high resolution, with the discovery of fluorescent proteins and 
advancements in fluorescent microscopy make it accessible to image fluorescence at single 
cell resolution within tissues [197].   
In 1962, green fluorescent protein (GFP) was discovered while isolating the 
bioluminescent protein aequorin from the jellyfish Aequoria victoria [198].  Aequorin emits 
blue light (470 nm), while the intact organism emits green light (509 nm).  It was 
demonstrated that the luminescence from aequorin is transferred to GFP, which then emits 
green light.  GFP has a maximal excitation at 400 nm with a second small peak at 480 nm 
and it has emission maximum at 508 nm with the quantum yield of 0.72 when excited at 470 
nm [199].  GFP has a spontaneously formed chromophore core (phydroxybenzylidene-
imidazolidinone) that is created by cyclization and dehydrogenation among the three amino 
acids Ser65-Tyr66-Gly67 [200, 201].  In addition, expression of GFP in E. coli and C. 
elegans displayed identical fluorescence properties to natively expressed GFP in A. victoria 
[202].  Since these earlier successful studies, fluorescent proteins have been used 
extensively as reporters of gene activity. 
Modifications in GFP were made of certain properties like the efficiency of folding 
and chromophore formation, endogenous expression levels, fluorescence intensity and the 
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excitation and emission wavelengths.  GFP variants were engineered by inducing random 
mutations of the 20 amino acids in and around its chromophore core.  One mutant (GFPmutl; 
F64L, S65T) exhibited a 35-fold increase in fluorescence and improved folding, which also 
results in about 100-fold increase in fluorescence in E. coli 1 hour after induction of its 
expression [203].  Based on this mutant, enhanced green fluorescent protein (eGFP) was 
developed by Clontech introducing silent mutations with preferred human codons which 
resulted in a 4-fold increase in expression of eGFP in human cells compared to GFPmutl 
[204, 205]. 
Similar mutational and screening experiments have been used to develop different 
color variants of GFP such as cyan, blue and yellow fluorescent proteins (eCFP, BFP and 
YFP, respectively) [206, 207].  Even variants with increased brightness, low sensitivity to pH 
and chloride ions and resistance to photobleaching were developed [208-211].  Also, DsRed, 
a tetrameric red fluorescent protein from Discosoma striata was discovered [212].  
Modifications gave rise to a variant of DsRed with less than a 1 hour maturation half-time 
[213] and another one with monomer called mRFP1 [214].  Then, mutations of the mRFP1 
were made to create a number of fluorescent proteins in the orange to far red spectrum, 
notably mOrange, tdTomato, mCherry [215] and mPlum [216]. 
As fluorescent proteins do not require a substrate like reporter genes do, imaging 
intracellular cell components and the localization, movements and interactions of desired 
proteins can be elucidated by generating fluorescent fusion proteins directly in living cells by 
fluorescent microscopy.  In addition, changes in gene expression in specific cells can be 
estimated indirectly.  Even, the study of several simultaneous processes can be achieved by 
tagging the desired proteins with differently-colored fluorescent proteins.  Especially, with 
certain pairs of fluorescent proteins like green and yellow fluorescent proteins, one can 
study interactions between different proteins if they are in close proximity by Förster 
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resonance energy transfer (FRET), which occurs over distances of less than 10 nm [217, 
218].  Recently, bimodal reporter systems with both bioluminescence and fluorescence were 
used to study human neural stem cells (hNSCs) and glioma cells implanted into the brains 
of mice.  This system provided the possibility for both real time imaging of global cell survival 
and migration using bioluminescence, as well as determining the fates of implanted cells at 
single cell resolution using fluorescent proteins [219]. 
In summary, reporter genes have many innovative approaches used for real-time 
imaging.  However, reporter gene technology utilizes the expression of proteins that needs a 
lot of energy.  Protein synthesis is a high energy-requiring event common in all cell types. In 
addition to the amount of energy required for amino acid synthesis, transport and activation 
of proteins contribute to this high energetic cost.  An estimate of 7.52 ATP energy 
equivalents was calculated from whole body measurements for the synthesis of protein from 
already formed amino acids [220].  Considering the size of commonly used reporter proteins 
in imaging as an average of 50 kDa protein, the energy needed for its synthesis can be 
calculated as 375K ATP molecules.  In addition, the studies with reporter gene systems 
generally analyze cell lines in culture, where they are provided with high concentrations of 
amino acids and other nutritional requirements in the medium.  Under these conditions, very 
few effects of expressed reporter proteins have been reported for cellular behavior and 
differentiation.  
RNA Detection 
Although protein-based imaging technologies have been extensively developed, the 
available methods for detecting and imaging RNA are significantly limited.  First of all, most 
of the available methods are not really suitable for imaging RNA in living cells because they 
either require the purification of RNA samples from cells and/or tissues or the fixation of cells.  
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However, irrespective of the method that has been used, the results from these detection 
methods have provided crucial information about the level of RNA expressed inside cells.  In 
this RNA detection section, Northern blotting, fluorescent in situ hybridization (FISH), 
fluorescence in vivo hybridization (FIVH), stem-looped probes designed for RNA detection, 
in vivo RNA labeling with bromouridine 5'-triphosphate (Br-UTP) and RNA detection with 
fluorescently-tagged proteins are discussed. 
One of the earliest methods used to detect the level of gene expression is northern 
blotting where its isolation, RNA is separated by electrophoresis, transferred onto a 
membrane then hybridized with labeled nucleic acid probes while associated with the 
membrane[221].  The detected signal on the membrane coming from the labeled-probe 
hybridized to the target is proportional to the amount of the RNA present in the sample. 
Unlike in northern blotting, which requires purification of RNA, nucleic acids can also 
be detected and imaged in fixed cells using fluorescent in situ hybridization (FISH) which 
utilizes fluorescently-labeled oligonucleotide probes that are complementary to the target 
RNA or DNA sequence.  These probes are applied to fixed cells followed by the removal of 
unbound probes by washing [222].  FISH has been used mainly in applications where the 
target is DNA, such as localizing a specific sequence on chromosomes [223]. However, 
FISH was also used to visualize single mRNA transcripts [224] and the cellular distribution of 
mRNA [225].  Although FISH is very useful for identification and localization of specific 
mRNA species, this technique requires that the cells or tissues to be studied are first fixed. 
Fluorescence in vivo hybridization (FIVH) was developed as a method of using 
fluorescent labeled unstructured linear nucleic acid probes to detect and image specific 
RNAs in the living cells [226-228].  Unlike in FISH experiments, the washing step to remove 
excessive probes cannot be done in FIVH.  Therefore, to differentiate the true signal from 
background caused by unbound probes in the cell, dual probes for a specific RNAs were 
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designed in which one probe has a fluorescence molecule attached to the 3' end to act as a 
donor and the second probe attached to the 5' end to act as an acceptor in the FRET pair 
[228].  Two probes were designed to target adjacent regions on the selected RNA molecule; 
so that, a FRET signal was only produced when both probes interacted with the RNA target.  
Although the dual probe FlVH was considered as an improvement in reducing the high 
background in FIVH, it is not feasible as a method due to the unstructured linear probes that 
limit its application in cell culture.  For instance, detecting single nucleotide polymorphisms 
(SNPs) is not possible with linear probes in the temperature range in which cells can survive.  
In addition, micro-injection of the probes is necessary in order to have a high enough 
concentration of the chemically modified probes in the cells because the probes cannot be 
produced by the cells [229, 230]. 
To eliminate the disadvantages of the linear probes used in FIVH, the stem-loop 
structured probes have been developed.  Stem-loop structured hybridization probe is a 
single-stranded oligonucleotide and consists of a sequence complementary to the target and 
harbors a fluorophore-quencher pair at the 5′- and 3’ ends.  They can go through a 
conformational change upon binding to the target and release the fluorescence signal that 
was quenched due to the presence of the quencher.  These structurally constrained probes 
were shown to have significantly higher specificity than unstructured linear probes by 
thermodynamic analysis of stem-loop probes with matched and mismatched targets [231, 
232].  This can be explained by the smaller number of configurations with lower free 
energies for annealing with the target [233].  Besides, these probes are highly stable, and 
stems of 5 to 6 nucleotide seem to offer the best option for its efficient hybridization to the 
target RNA and for high signal to noise ratio [234].  Because of these advantages of stem-
loop structured probes over linear unstructured probes, it is reasonable to use stem-loop 
structured probes in the detection and imaging of specific RNA in living cells.   
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One stem-loop structured probe that has also been used in real-time RNA imaging is 
the ‘molecular beacon’ [235], single stranded oligonucleotides containing a 15-30 nucleotide 
loop region closed with 5 to 6 base pairs long stem.  A quencher and a fluorophore are 
attached to ends so when the molecular beacons form stem-loop structures in the absence 
of target RNA, the fluorescence is quenched.  Hybridization with the target nucleic acid 
opens the stem and the fluorescent signal from the fluorophore is freed.  For detecting the 
mRNA, which is located in the cytoplasm, the location of nucleic acid probe is important.  
However, because they are chemically modified, the molecular beacons must be 
microinjected and it was found that once microinjected oligonucleotides were rapidly 
transported into the nucleus from the cytoplasm [236, 237].  Conjugating a peptide to 
molecular beacons that can pass through membranes made an efficient delivery and 
prevented the molecular beacons from accumulating in the nucleus.  Tat-peptide-conjugated 
molecular beacons were used to detect human GAPDH and survivin mRNA in living cells 
using fluorescence [238].  Nuclease-resistant molecular beacons were conjugated with 
streptavidin and used to target native p-actin mRNA in living cells and motile chicken 
embryonic fibroblasts [239, 240].   
Fluorescent labeling of nascent RNA was achieved by incorporating 5-bromouridine 
5'-triphosphate (Br-UTP) into RNA transcripts by RNA polymerase II (RPII) followed by 
fixation then detection with anti-BrdU antibodies [241].  The spatial distribution of 
transcriptionally active chromatin is essential to better understand the functional significance 
of nuclear compartmentalization.  The distribution of sites of active transcription by RPII was 
detected by labeling nascent RNA with Br-UTP, in vitro and in vivo.  Nascent RPII transcripts 
were found in over 100 defined areas, scattered throughout the nucleoplasm with no 
preferential localization in either the nuclear interior or the periphery.  As a result, they 
concluded that each of these transcription sites may represent either the activity of a single 
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gene or of a cluster of active genes.  Also, including antibodies against a splicing factor, SC-
35, they observed no correlation between intensely labeled SC-35 domains and sites of pre-
mRNA synthesis.  On the contrary, many sites of RPII synthesis co-localized with weakly 
stained areas implying that co-transcriptional splicing took place in these weakly stained 
regions.  They conclude that these areas might have also been the sites where splicing was 
completed post-transcriptionally and the intensely labeled SC-35 domains might have 
functioned as sites for assembly, storage, or regeneration of splicing components, or as 
compartments for degradation of introns [241].  Nonetheless, imaging the nascent 
transcripts in the living cells with Br-UTP label all mRNAs in general and unfortunately can 
not be applied to specific RNA species. 
A method of tracking RNA in living cells was developed by tagging an mRNA with six 
tandem repeats of a 19-nucleotide RNA stem loop that serve as targets for the RNA binding 
protein MS2.  In that study, MS2-GFP fusion proteins were used to detect the tagged Ash1 
mRNA [242].  A nuclear-localization signal was included in MS2-GFP fusion protein which 
was co-expressed with the MS2-tagged Ash1 mRNA in cells. After Ash1 mRNA was 
synthesized in the nucleus, its movement and localization could be traced and observed in 
the living cells by tracking the fluorescence of GFP.  Then, it was also confirmed that Ash1 
mRNA molecules were also associated with other proteins related to the transportation and 
localization [119, 243].  Although this method can be used for any RNA of interest, it has 
disadvantages.  First, it requires the co-expression of the MS2-GFP protein and, as 
explained in the ‘reporter genes in imaging’ section, expressing proteins is energetically not 
favorable.  Also, same amount of GFP signal is always present and is redistributed upon 
binding to the tagged RNA, which makes detection very difficult due to the background noise.  
Additionally, the extra RNA sequence and multiple MS2-GFP fusion proteins add 
approximately 270kDa on the nascent RNA, which could have significant effects on the 
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movement and function of the RNA [189].  In a similar study, the ability of Exu to bind bicoid 
mRNA was used to trace bicoid mRNA inside living cells with GFP-Exu fusion protein.  
Drawbacks of this method were that these constructs could only be used to visualize bicoid 
mRNA the GFP signal remains in the cells whether or not the RNA exists, thereby 
decreasing the signal to noise ratio.  Although the latter is not a problem as long as the 
signal to noise is large enough, it remains necessary to distinguish the true signal from 
background in these systems.  Thus, there are still a number of challenges for detecting and 
quantifying RNA targets in living cells in real time. 
More recently, new strategies have been adopted by using split-GFP for the 
visualization of specific mRNAs in live cells by which it was aimed to eliminate the 
fluorescence background signal.  In the expression systems, two motifs that bind to two 
different RNA binding proteins are placed next to each other on the target mRNA.  Then, the 
binding of two RNA binding proteins fused with two 'halves' of GFP in proximity on the target 
RNA mediates the assembly of a functional GFP.  By this split-GFP method, researchers 
have visualized intracellular RNA distribution and dynamics in living cells [244].  However, 
this method has also a potential limitation, pointed out by in vitro studies, due to the meta-
stability of the reconstituted GFP: once the two halves have assembled into a functional 
conformation, they do not dissociate, even if the molecule that initially brought them together 
disappears [245].  As a result, it may be difficult to use this approach to image fast dynamic 
processes related to the synthesis and degradation of mRNAs. 
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DRUG DEVELOPMENT AND RESISTANCE  
Drug Development 
Drug development is a general term used to define the whole process of bringing a 
new drug with a promising activity against a particular biological target in disease to the 
market.  This process starts with drug discovery and its chemical characterization (makeup, 
stability, solubility) followed by pre-clinical research, which includes microorganisms and/or 
animals and then clinical trials on humans.  Drug development constitutes a number of tests 
designed to determine the major toxicities of a newly-developed compound before its use in 
human.  An assessment of major organ toxicity has to be performed to make sure the 
candidate drug does not have negative effects on the functioning of the heart and lungs, 
brain, liver, kidney, digestive system, and on other parts of the body.  Because the complex 
interplay of metabolism and drug exposure on toxicity can only be examined in an intact 
organism, some of the tests need the use of experimental animals while some others can 
still be performed using in vitro cultured cells.  The process of drug development continues 
after human clinical trials because it is also crucial to ensure that long-term or chronic 
toxicities of the drug are determined, as well as its effects on other systems like fertility, 
reproduction and immune system.  Then, the compound goes through carcinogenicity 
testing to determine its risk of causing cancers.  Most drugs fail during drug development, 
either because they have some unacceptable toxicity, or simply because they do not work in 
clinical trials.  Finally, the ones that pass through all these tests can be submitted for 
marketing approval in the various countries in which they will be sold.   
It was estimated in 2002 that approximately $800 million was needed to be spent to 
bring a new innovative drug to market [246, 247].  In a more recently published study the 
cost was reported to vary between around 500 million to 2,000 million dollars depending on 
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the therapy or the developing company [248].  This $800 million quoted is the cost of all 
drug development including those that did not result in a new drug.  It also includes some 
$400 million of opportunity costs.  There are also thousands of other drugs whose 
development costs are much lower.  In sum, all together the pharmaceutical industry spends 
about half of its research budget on drug development but unfortunately has not made any 
direct improvements to a physician's ability to treat disease due to the emergence of new 
drug resistant strains. 
Drug Resistance  
Many drugs are developed each year by drug resistance continues to be a big hurdle 
for treatment of many diseases including cancer, HIV, tuberculosis and many others caused 
by bacteria, fungi and protozoa.  Drug resistance is the result of evolutionary selective 
pressure, which in turn results in many drug resistant organisms.  In clinical practice, drug 
resistance becomes a critical problem when the drug dosages needed to kill infectious 
agents are toxic.  In this section, only cancer and antibacterial drug resistance are discussed. 
Antibacterial resistance is the ability of certain cells and/or microorganisms to 
withstand attack by antimicrobials.  The rise of resistant pathogens threatens lives and 
wastes limited healthcare resources.  According to the World Health Organization (WHO) 
2010 report, antimicrobial resistance is mainly due to ‘the overuse and misuse of 
antimicrobials in human medicine and animal husbandry over the past 70 years and has 
resulted in death, increased suffering and disability and higher healthcare costs’.  Some 
cancer cells can become resistant to more than one drug.  This is observed in tumors where 
cells develop resistance to the drugs used in chemotherapy [249].   
There are four main mechanisms by which drug resistance is acquired [250].  The 
first is drug inactivation or modification by enzymatic deactivation and/or detoxification.  An 
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example of this mechanism is the production of β-lactamases by some penicillin-resistant 
bacteria [251].  The second mechanism is the alteration of target site/s.  A good example for 
this mechanism is the methylation of 23S rRNA resulting in erythromycin resistance.  A 
plasmid-determined methylase dimethylates two specific adenine residues in 23S rRNA of 
the 50S ribosomal subunit so that binding of the erythromycin-lincomycin type of antibiotics 
is prevented, thereby making the cell resistant to high levels of these drugs [252].  A third 
way to get drug resistance is by altering one or more endogenous metabolic pathways.  
Sulfonamide-resistant bacteria are an example for acquiring drug resistance that results 
from alterations in the chromosomally encoded dihydropteroate synthase (DHPS) gene, 
which was linked to at least three other genes of folic acid pathway [253]. 
Reduced drug accumulation inside the cells is the fourth mechanism for drug 
resistance.  It results in decreasing drug permeability and/or increasing active efflux of the 
drugs across the cell surface.  This is a common way for many cell types like bacteria, fungi 
and cancerous cells to become drug resistant [254-257].  The main players in reducing drug 
accumulations are the multidrug resistant pumps, which can be categorized based on their 
bioenergetics and structural characteristics [258, 259].  They include the following members 
in bacteria; 1) the major facilitator superfamily (MFS), 2) the ATP-binding cassette (ABC) 
superfamily, 3) the small multidrug resistance (SMR) family, 4) the resistance-nodulation-cell 
division (RND) superfamily and 5) the multidrug and toxin extrusion (MATE) protein family 
[260].  The Acr family members in the RND superfamily play an important role in 
aminoglycoside resistance through expelling the drugs from cytoplasm [261].  
First category: The major facilitator superfamily (MFS) is one of the largest families 
of transporters and QacA, QacB and QacR were the first examples of this class [262].  They 
actively pump out monocationic biocides and dyes like benzalkonium chloride, 
cetyltrimethylammonium bromide and ethidium bromide and QacA additionally can pump 
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out dicationic biocides such as chlorhexidine and pentamidine isethionate.  The crystal 
structure of QacR showed that drug-binding pocket is large (1100 Å3) and binds a variety of 
drugs [263].  In the same study, it was found that drug binding relies mostly on stacking and 
van der Waals interactions but also involves a few hydrogen bonds and the charges of the 
ligands are usually neutralized by acidic residues in the pocket.  Two ligands can 
simultaneously interact with QacR in different mini-pockets of the binding site [264].  The 
MFS family is EmrB of E. coli, conveys resistance to carbonyl cyanide, m-
chlorophenylhydrazone and to antibiotics such as nalidixic acid and thiolactomycin [265].  
EmrB functions with a periplasmic adaptor protein, EmrA, that connects the pump to an 
outer membrane channel, TolC, to export the drugs directly into the medium.  Another MFS 
member, NorA produces resistance of S. aureus to fluoroquinolones, cationic dyes and 
cationic inhibitors including puromycin and tetraphenylphosphonium in [265].  Drug efflux 
makes a strong contribution to resistance through chromosomally encoded MFS pumps, 
NorA, NorB and NorC, in more than half of S. aureus strains isolated from the bloodstream 
of patients [266]. 
Second category: The transporters of the ATP-binding cassette (ABC) superfamily 
have a limited role in drug resistance in bacteria [267] whereas in cancer cells they play 
crucial roles [268].  For example, LmrA of L. lactis is homologous to 50% of the mammalian 
MDR1 proteins [269] but it has no role in drug resistance of L. lactis.  Nevertheless, its 
overproduction in E. coli conferred resistance to the cationic dyes, daunomycin, and 
triphenylphosphonium.  Biochemical studies led to a proposed mechanism in which ATP 
hydrolysis is coupled with drug extrusion [270].  Furthermore, X-ray crystallographic studies 
of BmrA of B. subtilis [271], Sav1866 of S. aureus [272] and MacB of E. coli [273] confirmed 
their potential role in resistance to macrolides when overexpressed. 
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Third category: Small multidrug resistance (SMR) family members contribute to the 
efflux of cationic compounds such as quaternary ammonium biocides or ethidium.  In this 
class, EmrE of E. coli is the smallest transport protein known with a single charged residue 
(Glu14) in the transmembrane domain [274].  This residue has an unusually high pKa of 
about 8.5 and it becomes deprotonated upon substrate binding.  In this way, efflux of the 
substrate is coupled to influx of proton(s) by a common binding site.  
Fourth category: RND-containing pumps of gram-negative bacteria are energized 
by a proton motive force and can pump out drugs, from the periplasmic space capturing 
various nonphospholipid, amphiphilic molecules.  Structurally, they exist as a tripartite 
complex containing an outer membrane protein, TolC [275] and the periplasmic protein, 
AcrA [276].  This tripartite complex works synergistically with the outer membrane barrier 
because it allows the efflux of drugs into the external medium from which the drugs must 
pass through the outer membrane barrier to reenter the bacterial cells [277].  The intrinsic 
resistance of most gram-negative bacteria is due to the physical exclusion of the mostly 
lipophilic drugs like penicillin G, linezolid, oxacillin, nafcillin, macrolides, cloxacillin by the 
outer membrane.  With the outer membrane disrupted E. coli are vulnerable to these agents 
[278].   Inactivating AcrB in the presence of an intact outer membrane also results in 
sensitivity of E. coli to these drugs [279].   
AcrB of E. coli has extremely wide substrate specificity for common antibiotics and 
dyes, detergents and even solvents.  AcrD, on the other hand, specifically pumps out 
aminoglycosides.  There are several chromosomal genes coding for these pumps and their 
expressions are increased in response to regulators or due to mutations so that the bacteria 
can become more resistant to almost all antimicrobial agents in a single step. 
Drugs can also be captured from the periplasmic space by at least some RND 
pumps.  Consequently, these pumps not only prevent the entry of drugs but also extrude 
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agents, such as β-lactams that target periplasmic substrates.  Carbenicillin, a drug 
impermeable to the inner membrane due to having two carboxylate groups is another 
example of an RND substrate [277].  Large periplasmic extramembrane and mutantions in 
this domain show altered substrate specificities [280].  The RND tripartite pumps allow 
collaborative drug-export with simple pumps that can extrude their substrate drugs only into 
the periplasm [281].  
The structure of the outer membrane channel TolC exists as a trimer with a single β-
barrel and a remarkably long (~70-Å) periplasmic extension in the form of long α-helical 
bundles [282].  Similarly, AcrB exists as a trimer with a periplasmic portion as large as its 
transmembrane portion and the top of the periplasmic domain had a dimension similar to the 
α-helical bundle of TolC [283].  Co-crystallization of AcrB with various drugs suggested that 
drugs could diffuse through the enclosed area in the pump, the vestibule and be captured 
into the central cavity so they can leave the cell [284].  Also, crystallizing mutants of the 
AcrB altered at one of the putative residues involved in proton translocation showed only 
minimal conformational alterations in the periplasmic domain.  This result suggested that the 
central cavity is the main site of substrate binding followed by its extrusion [285].  In addition, 
two substrates, minocycline, and doxorubicin, cocrystalized with AcrB were found in 
somewhat different parts of the cavity, which explains the range of AcrB specificity.  For 
example, the pocket with hydrophobic surface in AcrB favors lipophilic substrates.  In the 
bound state, an expanded binding pocket with several aromatic residues was found nearby 
the enclosed periplasmic domain that opens a pathway between the binding pocket and the 
vestibule.  In the efflux mode, the binding pocket was shown much narrower and the 
pathway to the vestibule was closed as expected for peristaltic movement [286].  Therefore, 
the opening and closing of the large external cleft in the periplasmic domain is proposed to 
confer a cyclic motion.  By homology modeling it was shown that the hypothetical binding 
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pocket of AcrD was indeed the binding site of AcrB, pumping out basic and hydrophilic 
aminoglycosides, and it contains many electronegative atoms in the binding pocket [287].  
Also, in the same study, AcrD was shown that it could capture aminoglycosides from both 
periplasm and cytoplasm and export out of the bacteria [287]. 
In clinic, RND pumps make major contributions to both intrinsic and elevated 
resistance to relevant pathogens [288-290].  For example, AcrA overproduction was 
confirmed responsible for high-level of fluoroquinolone resistance in clinical isolates of E. 
coli [291].  Fluoroquinolone resistance in P. aeruginosa is rapidly increasing and efflux 
pumps are major contributors in most cases [290].  Lately, adding disinfectants to household 
products like soaps has become increasingly popular.  However, this may bring another 
huge problem because these compounds may place evolutionary selection pressure for 
pump overproducing microbial mutants that could become pathogenic [292].  Therefore, 
people need to use detergents with precaution as they do for antibiotics. 
Fifth category: The MATE (multidrug and toxin extrusion) family of efflux 
transporters includes NorM of Vibrio parahaemolyticus, a protein with 12 transmembrane 
helices, pumps out mainly hydrophilic fluoroquinolones, cationic drugs and ethidium in 
exchange for the influx of sodium ions [293].  Also, a similar MATE family pump was found 
in Bacteroides fragilis [294].  The E. coli homolog of NorM, YdhE was also shown to pump 
out aminoglycosides [295].  
Physiological Functions of Efflux Pumps 
Because the genes that encode most efflux pumps that contribute to drug resistance 
were already present in the chromosomal of bacterial strains isolated long before the 
antibiotic era, the RND-type multidrug pumps could not have primary functions against 
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antibiotics.  Therefore, multidrug efflux pumps must have had natural physiological functions 
other than the extrusion of exogenous chemicals.   
The roles of some pumps are known for normal bacterial physiology and for others a 
normal physiological role is speculated based on the operon they are in or some other 
feature or combination of features of the gene or protein.  For example, the MFS pump in B. 
subtilis was found in an operon that detoxifies spermidine, implying that MFS pump had role 
in that detoxification pathway [296].  Secondly, AcrB was shown to protect E. coli against 
bile salts and detergents, which are highly abundant where the bacteria live [297].  Similarly, 
Pseudomonas putida can tolerate high concentrations of solvents and was shown to 
achieve this via RND transporters optimized for the efflux of solvents [298].  Also, as their 
name includes, RND transporters are involved in the secretion of nodulation factors or 
lipochitin oligosaccharides by Rhizobium [299].  Lastly, RND pumps play role in protecting 
the bacteria against plant secondary metabolites [263]. 
In M. tuberculosis there are many examples of RND transporters, two of which are 
exemplified here.  Firstly, MmpL7 is involved in the export of complex, apolar lipid, 
phthiocerol dimycocerosate [300] and secondly, MmpL8 exports 2,3-diacyl-α,α′-trehalose-2′-
sulfate, a precursor of sulfatides [301].  
Multidrug Resistance in Cancer Therapy 
As in the case of bacteria, cancer cells can develop multidrug resistance (MDR) and 
it is still one of the major problems in clinical anticancer therapy despite the recent advances 
in cancer treatment.  MDR is mainly facilitated by the members of the adenosine 
triphosphate (ATP)-binding cassette (ABC) superfamily proteins including P-glycoprotein (P-
gp or MDR1) [249], MRP family members [302] and MXR (ABCG2) [303].   
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ABC-transporters were the first transporters identified as critical in multidrug-resistant 
phenotype in an in vitro model.  This membrane protein family includes the well-known drug 
efflux pump MDR1/P-glycoprotein (MDR1/P-gp or ABCB1).  The MDR1/P-gp was isolated in 
1979 [304] and later found to be encoded by the MDR1 gene, the ABCB1 gene [305].  A 
huge number of other multidrug-resistant human and mammalian cells were found to be 
over-expressing the MDR1 [306-308].  In these cells, the MDR1 functions as a drug efflux 
pump that causes a dramatic decrease in intracellular drug concentration; thus, the extruded 
antineoplastic agents can no longer act on their target molecules.  The MDR phenotype is 
characterized by a typical cross resistance pattern against a variety of anticancer agents like 
vinca alkaloids, epipodophyllotoxins, anthracyclines, or taxanes, and the reversibility by 
verapamil and cyclosporin A derivatives [257, 309-311].  Beside the cytoplasmic membrane, 
these efflux pumps were found in both the nuclear membrane [312] and vesicular 
membranes [313].  So far, 49 different transporter proteins have been identified as ABC 
transporters in humans [314]. 
In general, ABC-transporters function as ATP-dependent drug efflux pumps and 
have a highly conserved consensus sequence designated as the ATP-binding cassette 
(ABC) or nucleotide binding domain (NBD).  The ABC domain contains two short peptide 
motifs, both involved in ATP binding and common in all nucleotide-binding proteins [315].  
Another consensus sequence is called the ABC signature [316] and is unique in ABC 
domains.  The ABC-transporter is different from the other NBD containing proteins because 
it includes a hydrophobic transmembrane domain (TMD) that is usually composed of at least 
six transmembrane (TM) α-helices.  These TMDs are the specificity determinants for the 
substrate to be transported.  The human MDR1/P-gp consists of two TMD and two NBD 
within 1280 amino acids residues.  It has been shown to be intrinsically over-expressed in 
tissues such as colon, kidney, breast and results in a primary multidrug-resistant phenotype 
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[309, 317, 318].  These data indicate that MDR1/Pgp-mediated MDR is the primary cause of 
poor treatment of MDR1/P-gp-positive tumors 
In 1992, ABC-transporters of the MRP (ABCC) subfamily were identified as the 
mediators of a multidrug-resistance [319].  In addition to the two TMD/two NBD core of 
MDR1/P-gp, MRP1, 2, 3, 6, and 7 have an additional NH2-proximal TMD0 domain consisting 
of 5 TM α-helices.  MRP4, 5, 8, and 9 lack the TMD0 domain.  MRP1– 8, but not MRP9, 
have been determined to export any type of anticancer compound.  MRPs can pump out 
organic anions and several Phase II metabolic products including anthracyclines, Vinca 
alkaloids, Epipodophyllotoxins, and methotrexate [320].  Although MRP1 expression was 
analyzed in breast cancer [321] and ovarian cancer [322], the role of MRP1 in clinical MDR 
remains to be elucidated due to inconsistent data between MRP1 expression and its clinical 
outcome.   
MRP2 or ABCC2 was originally identified as a platinum drug transporter [323], but it 
also has the ability to extrude MRP1 substrates [320].  During normal physiology, it 
transports bilirubin glucuronide into the bile canaliculi of the liver from the apical membranes 
of hepatocytes and disorders of MRP2 activity results in accumulation of bilirubin 
glucuronide and unconjugated bilirubin in the liver known as Dubin-Johnson syndrome 
(DJS).  MRP2 expression was detected in breast cancer [324] and ovarian carcinoma [325].   
MRP3 (ABCC3) has less affinity for anticancer agents than MRP1 and 2 and it only 
confers low levels of resistance to Epipodophyllotoxins and Vinca alkaloids [326].  In 
contrast to MRP1 and 2, MRP3 does not require glutathione for drug transport. MRP3 is 
usually expressed at the basolateral surface of hepatocytes [327], where it may pump 
organic anions into the sinusoidal blood.  Although MRP3 was detected in breast cancer 
[328], primary ovarian cancer [329], pancreatic carcinoma [330], and glioma [331], so far no 
link between MRP3 and clinical parameters has been demonstrated.  
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MRP4, 5, and 8, (ABCC4, ABCC5, ABCC11) mainly transport purine and pyrimidine 
nucleosides as well as their cyclic derivatives [326, 332, 333].  The MRP4 transcripts 
predominantly localized in prostate and kidney whereas MRP5 is generally seen in 
urogenital tissue [334][51] although both can be detected in various tissues [302].  Also, 
MRP8 is assumed to be expressed widely in human cancer tissues [332].  
MRP6 (ABCC6) can act as a drug efflux pump and mediates low levels of resistance 
to some epipodophyllotoxins, anthracyclines and cisplatin, in vitro [335].  Its physiological 
substrates are hydrophobic organic anions including cyclic peptides and glutathione 
conjugates but not glucuronate conjugates.  In contrast to the early studies indicating that 
MRP6 expression was limited primarily to the liver and, to a lesser extent, to the kidney, 
more recent data showed a widespread distribution pattern of MRP6 expression [336].  So 
far, no clear MRP6 levels could be detected in frozen sections of human tumor samples 
from different tissues, indicating that the contribution of MRP6 to drug-resistance may be 
rather limited [337].  However, MRP7 can be found in cancer cell lines to mediate resistance 
against taxanes and Vinca alkaloids [332, 338]. 
BCRP (breast cancer resistance protein) or ABCG2 is the most important drug efflux 
pump in the context of anticancer drug resistance.  It was identified by three independent 
studies [339-341].  The pump protein of 72 kDa has a NBD and a TMD probably to form 
homodimers in an active transport complex [342].  BCRP expression was found in various 
normal tissues including placenta, colon, small and large intestine, sebaceous glands, islet 
and acinar cells of the pancreas, hepatocytes and biliary canaliculi, alveolar pneumocytes, 
breast tissue, venous endothelium, and in capillaries, zona reticularis of the adrenal gland, 
cortical tubules of the kidney, and prostate epithelium, suggesting a protective role for 
ABCG2 [343, 344].  It was shown that BCRP secreted xenotoxins, including carcinogens 
  
65 
and anticancer drugs, into milk [345].  BCRP was detected in AML and acute lymphoblastic 
leukemia (ALL) [346, 347]. 
Other human ABC-transporters were found to transport antineoplastic agents in vitro.  
Over-expression of ABC2 (ABCA2) contributes to estramustine resistance [348], ABC3 
(ABCA3) was associated with resistance to doxorubicin [349].  Over-expression of both 
TAP1 (transporter associated with antigen presentation) and TAP2 results in increased 
resistance to mitoxantrone or etoposide [350, 351].  Similarly, in vitro studies indicated that 
MDR3/P-gp (ABCB4) contribute to resistance to taxanes and Vinca alkaloids [352] in 
coordination with BSEP (ABCB11) that is also involved in resistance to taxanes [353, 354].  
Overexpression of MTABC3 (ABCB6) was determined in cell lines resistant to cisplatin [355] 
or camptothecin [356]. 
Doxorubicin transport and chemo-resistance in human melanoma cells is mediated 
by ABCB5 [357].  A subpopulation of tumor-initiating cells having cancer stem cell (CSC)-
like characteristics in a human malignant melanoma was shown to express ABCB5 [358].  
ABCB5-positive tumor cells were correlated with clinical melanoma progression having 
greater tumorigenic capacity than cells negative for ABCB5 in melanoma patients.  A 
monoclonal antibody against ABCB5 induced antibody-dependent cell mediated cytotoxicity 
in ABCB5-expressing melanoma subpopulations. This result and the capability of ABCB5 to 
mediate drug resistance suggest that this transporter may have important implications for 
clinical management of melanoma patients.   
Unfortunately, the exact role of many members of the ABC-transporter family in drug 
resistance is still unknown or not fully understood.  It is not even known if the same ABC-
transporter is active from the beginning of drug treatment to the end.  Therefore, the 
possibility that the high expression of all three pumps, MDR1/P-gp, MRP1 and BCRP, that 
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export mitoxantrone are taken into consideration during the mithridatism period in response 
to mitoxantrone [359]. 
In cancer cell lines, increased expression of other drug resistance associated 
transporters were detected in addition to the expected well characterized ABC-transporters.  
These results suggest that drug resistance in cancer cells can be mediated through several 
ABC-transporters of unknown function [360, 361].  In acute lymphoblastic leukemia (ALL) 
and breast cancer patients, the expression of most ABC-transporters was detected and 
comparison of their expression levels in drug treated and untreated tumors showed an 
unexpected similarity [362].  Overall, the results suggest that drug-resistant phenotypes 
have shown high expression level of ABC-transporters. 
A non-ABC-transporter, RALBP1 (RLIP76), which is a 76 kDa Ral-binding Rho/Rac-
GAP and Ral effector protein, can transport structurally unrelated amphiphilic 
chemotherapeutic drugs such as doxorubicin and glutathione-electrophile conjugates [363, 
364].  RALBP1 transports xenobiotics in an ATP-dependent manner as in the case of the 
ABC-transporters, but it lacks sequence homology with the ABC-transporter family members.  
This transporter has multiple motifs including tyrosine kinase phosphorylation sites, two 
distinct ATP-binding domains, a H(+)-ATPase domain, a Rho/Rac GAP domain and a Ral 
effector domain binding motif.  As for many of the other efflux pumps, so far no data are 
available as to whether this non-ABC-transporter has an impact on clinical drug resistance, 
despite a current study demonstrating RALBP1 expression in human tumors such as 
ovarian cancer [365].  
Inhibitors of Efflux Pumps 
In cancer treatment: MDR pump antagonists have been developed and used in 
cancer treatment in order to reverse the effects of efflux pumps, [366].   Cyclosporine A, 
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verapamil, biricodar citrate, valspodar, tariqudar and quercetin are some of these drugs that 
were successfully used as MDR antagonists to increase the efficacy of the antineoplastic 
agents,  
The development of Pgp inhibitors has a history of about 30 years.  In the 1980s, 
cyclosporine A, verapamil and tamoxifen were identified as Pgp substrates and developed 
to inhibit Pgp.  However, their mechanism of action was to compete with the cytotoxic 
compounds.  Thus, a high concentration was needed to observe their effect, which in turn 
caused serious toxicity in vivo [367].  In addition, these compounds were later identified as 
substrates of other transporters and inhibitors of enzymes that could have been the reason 
for unexpected high toxicity in vivo [368]. 
Second-generation Pgp modulators have been developed to decrease the toxicity of 
the first Pgp antagonists.  Biricodar citrate, a pipecolinate derivative, binds Pgp with a very 
high affinity and reverses its activity [369].  Also, valspodar (PSC 883), a derivative of 
cyclosporin D is 20-fold more effective than cyclosporin A [370].  These second-generation 
drugs had much better inhibitory activity than the early-generation Pgp inhibitors. However, 
these second-generation drugs unfortunately still had serious limitations.  For example, 
valspodar was identified as the inhibitor of cytochrome P450 3A4 (CYP3A4), which also 
metabolizes paclitaxel and vinblastine [371].  This created a serious problem for the patients 
who used paclitaxel and vinblastine.  The biochemical analysis showed that these patients 
had higher serum concentrations of these cytotoxic agents because valspodar was acting as 
an inhibitor of CYP3A4 [372].  As a result, there was a need for the development of new 
drugs. 
Third-generation Pgp modulators, tariqudar [373], the cyclopropyldibenzosuberane 
zosuquidar [374], laniquidar [375], have been developed that do not have the side effects of 
the second and early-generation MDR pump antagonists.   They were required to have 
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better selectivity and specificity for the pump and lower potential to interact with CYP3A4.  
Tariqudar (XR9576) was one these third generation drugs and it specifically and 
noncompetitively bound to the pump with better affinity than the intrinsic substrates of the 
pump [373, 375].  It also exhibited an enhanced clearance time compared to cyclosporine A 
[376], and it did not affect the activity of CYP3A4.  The other two compounds share similar 
properties of better selectivity, specificity and also less chance to affect off-target activities.  
Therefore, third-generation drugs offer better advantages over the drugs developed earlier.  
However, there are still more MDR antagonists under development. 
More recently, quercetin, a flavonoid derivative, was used as a chemosensitizer to 
modulate cancer multidrug resistance (MDR) [314{Chen,  #3295].  It is ubiquitously found in 
onion, apples, tea and berries and shown to have antioxidative, anti-inflammatory and 
vasodilating effects [377].  Biochemical and biophysical studies indicated that it had also the 
ability to sensitize multiple MDR pumps including Pgp [378, 379], BCRP [380] and MRP 
[381] to several chemotherapeutic anticancer drugs.  Also, in vivo studies indicated that it 
could increase the bioavailability of tamoxifen, paclitaxel, etoposide, diltiazem and 
fexofenadine [314].  The mechanism of its action was shown to competitively inhibit the 
MDR pumps by binding to the ATP binding site or substrate binding site [382, 383].  
Ongoing clinical trials with third-generation inhibitors, quercetin and some unmentioned 
compounds are hoped to result in better survival rates in patients with cancer.  
To treat Bacterial Infections: The clinical significance of antibiotic resistance has 
prompted the search for efflux pumps inhibitors (EPIs), which can be used against multidrug 
resistant bacteria.  These EPIs include both natural and synthetic molecules.  Reserpine 
and berberine are isolated from plants and used as natural products to inhibit MDR pumps.  
Synthetic compounds include the hybrid compounds of berberine, phenylalanyl arginyl β-
naphthylamide (PAβN), arylpiperazine derivatives and derivatives of the expelled antibiotics.   
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Plants have been shown to produce several of these natural inhibitors.  Reserpine is 
one of the first EPIs, which was isolated from dried root of Rauwolfia serpentina. It has 
demonstrated an ability to potentiate antibiotics in Gram-positive bacteria by inhibiting the 
MDR pumps [384].  Also, another plant species called Berberis fremontii was found to 
simultaneously produce an antibiotic berberine and an MDR inhibitor 5’-
methoxyhydnocarpin (5′-MHC).  5′-MHC blocks the NorA pump to overcome the problem of 
antibacterial resistance but 5′-MHC alone had no antimicrobial activity.  Later 5′-MHC was 
found to potentiate the antibiotic action of berberine and other NorA substrates against S. 
aureus [385].  The latter has aided the development of synthetic EPIs. 
One of the synthetic compounds was obtained by conjugating berberine with an 
inhibitor of major facilitator MDRs, INF 55.  Then, it was used as a successful hybrid 
compound with activity against resistant bacteria [386].  Recently, the 13-substituted 
berberine-NorA inhibitor hybrid was synthesized via chemically linking berberine with the 
NorA inhibitor, 5-nitro-2-phenyl-1H-indole.  This new compound had 382-fold more activity 
than the parent antibacterial berberine against S. aureus [387]. 
Another synthetic EPI is called phenylalanyl arginyl β-naphthylamide (PAβN). It is a 
substrate for the MexAB-OprM pumps and was shown to increase the activity of levo-
floxacin in resistant P. aeruginosa strains [388].  In addition, high concentration of PAβN 
was able to disrupt the membrane integrity that directly influences the drug penetration [388].  
Later, a better compound called MC-04, 124 was identified with better stability and lower 
toxicity than PAβN against P. aeruginosa.  Finally, to inhibit MexAB–OprM efflux pump, the 
pyridopyrimidine derivatives have extensively been assayed to improve their inhibitory 
activities against the P. aeruginosa [389].  Nevertheless, these compounds had intrinsic 
problems like low solubility, low stability and high affinity towards the serum proteins.  New 
derivatives of these compounds are under development with  
  
70 
There have been EPIs developed against E. coli with high expression of efflux 
pumps.  For example, 3-arylpiperidine, an arylpiperazine derivative, helped to reverse the 
effect of MDRs and potentiate novobiocin in E. coli [390, 391].  Also, bacteria exposed to 1-
(1-naphthyl)piperazine and 1-(1-naphthylmethyl)-piperazine have got more susceptible to 
levofloxacin, clarithromycin, linezolid, oxacillin, rifampin, chloramphenicol and tetracycline 
[391].  Finally, scientists successfully developed efflux pump inhibitors by using derivatives 
of the expelled-antibiotics.  For example, tetracycline-analogues were used to restore the 
activity of tetracycline activity against resistant bacteria [392].  Based on the developed 
antagonists, the main mechanism of inhibition is so much dependent on molecular volume, 
charge and the position of substituted groups that these new compounds can induce steric 
hindrances that collapse the drug transport.  Therefore, inhibition of efflux pumps can 
restore the drug susceptibility of resistant strains and thus some of the old antibiotics can 
again be effective.  In spite of these developments in EPIs, none of the above-mentioned 
inhibitors are yet in clinical use. 
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MECHANISMS OF RESISTANCE TO AMINOGLYCOSIDES 
Aminoglycosides are compounds characterized by the presence of an aminocyclitol 
ring bound to aminosugars.  Their bactericidal activity is attributed to the irreversible binding 
to the ribosomes so they exhibit a broad antimicrobial spectrum.  Aminoglycosides have 
been extensively used against aerobic and facultative aerobic Gram-negative bacilli and 
some Gram-positive staphylococci but they are not active against anaerobes and rikettsia.   
The misuse of aminoglycoside antibiotics has resulted in bacteria that have evolved 
mechanisms for eliminating the effects of aminoglycosides.  Three major mechanisms of 
resistance to aminoglycosides have been recognized; ribosome alteration, decreased 
permeability and inactivation of the drugs by aminoglycoside modifying enzymes.  Ribosome 
alteration is not so common due to the fact that the function of the rRNA and ribosomes is 
central in the protein synthesis process which is so well-conserved across many generations 
that it cannot be impaired by the possibility of such structural alteration/s.  However, 
aminoglycoside inactivation has the most clinical importance since the genes encoding 
aminoglycoside modifying enzymes can easily be transferred by plasmids and/or 
transposons.  Each of these mechanisms is discussed below with common examples given. 
Ribosome Alteration 
The first mechanism to get aminoglycoside resistance is through modifying the 
ribosomes.  Once there occur modifications or mutations either in rRNA or in the ribosomal 
proteins, where aminoglycosides bind, they lower binding affinity of the aminoglycoside 
antibiotics.  For example, alterations in ribosomes resulted in problems in treating 
Mycobacterium tuberculosis with streptomycin, which was primarily used for tuberculosis 
treatment.  Streptomycin functions by binding to 16S rRNA in ribosomes and all 
streptomycin-resistant M. tuberculosis strains were found to have point mutations leading to 
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alterations in the streptomycin binding site.  These changes resulting in streptomycin 
resistance were identified in both 16S rRNA and ribosomal proteins, S4, S12 and S5 of the 
30S ribosomal subunit [393, 394].    
In addition to mutations in the ribosomes of M. tuberculosis, mutations in the 
ribosomal protein L22 confer resistance to erythromycin in Thermus thermophilus.  The X-
ray crystal structure of this protein indicated that the mutations causing resistance to 
erythromycin were found on a beta-hairpin loop of L22 [395].  Also, it was postulated that 
this region was in close proximity to the erythromycin-binding site near the peptidyl transfer 
center [395]. 
Methylation of 16S rRNA at N7 of guanine residues can result in aminoglycoside 
resistant strains, as well.  However, this is mainly confined to aminoglycoside-producing 
organisms and it gives high-level of resistance to the actions of these antibiotics [396-398],  
Therefore, these organisms can still survive in the presence of the aminoglycosides via 
modifications as in the case of mutations in the ribosomes other aminoglycoside resistant 
organisms. 
Decreased Permeability and Active Extrusion 
The second way to obtain aminoglycoside resistance is via decreasing permeability 
of the aminoglycosides [288, 289].  Absence of or alteration in the aminoglycoside transport 
system, inadequate membrane potential, modification in the lipopolysacchaccarides (LPS) 
phenotype can be given as mechanisms for decreasing the aminoglycoside permeability 
[399].  It was also shown that these mechanisms were chromosomally mediated thus result 
in cross-reactivity to all aminoglycosides and that why it was highly significant in the clinic 
[400].   
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Some strains of Pseudomonas aeruginosa and other Gram-negative bacilli can be 
given as examples which obtained aminoglycoside resistance due to a transport defect, 
inadequate membrane potential or membrane impermeabilization [401].  Active efflux of the 
aminoglycosides is the other mechanism how some organisms can get resistance as it was 
explained in detail in the previous section.  In sum, bacteria can get resistant to the 
aminoglycosides with decreasing the permeability of the aminoglycosides which in turn 
lowers the amount of available aminoglycoside in bacteria. 
Inactivation of aminoglycosides 
Inactivation of aminoglycosides is achieved by the expression and action of three 
major classes of aminoglycoside-modifying enzymes based on their modification type: 
acetyltransferases (AAC), nucleotidyltransferases or adenyltransferases (ANT), 
phosphotransferases (APH).  These modifications occur through N-acetylation, O-
nucleotidylation and O-phosphorylation as shown in Figure 2.  In each class, there are 
enzymes with different side chain specificities for aminoglycoside modifications.  For 
example, there are four nucleotidyltransferases [ANT(6), ANT(4’), ANT(3’’) and ANT(2’’)], 
seven phosphotransferases [APH(3’), APH(2’’), APH(3’’), APH(6), APH(9), APH(4) and 
APH(7’’)] and four acetyltransferases [AAC(2’), AAC(6’), AAC(1), and AAC(3)].  Also, there 
are bifunctional enzymes like AAC(6’)-APH(2’’), which can sequentially acetylate and 
phosphorylate its substrates [402, 403] and  ANT(3’’)-AAC(6’), which can acetylate the 6'-
amine of kanamycin-A and adenylate the 3''- and 9-hydroxyl groups of streptomycin and 
spectinomycin [404].   
Structural studies indicated that mainly the same electrostatic interactions that drove 
the evolution of aminoglycosides for binding to the ribosomal sites also appeared to be 
similarly involved in evolution of the resistance enzymes [405-407].  The presence of acidic 
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groups in the aminoglycoside binding sites appears to be a recurring theme in 
aminoglycoside-modifying enzymes.  For example, the active site of the enzyme APH(3’)-
IIIa has excessive negative charge distribution that provides favorable interactions with 
positively charged aminoglycosides [406, 408].  Also, the amines in aminoglycosides, 
important for binding to 16S rRNA A-site, appeared to be significant for recognition of the 
drugs by the resistance enzymes [409]. 
ANT(2”)-Ia is frequently associated with clinical resistance in Gram-negative 
organisms to gentamicin and tobramycin [410].  This enzyme transfers mononucleotide to 
the aminoglycosides as shown in Figure 2 and it shows a broad substrate specificity [411].  
Mechanistically, its rate limiting step was shown as the release of adenylated 
aminoglycoside [412].  The structure of ANT(2’’) has not been known, yet. 
However, the structure of ANT(4’)-Ia in complex with kanamycin and the non-
hydrolyzable ATP analogue (AMPCPP) has shed light on the details of the mechanism of 
action for the aminoglycoside nucleotidyltransferases (ANTs) [407].  For example, the active 
enzyme was found as a dimer with two heterodimeric catalytic sites.  These catalytic sites 
contain residues from one monomer predominantly contributing to the magnesium and ATP 
binding as well as with residues from the other monomer for aminoglycoside binding [407, 
413].  Acidic residues generate a negatively charged surface patch to guide the positively 
charged aminoglycosides to the active site to facilitate their binding.  For example, a 
glutamic acid (Glu145) residue functioned as the general base to deprotonate the incoming 
aminoglycoside thereby increasing the nucleophilicity of the attacking 4’ hydroxyl group.  
The substrate promiscuity of this class of enzymes can also be attributed to the abundance 
of negatively charged hydrogen acceptor groups which can therefore accommodate a broad 
spectrum of positively charged aminoglycoside substrates.  Also, a positively charged 
residue, Lys149, was in close proximity with the α-phosphate group of ATP and it possibly 
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increased electrophilicity of this phosphate, making it more susceptible to nucleophilic 
attacks.  Such a direct attack mechanism was shown to be consistent with the results of 
stereochemical analysis of the ANT(2”)-Ia reaction with tobramycin, as well [414].  
Bioinformatics studies revealed that part of the ANT(4’) fold was also present in the 
crystal structure of eukaryotic DNA polymerase β (Polβ), an enzyme catalyzing O-
nucleotidyl transfer, despite their minimal sequence similarity with ANTs [415].  This 
structural similarity implied that these two nucleotide monophosphate transferases are 
evolutionary related, suggesting the existence of a Polβ-like nucleotidyltransferase 
superfamily.  Later studies indicated that this superfamily involved enzymes, which took role 
in antibiotic resistance (ANT(4’)-Ia), DNA replication and repair (DNA Polβ), chromatin 
remodeling (yeast Trf4p) and signal transduction (GlnD) [416].  This superfamily is well-
conserved through all three kingdoms of life and has members in bacteria, archaea and 
eukaryotes. 
Aminoglycoside acetyltransferases (AACs) are the second type of enzymes which 
catalyzes the acetyl-CoA dependent N-acetylation of aminoglycosides as shown in Figure 2 
and Figure 3.  They can modify amino groups on both the aminoglucose ring [AAC(6’), 
AAC(2’)] and the 2-deoxystreptamine ring [AAC(1), AAC(3)].  Both AAC(6’) and AAC(3) 
were found as common resistance elements in Gram-negative bacteria [410].  Also, in 
Gram-positive bacteria, AAC(6’)-Ie was found as the major acetyltransferase associated with 
clinically important gentamicin resistance [410].  Acetylation of the amine groups directly 
results in unfavorable steric clashes and electrostatic attraction in the A-site RNA [417].  As 
mentioned earlier, there are also bifunctional enzymes one of which is AAC(6’)-APH(2”), N-
terminal portion of which was formed by AAC(6’)-Ie [418]. It was later found in Gram-positive 
Staphylococci, Enterococci, and Streptococci [419]. 
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Structural studies indicated the positioning of the aminoglycosides butirosin-A and 
isepamicin when bound to AAC(6’)-Ii in NMR experiments [420].  These studies suggest that 
the 4,5- and 4,6-disubstituted aminoglycosides bind differently to AAC(6’)-Ii.  For example, 
4,5 disubstituted aminoglycoside butirosin-A has only one binding mode whereas 4,6-
disubstituted aminoglycoside isepamicin has two alternative conformations, one of which 
may be a non-productive complex.  
Also, two available crystal structures resolved the position and orientation of the CoA 
and AcCoA groups for AAC(3)-Ia and AAC(6’)-Ii, respectively.  A negatively charged surface 
patch, analogous to the aminoglycoside binding region of ANT(4’)-Ia, was found next to the 
CoA sulfur atom in both AAC(3)-Ia and AAC(6’)-Ii.  Therefore, it is probable that the two AAC 
enzymes share similar strategy to interact with aminoglycoside substrates with the ANT 
enzymes.  The common structural motif found in AAC(3)-Ia and AAC(6’)-Ii was also present 
in other enzymes like yeast histone acetyltransferase (yHat1) and the fungal N-
myristoyltransferase (Nmt) [421, 422].  These observations confirmed that both AAC(3)-Ia 
and AAC(6’)-Ii belong to the GCN5-related N-acetyltransferase (GNAT) superfamily [423].   
Aminoglycoside phosphotransferases (APHs) catalyze the ATP-dependent O-
phosphorylation of aminoglycoside hydroxyl groups as shown in Figure 2 and Figure 3.  
They are found in both Gram-negative and Gram-positive bacteria.  In the Gram-positive 
cocci, the bifunctional enzyme AAC(6’)-APH(2”) has the main mechanism for gentamicin 
resistance [419].  Additionally, the C-terminal APH(2”) activity of this enzyme has a broad 
substrate specificity and also has the capacity to phosphorylate aminoglycosides on the 6-
aminohexose and 3-aminohexose rings. 
The APH(3’)s are the most abundant class of APH enzymes that modify both the 
neomycin and kanamycin-class aminoglycosides.  APH(3’)-IIIa was shown to have a broad 
substrate specificity with the capacity to modify many aminoglycosides with an exclusion of 
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the clinically important gentamicin-C.  Kanamycin-class aminoglycosides are 
phosphorylated on the 3’-hydroxyl, whereas neomycin-class antibiotics on both 3’- and 5”-
positions.  Even, some of these groups can be readily di-phosphorylated.  The crystal 
structure of APH(3)-IIIa in complex with ADP indicated the nucleotide binding site was deep 
in the active site with only the terminal phosphate group being solvent accessible.  This 
indicated that the ADP-release was the rate limiting step of the reaction [406].   
Very similar to the ANTs and AACs, aminoglycoside binding pocket of APHs 
contains acidic residues, which supplies electrostatic potential for guiding and binding a 
broad spectrum of aminoglycosides.  The crystal structure also revealed the order of 
substrate binding and product release.  ATP binds prior to the aminoglycoside, and release 
of the phosphorylated aminoglycoside precedes that of ADP, because binding of an 
aminoglycoside obstructs the entrance to the nucleotide binding pocket [406].   
Nearly 50% of these enzymes exhibited a fold identical to that of protein kinases 
despite the lack of amino acid sequence similarity (<3%) [424].  Even, APH(3’)-IIIa was 
found more closely related to the eukaryotic protein kinases than type II  phosphatidylinositol 
phosphate kinase (PIPKII) [425].  This similarity between aminoglycoside 
phosphotransferases and protein kinases suggests an evolutionary link between these two 
classes of proteins.  Therefore, it was not surprising that they showed similar sensitivity to 
the inhibitors.  For example, the flavanoids quercein, genestein and the isoquinoline 
sulfonamides, which inhibit protein kinases as competitive inhibitors of ATP binding, 
exhibited similar effects on the APHs [426].  
Modified aminoglycosides lose their ability to bind to the target A-site due to 
unfavorable steric and/or electrostatic interactions as a result of the action of AACs, ANTs 
and APHs.  For example, acetylation of the amine group at position 3 on paromomycin 
results in unfavorable steric clashes and electrostatic attraction in the A-site RNA [417].  
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Another example is the phosphorylation at the 3’ position by the action of APH (3’) in which 
the phosphate group at the 3’ position would interfere with the binding due to the repulsive 
electrostatic and steric interactions between the phosphate backbone of the rRNA, resulting 
in very poor binding [417].  Tobramycin and gentamicin-C are susceptible to five or six of 
these aminoglycoside modifying enzymes as summarized in Figure 3.  However, a 
kanamycin-A derivative with acylated amino group at position 1 by 4-amino-2-
hydroxybutyrate, amikacin was saved from the enzymatic modification at multiple positions.  
Also, the aminohydroxybutyryl modification at position 1 of amikacin appears to fit well into 
the extended cleft and the amino group in this moiety may also enhance binding of amikacin 
to rRNA through electrostatic interactions [417].  Consequently, greater than 80% of the 
gentamicin-resistant members of Enterobacteriaceae and 25 to 85% of Pseudomonas 
aeruginosa-resistant strains were found sensitive to amikacin [427, 428]. 
In conclusion, the structural information of all three classes of aminoglycoside 
modifying enzymes has detailed the mechanism of resistance to this important class of 
antibiotics.  Therefore, the combination of both structural and functional analysis should 
enhance the rational design of novel inhibitors of these enzymes, which can be identified 
from other protein kinase inhibitors.  Potent and selective inhibitors of these enzymes have 
the potential to block aminoglycoside resistance in vivo and therefore could extend the 
clinical use of aminoglycosides.  Finally, rational design of new aminoglycoside derivatives 
that are not susceptible to the enzymes can be synthesized and tested. 
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APPROACHES TO PREVENT DRUG RESISTANCE 
Antibiotic resistance is a huge concern for treating disease. The increasing number 
of antimicrobial resistant strains in the hospitals makes it even harder to fight bacterial 
infections.  These resistant bacteria easily multiply and spread their antibacterial immunity to 
others through lateral gene transfer.  We can prevent the development of antibiotic 
resistance by three main ways; 1) simultaneous application of  multiple drugs, 2) minimizing 
our use of antibiotics or 3) by developing alternative ways to treat bacterial infections.   
Simultaneous Use of Multiple Drugs 
The chance of drug resistance can sometimes be minimized by simultaneous use of 
multiple antibiotics.  This works because individual mutations can be independent and may 
only create resistance to one group of drug.  Hence, if the individual mutants are killed by 
another in the mix of drugs, then mutations cannot accumulate to produce a resistant 
progeny.  This strategy was used successfully against tuberculosis [429, 430].  The 
combination of isoniazid and ethambutol, which have two independent targets and modes of 
action, has been used to treat tuberculosis in many countries [430].  However, cross 
resistance where mutations confer resistance to two or more treatments can be problematic.  
Interventions in improving antimicrobial use and blocking transmission of resistant 
organisms are required to combat antimicrobial resistance. 
Reducing Antibiotic Use 
The main cause of antibiotic resistance is the overuse of antibiotics; thus, it is highly 
recommended to use antibiotics when only necessary.  They should not be taken for a viral 
infection like a cold, a cough or the flu.  This is because every time antibiotics are used, they 
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create a selective pressure on bacteria that promotes the expansion of resistant strains 
[431].  However, one can minimize this selection with the proper use of antibiotics. 
Alternative Ways to Combat Bacterial Infections 
The emergence of bacterial strains resistant to many available drugs pointed to the 
need for new therapeutic methods.  These new therapeutic methods have included bacterial 
interference, phage therapy, bacterial vaccines, cationic peptides and cyclic D,L-α-peptides. 
Bacterial interference  
Bacterial interference can be achieved by inoculating hosts with nonpathogenic 
bacteria, which can prevent infection by pathogenic strains.  The mechanism of bacterial 
interference is the competition of nonpathogenic bacteria with pathogenic bacteria for 
nutrients and adhesion receptors, necessary to establish infections and propagate diseases.  
Nonpathogenic bacteria may also attack the pathogenic strains through secretion of 
antimicrobial compounds.  This treatment has had promising results in infections of the gut, 
urogenital tract, and wound sites. A major advantage is that these nonpathogenic species 
do not stimulate the host’s immune system and do not promote selection for antibiotic 
resistance [432]. 
Bacteriophage Therapy  
Bacteriophages are viruses known as natural killers of bacteria by directing the host 
to make their own viral proteins.  Their first use as therapeutics was in prophylaxis against 
cholera, typhoid fever and dysentery [433].  Now phage therapy once again has come to the 
forefront due to emergence of multi-drug-resistant bacteria [434].  In this way, specific 
strains of pathogens can be targeted through manipulation of phage DNA.  Exponential 
growth and natural mutational ability make bacteriophages great candidates for counter 
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attacking bacterial resistance; however, the technology is still developing and may be a way 
off before seeing daily use. 
Bacterial vaccines 
Developing bacterial vaccines has become a popular idea with the advent of 
complete microbial genomic sequencing and with the understanding of virulence regulatory 
mechanisms [435].  By scanning the bacterial genome, drugs can be developed through 
target-based approaches.  Also, protein sequences can be identified to stimulate a 
protective immune response against specific bacterial strains.  Regulatory genes that control 
virulence protein production are excellent vaccine candidates for priming the human immune 
system or inhibiting virulence production [435].  Bacterial genomics can also be used to 
detect conserved sequences from bacterial species and strains worldwide.  Therefore, this 
technology can yield clinical vaccine candidates. 
Cationic peptides 
Cationic peptides are either found throughout nature in the immune systems of 
bacteria, plants, invertebrates and vertebrates and have been used to kill bacterial cells.  
They have both hydrophobic and hydrophilic characteristics Cationic peptides have several 
mechanisms of action involving interaction with the bacterial cell membrane leading to cell 
death [436].  From a therapeutic standpoint, these proteins have a great promise, as they 
have co-evolved with bacteria yet have maintained the ability to target pathogenic bacteria. 
Cyclic D,L-α-peptides  
Cyclic D,L-α-peptides are synthetic and amphipathic molecules with cell membrane 
disruption capabilities.  As their name implies these natural peptides are composed of 
alternating D and L amino acids with cyclic structures [437].  Some have been specifically 
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engineered to target Gram-positive and Gram-negative bacterial membranes but not 
mammalian cell membranes.  In contrast to any other known class of peptides, these 
peptides can self-assemble into flat ring shaped nanotubes, which specifically target and 
puncture bacterial cell membranes.  Therefore, they increase membrane permeabilityand 
collapse transmembrane ion potentials causing rapid cell death [438].  The effectiveness of 
this class of materials was shown against lethal methicillin-resistant Staphylococcus 
aureus (MRSA) infections in mice [438]. These molecules can be used as complement to 
the current naturally derived antibiotics and help to combat a variety of existing and 
emerging antibacterial drug resistant infectious diseases. 
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AMINOGLYCOSIDES AS INTRACELLULAR RNA APTAMER TARGETS 
Aminoglycosides are one of the most important families of antibiotics and are mostly 
derived from Streptomyces spp.  They are water soluble and their polycationic nature results 
in a very broad-spectrum of anti-bacterial activity against both Gram-positive and Gram-
negative bacteria, mycobacteria and protozoa.  Aminoglycosides contain 4 to 6 amino 
groups that are protonated at biological pH [417], which makes them very effective RNA 
targeting reagents.  The neomycin-class of aminoglycosides, considered the most effective 
bactericidal agents, has been used clinically for many years.   
Aminoglycoside antibiotics are composed of amino sugars linked to a 
deoxystreptamine ring (ring II) (Figure 4).  The structurally conserved elements, among the 
neomycin-class aminoglycosides, rings I and II and the amino groups at positions 1 and 3 
on the ring II (Figure 4) are essential for their RNA interactions [439].  Several analogues 
based on the neamine core have comparable or better binding affinities and antimicrobial 
activities than the parent aminoglycosides [440, 441].  With these conserved chemical units, 
they exhibit high affinities for certain parts of the prokaryotic ribosomal RNA (rRNA) based 
on electrostatic and hydrogen-bonding interactions [186].  Biochemical and biophysical 
techniques have located the site of aminoglycoside binding to an adenine-rich internal loop 
at the 3’end of helix 44 in 16S rRNA in the 30S ribosomal subunit that consists of 16S rRNA 
and 21 proteins [132, 133].  Helix 44 binds aminoglycosides via its major groove and 
contacts the codon-anticodon complex with its minor groove and is therefore part of the 
aminoacyl-transfer RNA site (A-site) [186].  The consequence of aminoglycoside binding 
near the A-site, which is in the decoding region, is a conformational change in the 16S RNA, 
displacing two well-conserved adenine residues (A1492 and A1493) towards the minor 
groove [186, 439, 442-444].  This conformational change converts the A-site into a higher 
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affinity environment for tRNA-mRNA interaction, thereby lowering the rejection rate of near-
cognate tRNAs [445].  Therefore, aminoglycosides inhibit translocation of the tRNA-mRNA 
from A-site to peptidyl-tRNA site (P-site) [446] and this causes a second consequence of 
misreading of the genetic code [447, 448].  Besides causing misreading, paromomycin and 
neomycin can arrest assembly of the 30S subunit formation resulting in the accumulation of 
a 21S subunit, which is a possible precursor of the 30S subunit [449].  In addition, they 
preferentially interact with prokaryotic ribosomes over the eukaryotic ones [450].  As a result, 
bacteria cannot synthesize vital proteins for their survival and they eventually die.  Therefore, 
aminoglycosides have been successfully used against bacterial infections for over 50 years 
[408]. 
The continuing emergence of new strains of pathogens that are resistant to existing 
antibiotics drives the discovery of new antibiotics that overcome the resistance.  One 
approach, which has seen some success, is to modify the existing antibiotics for more 
effective target binding.  Aminoglycosides have been the subject of many modifications to 
enhance their interactions with the variety of RNA targets [451-456].   Some of these RNA-
aminoglycoside interactions have been structurally characterized.  All of these NMR solution 
structures share general features with the aminoglycosides located in the major groove.  
This specific feature of helix 44 is not shared by the standard A-type RNA helix, which has 
too narrow and deep a major groove to bind aminoglycosides [457]. 
Nucleotides at the cores of aptamers play multiple structural roles by directly 
contacting the ligands and by participating in various mismatch and triplex Watson-Crick 
base pairing as well as other interactions with neighboring nucleotides in the aptamer.   In 
this way, they determine the overall structure of the binding site, which, for aminoglycosides, 
is mainly a widened major groove with irregular helical domains.  Such overlapping features 
of aminoglycoside binding sites resulting in similar binding site characteristics that may 
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make it difficult to generate altered specificities for aminoglycosides within the same 
structural context [458]. 
Small RNA aminoglycoside interactions have been widely recognized over the past 
few decades [450, 459, 460].  In addition to their ribosomal targets, aminoglycosides can 
also bind, in a saturable fashion and with high affinity, to a variety of RNA structures 
containing non-duplex elements, such as bulges or interior loops.  For example, they have 
been reported to interact with the type 1 human immunodeficiency virus (HIV-1) RNAs; Rev-
responsive element (RRE) [461] and trans-activating region (TAR) [462, 463].  One target is 
the Rev-response element (RRE) in type 1 human immunodeficiency virus (HIV-1) RNA, 
which binds the Rev protein and plays an essential role in regulating maturation of the viral 
RNAs [461].  Binding by aminoglycosides inhibited the Rev-RRE interaction and thus the 
production of HIV-1 in tissue culture [461].  Another stem-loop structure, the trans-activation 
response (TAR) element in HIV-1 RNA, is also targeted by aminoglycosides [464].  The 
interaction between TAR and the Tat protein is crucial in the initiation of RNA transcription 
for viral replication, which can be inhibited by neomycin-B [465].  Besides viral RNAs, 
aminoglycosides can target the following intracellular RNAs; iron response element (IRE) 
[455], the site 1 mRNA of thymidylate synthase (TS) [466], group 1 self-splicing introns [467, 
468], RNase P [469] and tRNAPhe [470].  As a result of these intracellular RNA targeting 
capabilities, aminoglycosides have been successfully used as therapeutic agents for several 
decades. 
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TABLES AND FIGURES 
Table 1. Comparison of aptamers and antibodies.  
  Aptamers Antibodies 
Targets From ions to cells Haptens or macromolecules 
Molecular Weight 5-25 kDa 150 kDa 
Affinity pM to µM pM to nM 
Specificity Distinguish a single 
chemical group and 
conformational differences 
Distinguish a single chemical 
group and conformation 
difference 
Immunogenicity No Yes 
Tissue penetration Moderate ability to enter 
into cells and tissues 
Difficult to penetrate into tissues 
and cells 
Function in cells Yes No 
Antidotes Antisense oligonucleotides No 
Breaking the interface 
between 
macromolecules  
Capable of blocking 
macromolecule 
interactions 
Capable of blocking 
macromolecule interactions 
Screening/Selection 
process 
Combinatorial chemistry 
selection (in vitro)  
Selection  in biological systems 
(in vivo)  
Chemical modifications Various and convenient Limited and not convenient 
Thermostability Stable Temperature sensitive 
Shelf life Unlimited ~5 years 
Active half life  Hours to days Hours to days 
Cost Relatively expensive Very expensive 
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Table 2. Metabolite binding riboswitches.  
Riboswitch Ligand Organism PDB ID References 
Amino Acid Class 
   Glycine 
   Lysine 
   S-adenosylhomocysteine 
Purine Class 
   Guanine 
   Guanine 
   Adenine 
   PreQ1  
    
   PreQ1 
   c-di-GMP 
SAM-I 
   SAM-I 
   SAM-I (A94G) 
   SAM-I 
   SAM-II 
    
   SAM-III 
Cofactors 
   FMN 
   TPP 
   TPP 
Small Molecules 
   glmS 
   M-box 
Engineered in vitro 
   Neomycin-B 
   Tetracycline 
   Theophylline 
   Hoechst 
   Malachite green (MG) 
 
Glycine 
Lysine 
SAH 
 
Hypoxanthine  
Guanine  
Adenine  
PreQ0, PreQ1  
 
PreQ1 
c-di-GMP 
 
SAM 
_ 
SAM 
SAM 
 
SAM 
 
FMN 
TPP 
TPP 
 
GlcN6P 
Mg(II) 
 
Ribostamycin 
Tetracycline 
Theophyliine 
Hoechst-33342 
Tetramethylrosamine 
 
 
Vibrio cholerae 
Thermotoga maritima 
Ralstonia solanacearum 
 
Bacillus subtilis  
B. subtilis 
Vibrio vulnificus  
Thermoanaerobacter 
tengcongensis 
B. subtilis 
V. cholerae 
 
T. tengcongensis 
T. tengcongensis 
B. subtilis 
Sargasso Sea 
metagenome 
Enterococcus faecalis 
 
Fusobacterium nucleatum 
Arabidopsis thaliana 
Escherichia coli 
 
T. tengcongensis 
B. subtilis 
 
Saccaromyces cerevisiea 
S. cerevisiae 
 
E. coli 
S. cerevisiae 
 
3OWW, 3OX0 
3D0U, 3D0X 
3NPQ 
 
1U8D 
1Y27 
1Y26 
3Q50, 3Q51 
 
3FU2 
3MXH 
 
2GIS 
3IQP 
3NPB 
2QWY 
 
3E5C 
 
3F2Q 
2CKY 
2GDI 
 
2Z75 
2QBZ 
 
2KXM 
 
 
[471] 
[472] 
[473] 
 
[474] 
[475] 
[476] 
[477] 
 
[478] 
[479] 
 
[480] 
[481] 
[482] 
[483] 
 
[484] 
 
[485] 
[486] 
 
 
[487] 
[488] 
 
[489] 
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Figure 1. Predicted Secondary Structures of the studied Small RNAs.  
  
 
Secondary structures of the RNAs that have been shown to interact tightly with 
aminoglycoside antibiotics are summarized here. The RNAs shown in the top row are the 
RNA motifs found in nature whereas the bottom row shows the in vitro selected RNAs. The 
secondary structures of these small RNAs were predicted using RNAStructure 4.6 software 
and were then re-constructed in Adobe Illustrator®. 
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Figure 2. Type of possible enzymatic modification of aminoglycoside antibiotics. 
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Figure 3. Sites of enzymatic modifications on kanamycin-B by various 
aminoglycoside-modifying enzymes. 
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Figure 4. Chemical structures of the neomycin- and kanamycin-class 
aminoglycosides that interfere with the decoding process and with ribozyme catalysis. 
 
Aminoglycoside antibiotics share similar chemical groups. A) Neomycin-class 
antibiotics have a 2-deoxystreptamine (ring II), disubstituted at positions 4 (ring I) and 5 
(rings III and IV) and B) kanamycin-class antibiotics have a 2-deoxystreptamine (ring II), 
disubstituted at positions 4 (ring I) and 6 (rings III and IV).   
  
92 
 
REFERENCES 
1. Gesteland, R.F., T. Cech, and J.F. Atkins, The RNA world : the nature of modern RNA 
suggests a prebiotic RNA. 3rd ed. Cold Spring Harbor monograph series ; 43. 2006, 
Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. xxiii, 768 p. 
2. Kruger, K., Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA 
intervening sequence of tetrahymena. Cell, 1982. 31: p. 147-157. 
3. Guerrier-Takada, C., et al., The RNA moiety of ribonuclease P is the catalytic subunit of 
the enzyme. Cell, 1983. 35(3 Pt 2): p. 849-57. 
4. Levine, E. and T. Hwa, Small RNAs establish gene expression thresholds. Curr Opin 
Microbiol, 2008. 11(6): p. 574-9. 
5. Tuerk, C. and L. Gold, Systematic evolution of ligands by exponential enrichment: RNA 
ligands to bacteriophage T4 DNA-polymerase. Science, 1990. 249: p. 505-510. 
6. Ellington, A.D. and J.W. Szostak, In vitro selection of RNA molecules that bind specific 
ligands. Nature, 1990. 346(6287): p. 818-22. 
7. Keefe, A.D., S. Pai, and A. Ellington, Aptamers as therapeutics. Nat Rev Drug Discov, 
2010. 9(7): p. 537-50. 
8. Blank, M. and M. Blind, Aptamers as tools for target validation. Curr Opin Chem Biol, 
2005. 9(4): p. 336-42. 
9. Sefah, K., et al., Nucleic acid aptamers for biosensors and bio-analytical applications. 
Analyst, 2009. 134(9): p. 1765-75. 
10. Nimjee, S.M., et al., The potential of aptamers as anticoagulants. Trends Cardiovasc 
Med, 2005. 15(1): p. 41-5. 
11. Zhang, Z., M. Blank, and H.J. Schluesener, Nucleic acid aptamers in human viral 
disease. Arch Immunol Ther Exp (Warsz), 2004. 52(5): p. 307-15. 
12. Jarosch, F., K. Buchner, and S. Klussmann, In vitro selection using a dual RNA library 
that allows primerless selection. Nucleic Acids Res, 2006. 34(12): p. e86. 
13. Lee, J.F., et al., Aptamer database. Nucleic Acids Res, 2004. 32(Database issue): p. 
D95-100. 
14. Jenison, R.D., et al., High-resolution molecular discrimination by RNA. Science, 1994. 
263(5152): p. 1425-9. 
  
93 
15. Geiger, A., et al., RNA aptamers that bind L-arginine with sub-micromolar dissociation 
constants and high enantioselectivity. Nucleic Acids Res, 1996. 24(6): p. 1029-36. 
16. Seiwert, S.D., et al., RNA aptamers as pathway-specific MAP kinase inhibitors. Chem. 
Biol., 2000. 7: p. 833-843. 
17. Drolet, D.W., et al., Pharmacokinetics and safety of an anti-vascular endothelial growth 
factor aptamer (NX1838) following injection into the vitreous humor of rhesus 
monkeys. Pharm Res, 2000. 17(12): p. 1503-10. 
18. Teyssier, E., Temperature-sensitive mutation in yeast mitochondrial ribosome-recycling 
factor (RRF). Nucleic Acids Res., 2003. 31: p. 4218-4226. 
19. Kaul, M. and D.S. Pilch, Thermodynamics of aminoglycoside-rRNA recognition: the 
binding of neomycin-class aminoglycosides to the A site of 16S rRNA. Biochemistry, 
2002. 41(24): p. 7695-706. 
20. Wlotzka, B., et al., In vivo properties of an anti-GnRH Spiegelmer: an example of an 
oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A, 2002. 
99(13): p. 8898-902. 
21. Vinores, S.A., Pegaptanib in the treatment of wet, age-related macular degeneration. Int 
J Nanomedicine, 2006. 1(3): p. 263-8. 
22. Presta, L.G., Engineering of therapeutic antibodies to minimize immunogenicity and 
optimize function. Adv Drug Deliv Rev, 2006. 58(5-6): p. 640-56. 
23. Griffiths, A.D., et al., Isolation of high affinity human antibodies directly from large 
synthetic repertoires. Embo J, 1994. 13(14): p. 3245-60. 
24. Yang, X., et al., Selection of thioaptamers for diagnostics and therapeutics. Ann N Y 
Acad Sci, 2006. 1082: p. 116-9. 
25. Baskerville, S., M. Zapp, and A.D. Ellington, Anti-Rex aptamers as mimics of the Rex-
binding element. J Virol, 1999. 73(6): p. 4962-71. 
26. Blind, M., W. Kolanus, and M. Famulok, Cytoplasmic RNA modulators of an inside-out 
signal-transduction cascade. Proc Natl Acad Sci U S A, 1999. 96(7): p. 3606-10. 
27. Werstuck, G. and M.R. Green, Controlling gene expression in living cells through small 
molecule-RNA interactions. Science, 1998. 282(5387): p. 296-8. 
28. Asahara, T., et al., VEGF contributes to postnatal neovascularization by mobilizing bone 
marrow-derived endothelial progenitor cells. Embo J, 1999. 18(14): p. 3964-72. 
  
94 
29. Peng, L., et al., A combined atomic force/fluorescence microscopy technique to select 
aptamers in a single cycle from a small pool of random oligonucleotides. Microsc 
Res Tech, 2007. 70(4): p. 372-81. 
30. Sassanfar, M. and J.W. Szostak, An RNA motif that binds ATP. Nature, 1993. 364(6437): 
p. 550-3. 
31. Joyce, G.F., Forty years of in vitro evolution. Angew Chem Int Ed Engl, 2007. 46(34): p. 
6420-36. 
32. Lato, S.M., A.R. Boles, and A.D. Ellington, In vitro selection of RNA lectins: using 
combinatorial chemistry to interpret ribozyme evolution. Chem Biol, 1995. 2: p. 291-
303. 
33. Kwon, M., et al., In vitro selection of RNA against kanamycin B. Mol Cells, 2001. 11(3): p. 
303-11. 
34. Cowan, J.A., et al., Recognition of a cognate RNA aptamer by neomycin B: quantitative 
evaluation of hydrogen bonding and electrostatic interactions. Nucleic Acids Res, 
2000. 28(15): p. 2935-42. 
35. Griffin, L.C., et al., In vivo anticoagulant properties of a novel nucleotide-based thrombin 
inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. 
Blood, 1993. 81(12): p. 3271-6. 
36. Richardson, F.C., et al., Quantification of 2'-fluoro-2'-deoxyuridine and 2'-fluoro-2'-
deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. 
Chem Res Toxicol, 2002. 15(7): p. 922-6. 
37. Pieken, W.A., et al., Kinetic characterization of ribonuclease-resistant 2'-modified 
hammerhead ribozymes. Science, 1991. 253(5017): p. 314-7. 
38. Burmeister, P.E., et al., Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. 
Chem Biol, 2005. 12(1): p. 25-33. 
39. Pagratis, N.C., et al., Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA 
inhibitors of keratinocyte growth factor. Nat Biotechnol, 1997. 15(1): p. 68-73. 
40. Lin, Y. and S.D. Jayasena, Inhibition of multiple thermostable DNA polymerases by a 
heterodimeric aptamer. J Mol Biol, 1997. 271(1): p. 100-11. 
41. White, R.R., et al., Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA 
aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A, 2003. 100(9): p. 5028-
33. 
  
95 
42. Schmidt, K.S., et al., Application of locked nucleic acids to improve aptamer in vivo 
stability and targeting function. Nucleic Acids Res, 2004. 32(19): p. 5757-65. 
43. Eulberg, D. and S. Klussmann, Spiegelmers: biostable aptamers. Chembiochem, 2003. 
4(10): p. 979-83. 
44. Nolte, A., et al., Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat 
Biotechnol, 1996. 14(9): p. 1116-9. 
45. Williams, K.P., et al., Bioactive and nuclease-resistant L-DNA ligand of vasopressin. 
Proc Natl Acad Sci U S A, 1997. 94(21): p. 11285-90. 
46. Kato, Y., et al., New NTP analogs: the synthesis of 4'-thioUTP and 4'-thioCTP and their 
utility for SELEX. Nucleic Acids Res, 2005. 33(9): p. 2942-51. 
47. King, D.J., et al., Novel combinatorial selection of phosphorothioate oligonucleotide 
aptamers. Biochemistry, 1998. 37(47): p. 16489-93. 
48. Floege, J., et al., Novel approach to specific growth factor inhibition in vivo: antagonism 
of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol, 
1999. 154(1): p. 169-79. 
49. Green, L.S., et al., Nuclease-resistant nucleic acid ligands to vascular permeability 
factor/vascular endothelial growth factor. Chem Biol, 1995. 2(10): p. 683-95. 
50. Di Giusto, D.A., et al., Multitasking by multivalent circular DNA aptamers. Chembiochem, 
2006. 7(3): p. 535-44. 
51. Umekage, S. and Y. Kikuchi, Production of circular form of streptavidin RNA aptamer in 
vitro. Nucleic Acids Symp Ser (Oxf), 2006(50): p. 323-4. 
52. Umekage, S. and Y. Kikuchi, Production of circular streptavidin RNA aptamer in vivo. 
Nucleic Acids Symp Ser (Oxf), 2007(51): p. 391-2. 
53. Brody, E.N. and L. Gold, Aptamers as therapeutic and diagnostic agents. J Biotechnol, 
2000. 74(1): p. 5-13. 
54. Clark, S.L. and V.T. Remcho, Aptamers as analytical reagents. Electrophoresis, 2002. 
23(9): p. 1335-40. 
55. Burgstaller, P., A. Girod, and M. Blind, Aptamers as tools for target prioritization and 
lead identification. Drug Discov Today, 2002. 7(24): p. 1221-8. 
56. Nimjee, S.M., C.P. Rusconi, and B.A. Sullenger, Annu. Rev. Med., 2005. 56: p. 555. 
57. Tombelli, S., M. Minunni, and M. Mascini, Analytical applications of aptamers. Biosens. 
Bioelectron., 2005. 20: p. 2424-2434. 
  
96 
58. Proske, D., et al., Aptamers--basic research, drug development, and clinical applications. 
Appl Microbiol Biotechnol, 2005. 69(4): p. 367-74. 
59. Nutiu, R. and Y. Li, Aptamers with fluorescence-signaling properties. Methods, 2005. 
37(1): p. 16-25. 
60. de Franciscis, V., et al., Aptamers as innovative diagnostic and therapeutic agents in the 
central nervous system. CNS Neurol Disord Drug Targets, 2009. 8(5): p. 393-401. 
61. Huizenga, D.E. and J.W. Szostak, A DNA aptamer that binds adenosine and ATP. 
Biochemistry, 1995. 34(2): p. 656-65. 
62. Brackett, D.M. and T. Dieckmann, Aptamer to ribozyme: the intrinsic catalytic potential of 
a small RNA. Chembiochem, 2006. 7(5): p. 839-43. 
63. Burgstaller, P., M. Kochoyan, and M. Famulok, Structural probing and damage selection 
of citrulline- and arginine-specific RNA aptamers identify base positions required for 
binding. Nucleic Acids Res, 1995. 23(23): p. 4769-76. 
64. Vianini, E., M. Palumbo, and B. Gatto, In vitro selection of DNA aptamers that bind L-
tyrosinamide. Bioorg Med Chem, 2001. 9(10): p. 2543-8. 
65. Jeong, S., et al., In vitro selection of the RNA aptamer against the Sialyl Lewis X and its 
inhibition of the cell adhesion. Biochem Biophys Res Commun, 2001. 281(1): p. 237-
43. 
66. Wang, Y. and R.R. Rando, Specific binding of aminoglycoside antibiotics to RNA. Chem 
Biol, 1995. 2: p. 281-290. 
67. Hamasaki, K., et al., Minimal RNA constructs that specifically bind aminoglycoside 
antibiotics with high affinities. Biochemistry, 1998. 37(2): p. 656-63. 
68. Yang, Y., et al., Structural basis of ligand discrimination by two related RNA aptamers 
resolved by NMR spectroscopy. Science, 1996. 272(5266): p. 1343-7. 
69. Lorsch, J.R. and J.W. Szostak, In vitro selection of RNA aptamers specific for 
cyanocobalamin. Biochemistry, 1994. 33(4): p. 973-82. 
70. Bell, S.D., et al., RNA molecules that bind to and inhibit the active site of a tyrosine 
phosphatase. J Biol Chem, 1998. 273(23): p. 14309-14. 
71. Kensch, O., et al., J. Biol. Chem., 2000. 275: p. 18271. 
72. Lebruska, L.L. and L.J. Maher, 3rd, Selection and characterization of an RNA decoy for 
transcription factor NF-kappa B. Biochemistry, 1999. 38(10): p. 3168-74. 
  
97 
73. Fabbrizio, E., et al., Inhibition of mammalian cell proliferation by genetically selected 
peptide aptamers that functionally antagonize E2F activity. Oncogene, 1999. 18(30): 
p. 4357-63. 
74. Zhai, G., et al., Characterization of RNA aptamer binding by the Wilms' tumor 
suppressor protein WT1. Biochemistry, 2001. 40(7): p. 2032-40. 
75. Urvil, P.T., et al., Selection of RNA aptamers that bind specifically to the NS3 protease 
of hepatitis C virus. Eur J Biochem, 1997. 248(1): p. 130-8. 
76. Boiziau, C., et al., DNA aptamers selected against the HIV-1 trans-activation-responsive 
RNA element form RNA-DNA kissing complexes. J Biol Chem, 1999. 274(18): p. 
12730-7. 
77. Darfeuille, F., et al., RNA and N3'-->P5' kissing aptamers targeted to the trans-activation 
responsive (TAR) RNA of the human immunodeficiency virus-1. Nucleosides 
Nucleotides Nucleic Acids, 2001. 20(4-7): p. 441-9. 
78. Yamamoto, R., et al., A novel RNA motif that binds efficiently and specifically to the Ttat 
protein of HIV and inhibits the trans-activation by Tat of transcription in vitro and in 
vivo. Genes Cells, 2000. 5(5): p. 371-88. 
79. Sekkai, D., et al., In vitro selection of DNA aptamers against the HIV-1 TAR RNA hairpin. 
Antisense Nucleic Acid Drug Dev, 2002. 12(4): p. 265-74. 
80. Sayer, N., et al., Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU 
glycoprotein, gp120. Biochem Biophys Res Commun, 2002. 293(3): p. 924-31. 
81. Hicke, B.J., et al., DNA aptamers block L-selectin function in vivo. Inhibition of human 
lymphocyte trafficking in SCID mice. J Clin Invest, 1996. 98(12): p. 2688-92. 
82. Ulrich, H., et al., In vitro selection of RNA aptamers that bind to cell adhesion receptors 
of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem, 2002. 277(23): p. 
20756-62. 
83. Jenison, R.D., et al., Oligonucleotide inhibitors of P-selectin-dependent neutrophil-
platelet adhesion. Antisense Nucleic Acid Drug Dev, 1998. 8(4): p. 265-79. 
84. Jellinek, D., et al., Inhibition of receptor-binding by high-affinity RNA ligands to vascular 
endothelial growth-factor. Biochemistry, 1994. 33: p. 10450-10456. 
85. Binkley, J., et al., RNA ligands to human nerve growth factor. Nucleic Acids Res, 1995. 
23(16): p. 3198-205. 
86. Bell, C., et al., Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in 
vitro. In Vitro Cell Dev Biol Anim, 1999. 35(9): p. 533-42. 
  
98 
87. Hartmann, G., et al., Cytokines and therapeutic oligonucleotides. Cytokines Cell Mol 
Ther, 1997. 3(4): p. 247-56. 
88. Hamaguchi, N., A. Ellington, and M. Stanton, Aptamer beacons for the direct detection 
of proteins. Anal Biochem, 2001. 294(2): p. 126-31. 
89. Blank, M., et al., Systematic evolution of a DNA aptamer binding to rat brain tumor 
microvessels. selective targeting of endothelial regulatory protein pigpen. J Biol 
Chem, 2001. 276(19): p. 16464-8. 
90. Nutiu, R. and Y. Li, Structure-switching signaling aptamers. J Am Chem Soc, 2003. 
125(16): p. 4771-8. 
91. Li, W., et al., FRET-based aptamer probe for rapid angiogenin detection. Talanta, 2008. 
75(3): p. 770-4. 
92. Kim, D., Y.Y. Jeong, and S. Jon, A drug-loaded aptamer-gold nanoparticle bioconjugate 
for combined CT imaging and therapy of prostate cancer. ACS Nano, 2010. 4(7): p. 
3689-96. 
93. Jayasena, S.D., Clin. Chem., 1999. 45: p. 1628. 
94. Murphy, M.B., et al., An improved method for the in vitro evolution of aptamers and 
applications in protein detection and purification. Nucleic Acids Res., 2003. 31: p. 
e110. 
95. Dick, L.W., Jr. and L.B. McGown, Aptamer-enhanced laser desorption/ionization for 
affinity mass spectrometry. Anal Chem, 2004. 76(11): p. 3037-41. 
96. Fredriksson, S., et al., Nat. Biotechnol., 2002. 20: p. 473. 
97. Stojanovic, M.N. and D.M. Kolpashchikov, Modular aptameric sensors. J. Am. Chem. 
Soc., 2004. 126: p. 9266-9270. 
98. Stojanovic, M.N. and D.W. Landry, Aptamer-based colorimetric probe for cocaine. J Am 
Chem Soc, 2002. 124(33): p. 9678-9. 
99. Smith, D., et al., In vitro selection of RNA-based irreversible inhibitors of human 
neutrophil elastase. Chem Biol, 1995. 2(11): p. 741-50. 
100. Charlton, J., G.P. Kirschenheuter, and D. Smith, Highly potent irreversible inhibitors of 
neutrophil elastase generated by selection from a randomized DNA-valine 
phosphonate library. Biochemistry, 1997. 36(10): p. 3018-26. 
101. Lin, Y., et al., Peptide conjugation to an in vitro-selected DNA ligand improves enzyme 
inhibition. Proc Natl Acad Sci U S A, 1995. 92(24): p. 11044-8. 
  
99 
102. Giver, L., et al., Selection and design of high-affinity RNA ligands for HIV-1 Rev. Gene, 
1993. 137(1): p. 19-24. 
103. Allen, P., S. Worland, and L. Gold, Isolation of high-affinity RNA ligands to HIV-1 
integrase from a random pool. Virology, 1995. 209(2): p. 327-36. 
104. Tuerk, C., S. MacDougal, and L. Gold, RNA pseudoknots that inhibit human 
immunodeficiency virus type 1 reverse transcriptase. Proc. Natl Acad. Sci. USA, 
1992. 89: p. 6988-6992. 
105. Lato, S.M., et al., Boron-containing aptamers to ATP. Nucleic Acids Res, 2002. 30(6): p. 
1401-7. 
106. Coughlin, S.R., Thrombin signalling and protease-activated receptors. Nature, 2000. 
407(6801): p. 258-64. 
107. White, W., Generation of species cross-reactive aptamers using 'toggle' SELEX. Mol. 
Ther., 2001. 4: p. 567-573. 
108. Ng, E.W. and A.P. Adamis, Targeting angiogenesis, the underlying disorder in 
neovascular age-related macular degeneration. Can J Ophthalmol, 2005. 40(3): p. 
352-68. 
109. Ruckman, J., et al., 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid 
form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding 
and VEGF-induced vascular permeability through interactions requiring the exon 7-
encoded domain. J Biol Chem, 1998. 273(32): p. 20556-67. 
110. Tucker, C.E., et al., Detection and plasma pharmacokinetics of an anti-vascular 
endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J 
Chromatogr B Biomed Sci Appl, 1999. 732(1): p. 203-12. 
111. Watson, S.R., et al., Anti-L-selectin aptamers: binding characteristics, pharmacokinetic 
parameters, and activity against an intravascular target in vivo. Antisense Nucleic 
Acid Drug Dev, 2000. 10(2): p. 63-75. 
112. Burke, D.H. and J.H. Willis, Recombination, RNA evolution, and bifunctional RNA 
molecules isolated through chimeric SELEX. Rna, 1998. 4(9): p. 1165-75. 
113. Di Giusto, D.A. and G.C. King, Construction, stability, and activity of multivalent circular 
anticoagulant aptamers. J Biol Chem, 2004. 279(45): p. 46483-9. 
114. Elbaz, J., et al., Parallel analysis of two analytes in solutions or on surfaces by using a 
bifunctional aptamer: applications for biosensing and logic gate operations. 
Chembiochem, 2008. 9(2): p. 232-9. 
  
100 
115. Santulli-Marotto, S., et al., Multivalent RNA aptamers that inhibit CTLA-4 and enhance 
tumor immunity. Cancer Res, 2003. 63(21): p. 7483-9. 
116. McNamara, J.O., et al., Multivalent 4-1BB binding aptamers costimulate CD8+ T cells 
and inhibit tumor growth in mice. J Clin Invest, 2008. 118(1): p. 376-86. 
117. Davis, K.A., et al., Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids 
Res, 1996. 24(4): p. 702-6. 
118. Babendure, J.R., S.R. Adams, and R.Y. Tsien, Aptamers switch on fluorescence of 
triphenylmethane dyes. J Am Chem Soc, 2003. 125(48): p. 14716-7. 
119. Fusco, D., et al., Single mRNA molecules demonstrate probabilistic movement in living 
mammalian cells. Curr Biol, 2003. 13(2): p. 161-7. 
120. Tucker, B.J. and R.R. Breaker, Riboswitches as versatile gene control elements. Curr 
Opin Struct Biol, 2005. 15(3): p. 342-8. 
121. Grate, D. and C. Wilson, Laser-mediated, site-specific inactivation of RNA transcripts. 
Proc Natl Acad Sci U S A, 1999. 96(11): p. 6131-6. 
122. Grate, D. and C. Wilson, Inducible regulation of the S. cerevisiae cell cycle mediated by 
an RNA aptamer-ligand complex. Bioorg Med Chem, 2001. 9(10): p. 2565-70. 
123. Buskirk, A.R., A. Landrigan, and D.R. Liu, Engineering a ligand-dependent RNA 
transcriptional activator. Chem Biol, 2004. 11(8): p. 1157-63. 
124. Wang, S., et al., Knocking down gene function with an RNA aptamer expressed as part 
of an intron. Nucleic Acids Res, 2010. 38(15): p. e154. 
125. Burke, D.H. and D.G. Nickens, Expressing RNA aptamers inside cells to reveal 
proteome and ribonome function. Brief Funct Genomic Proteomic, 2002. 1(2): p. 169-
88. 
126. Jain, C. and J.G. Belasco, Rapid genetic analysis of RNA-protein interactions by 
translational repression in Escherichia coli. Methods Enzymol, 2000. 318: p. 309-32. 
127. Nickens, D.G., J.T. Patterson, and D.H. Burke, Inhibition of HIV-1 reverse transcriptase 
by RNA aptamers in Escherichia coli. RNA, 2003. 9: p. 1029-1033. 
128. Chaloin, L., et al., Endogenous expression of a high-affinity pseudoknot RNA aptamer 
suppresses replication of HIV-1. Nucleic Acid Res., 2002. 30: p. 4001-4008. 
129. Joshi, P.J., T.W. North, and V.R. Prasad, Aptamers directed to HIV-1 reverse 
transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA 
in blocking HIV-1 replication. Mol Ther, 2005. 11(5): p. 677-86. 
  
101 
130. Yang, C., et al., RNA aptamers targeting the cell death inhibitor CED-9 induce cell 
killing in Caenorhabditis elegans. J Biol Chem, 2006. 281(14): p. 9137-44. 
131. Jian, Y., et al., RNA aptamers interfering with nucleophosmin oligomerization induce 
apoptosis of cancer cells. Oncogene, 2009. 28(47): p. 4201-11. 
132. Dahlberg, A.E., The functional role of ribosomal RNA in protein synthesis. Cell, 1989. 
57(4): p. 525-9. 
133. Pfister, P., et al., The molecular basis for A-site mutations conferring aminoglycoside 
resistance: relationship between ribosomal susceptibility and X-ray crystal structures. 
Chembiochem, 2003. 4(10): p. 1078-88. 
134. Bailor, M.H., X. Sun, and H.M. Al-Hashimi, Topology links RNA secondary structure 
with global conformation, dynamics, and adaptation. Science, 2010. 327(5962): p. 
202-6. 
135. Auffinger, P., S. Louise-May, and E. Westhof, Molecular dynamics simulations of 
solvated yeast tRNA(Asp). Biophys J, 1999. 76(1 Pt 1): p. 50-64. 
136. Schneider, C., M. Brandl, and J. Suhnel, Molecular dynamics simulation reveals 
conformational switching of water-mediated uracil-cytosine base-pairs in an RNA 
duplex. J Mol Biol, 2001. 305(4): p. 659-67. 
137. Correll, C.C., I.G. Wool, and A. Munishkin, The two faces of the Escherichia coli 23 S 
rRNA sarcin/ricin domain: the structure at 1.11 A resolution. J Mol Biol, 1999. 292(2): 
p. 275-87. 
138. Muriaux, D., P. Fosse, and J. Paoletti, A kissing complex together with a stable dimer is 
involved in the HIV-1Lai RNA dimerization process in vitro. Biochemistry, 1996. 
35(15): p. 5075-82. 
139. Reblova, K., et al., Molecular dynamics simulations of RNA kissing-loop motifs reveal 
structural dynamics and formation of cation-binding pockets. Nucleic Acids Res, 
2003. 31(23): p. 6942-52. 
140. Razga, F., et al., Hinge-like motions in RNA kink-turns: the role of the second a-minor 
motif and nominally unpaired bases. Biophys J, 2005. 88(5): p. 3466-85. 
141. Gilbert, W., The RNA world. Nature, 1986. 319: p. 818. 
142. Krasovska, M.V., et al., Structural dynamics of precursor and product of the RNA 
enzyme from the hepatitis delta virus as revealed by molecular dynamics simulations. 
J Mol Biol, 2005. 351(4): p. 731-48. 
  
102 
143. Sefcikova, J., et al., The genomic HDV ribozyme utilizes a previously unnoticed U-turn 
motif to accomplish fast site-specific catalysis. Nucleic Acids Res, 2007. 35(6): p. 
1933-46. 
144. Wang, T., et al., Computational and experimental analyses converge to reveal a 
coherent yet malleable aptamer structure that controls chemical reactivity. J Am 
Chem Soc, 2009. 131(41): p. 14747-55. 
145. Stelzer, A.C., et al., Constructing atomic-resolution RNA structural ensembles using 
MD and motionally decoupled NMR RDCs. Methods, 2009. 49(2): p. 167-73. 
146. Grundy, F.J. and T.M. Henkin, The S box regulon: a new global transcription 
termination control system for methionine and cysteine biosynthesis genes in gram-
positive bacteria. Mol. Microbiol., 1998. 30(4): p. 737-49. 
147. Yarnell, W.S. and J.W. Roberts, Mechanism of intrinsic transcription termination and 
antitermination. Science, 1999. 284(5414): p. 611-5. 
148. Waters, L.S. and G. Storz, Regulatory RNAs in bacteria. Cell, 2009. 136(4): p. 615-28. 
149. Mandal, M. and R.R. Breaker, Gene regulation by riboswitches. Nature Rev. Mol. Cell 
Biol., 2004. 5: p. 451-463. 
150. Henkin, T.M., Riboswitch RNAs: using RNA to sense cellular metabolism. Genes Dev, 
2008. 22(24): p. 3383-90. 
151. Boehr, D.D., R. Nussinov, and P.E. Wright, The role of dynamic conformational 
ensembles in biomolecular recognition. Nat Chem Biol, 2009. 5(11): p. 789-96. 
152. Winkler, W.C. and R.R. Breaker, Genetic control by metabolite-binding riboswitches. 
ChemBioChem, 2003. 4: p. 1024-1032. 
153. Grundy, F.J., S.C. Lehman, and T.M. Henkin, The L box regulon: lysine sensing by 
leader RNAs of bacterial lysine biosynthesis genes. Proc Natl Acad Sci U S A, 2003. 
100(21): p. 12057-62. 
154. Mandal, M., et al., A glycine-dependent riboswitch that uses cooperative binding to 
control gene expression. Science, 2004. 306(5694): p. 275-9. 
155. Fuchs, R.T., F.J. Grundy, and T.M. Henkin, S-adenosylmethionine directly inhibits 
binding of 30S ribosomal subunits to the SMK box translational riboswitch RNA. Proc 
Natl Acad Sci U S A, 2007. 104(12): p. 4876-80. 
156. Winkler, W.C., et al., An mRNA structure that controls gene expression by binding S-
adenosylmethionine. Nat Struct Biol, 2003. 10(9): p. 701-7. 
  
103 
157. Epshtein, V., A.S. Mironov, and E. Nudler, The riboswitch-mediated control of sulfur 
metabolism in bacteria. Proc Natl Acad Sci U S A, 2003. 100(9): p. 5052-6. 
158. Wang, J.X., et al., Riboswitches that sense S-adenosylhomocysteine and activate 
genes involved in coenzyme recycling. Mol Cell, 2008. 29(6): p. 691-702. 
159. Mironov, A.S., et al., Sensing small molecules by nascent RNA: a mechanism to 
control transcription in bacteria. Cell, 2002. 111(5): p. 747-56. 
160. Nahvi, A., et al., Genetic control by a metabolite binding mRNA. Chem Biol, 2002. 9(9): 
p. 1043. 
161. Winkler, W.C., et al., Control of gene expression by a natural metabolite-responsive 
ribozyme. Nature, 2004. 428: p. 281-286. 
162. Barrick, J.E. and R.R. Breaker, The distributions, mechanisms, and structures of 
metabolite-binding riboswitches. Genome Biol, 2007. 8(11): p. R239. 
163. Sudarsan, N., et al., Riboswitches in eubacteria sense the second messenger cyclic di-
GMP. Science, 2008. 321(5887): p. 411-3. 
164. Spinelli, S.V., et al., Regulation of magnesium homeostasis in Salmonella: Mg(2+) 
targets the mgtA transcript for degradation by RNase E. FEMS Microbiol Lett, 2008. 
280(2): p. 226-34. 
165. Regulski, E.E., et al., A widespread riboswitch candidate that controls bacterial genes 
involved in molybdenum cofactor and tungsten cofactor metabolism. Mol Microbiol, 
2008. 68(4): p. 918-32. 
166. Morita, M.T., et al., Translational induction of heat shock transcription factor sigma32: 
evidence for a built-in RNA thermosensor. Genes Dev, 1999. 13(6): p. 655-65. 
167. Nechooshtan, G., et al., A pH-responsive riboregulator. Genes Dev, 2009. 23(22): p. 
2650-62. 
168. Collins, J.A., et al., Mechanism of mRNA destabilization by the glmS ribozyme. Genes 
Dev, 2007. 21(24): p. 3356-68. 
169. Wachter, A., et al., Riboswitch control of gene expression in plants by splicing and 
alternative 3' end processing of mRNAs. Plant Cell, 2007. 19(11): p. 3437-50. 
170. Bocobza, S., et al., Riboswitch-dependent gene regulation and its evolution in the plant 
kingdom. Genes Dev, 2007. 21(22): p. 2874-9. 
171. Cheah, M.T., et al., Control of alternative RNA splicing and gene expression by 
eukaryotic riboswitches. Nature, 2007. 447(7143): p. 497-500. 
  
104 
172. Mandal, M. and R.R. Breaker, Adenine riboswitches and gene activation by disruption 
of a transcription terminator. Nat Struct Mol Biol, 2004. 11(1): p. 29-35. 
173. Gelfand, M.S., et al., A conserved RNA structure element involved in the regulation of 
bacterial riboflavin synthesis genes. Trends Genet, 1999. 15(11): p. 439-42. 
174. Miranda-Rios, J., M. Navarro, and M. Soberon, A conserved RNA structure (thi box) is 
involved in regulation of thiamin biosynthetic gene expression in bacteria. Proc Natl 
Acad Sci U S A, 2001. 98(17): p. 9736-41. 
175. Corbino, K.A., et al., Evidence for a second class of S-adenosylmethionine 
riboswitches and other regulatory RNA motifs in alpha-proteobacteria. Genome Biol, 
2005. 6(8): p. R70. 
176. Fuchs, R.T., F.J. Grundy, and T.M. Henkin, The S(MK) box is a new SAM-binding RNA 
for translational regulation of SAM synthetase. Nat Struct Mol Biol, 2006. 13(3): p. 
226-33. 
177. Yousef, M.R., F.J. Grundy, and T.M. Henkin, Structural transitions induced by the 
interaction between tRNA(Gly) and the Bacillus subtilis glyQS T box leader RNA. J 
Mol Biol, 2005. 349(2): p. 273-87. 
178. Yen, L., Exogenous control of mammalian gene expression through modulation of RNA 
self-cleavage. Nature, 2004. 431: p. 471-476. 
179. Yen, L., et al., Identification of inhibitors of ribozyme self-cleavage in mammalian cells 
via high-throughput screening of chemical libraries. RNA, 2006. 12(5): p. 797-806. 
180. Isaacs, F.J., et al., Engineered riboregulators enable post-transcriptional control of 
gene expression. Nat Biotechnol, 2004. 22(7): p. 841-7. 
181. Bayer, T.S. and C.D. Smolke, Programmable ligand-controlled riboregulators of 
eukaryotic gene expression. Nat Biotechnol, 2005. 23(3): p. 337-43. 
182. Suess, B., Conditional gene expression by controlling translation with tetracycline-
binding aptamers. Nucleic Acids Res., 2003. 31: p. 1853-1858. 
183. Weigand, J.E., et al., Screening for engineered neomycin riboswitches that control 
translation initiation. RNA, 2008. 14(1): p. 89-97. 
184. Hanson, S., et al., Tetracycline-aptamer-mediated translational regulation in yeast. Mol 
Microbiol, 2003. 49(6): p. 1627-37. 
185. Harvey, A.J. and M.R. Crompton, Use of RNA interference to validate Brk as a novel 
therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. 
Oncogene, 2003. 22(32): p. 5006-10. 
  
105 
186. Fourmy, D., et al., Structure of the A site of Escherichia coli 16S ribosomal RNA 
complexed with an aminoglycoside antibiotic. Science, 1996. 274(5291): p. 1367-71. 
187. Wallis, M.G., et al., A novel RNA motif for neomycin recognition. Chem Biol, 1995. 2: p. 
543-552. 
188. Hammond, M.C., RNA folding: a tale of two riboswitches. Nat Chem Biol, 2011. 7(6): p. 
342-3. 
189. Tsien, R.Y., Imagining imaging's future. Nat Rev Mol Cell Biol, 2003. Suppl: p. SS16-21. 
190. Rosenthal, M.S., et al., Quantitative SPECT imaging: a review and recommendations 
by the Focus Committee of the Society of Nuclear Medicine Computer and 
Instrumentation Council. J Nucl Med, 1995. 36(8): p. 1489-513. 
191. Gambhir, S.S., Molecular imaging of cancer with positron emission tomography. Nat 
Rev Cancer, 2002. 2(9): p. 683-93. 
192. Ozker, K., Current developments in single photon radiopharmaceuticals for tumor 
imaging. Curr Pharm Des, 2000. 6(11): p. 1123-6. 
193. Wu, J.C., et al., Molecular imaging of cardiac cell transplantation in living animals using 
optical bioluminescence and positron emission tomography. Circulation, 2003. 
108(11): p. 1302-5. 
194. Alam, J. and J.L. Cook, Reporter genes: application to the study of mammalian gene 
transcription. Anal Biochem, 1990. 188(2): p. 245-54. 
195. de Wet, J.R., et al., Firefly luciferase gene: structure and expression in mammalian 
cells. Mol Cell Biol, 1987. 7(2): p. 725-37. 
196. Contag, C.H. and M.H. Bachmann, Advances in in vivo bioluminescence imaging of 
gene expression. Annu Rev Biomed Eng, 2002. 4: p. 235-60. 
197. Mempel, T.R., et al., In vivo imaging of leukocyte trafficking in blood vessels and 
tissues. Curr Opin Immunol, 2004. 16(4): p. 406-17. 
198. Shimomura, O., F.H. Johnson, and Y. Saiga, Extraction, purification and properties of 
aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. J 
Cell Comp Physiol, 1962. 59: p. 223-39. 
199. Morise, H., et al., Intermolecular energy transfer in the bioluminescent system of 
Aequorea. Biochemistry, 1974. 13(12): p. 2656-62. 
200. Cody, C.W., et al., Chemical structure of the hexapeptide chromophore of the 
Aequorea green-fluorescent protein. Biochemistry, 1993. 32(5): p. 1212-8. 
  
106 
201. Heim, R., D.C. Prasher, and R.Y. Tsien, Wavelength mutations and posttranslational 
autoxidation of green fluorescent protein. Proc Natl Acad Sci U S A, 1994. 91(26): p. 
12501-4. 
202. Chalfie, M., et al., Green fluorescent protein as a marker for gene expression. Science, 
1994. 263(5148): p. 802-5. 
203. Cormack, B.P., R.H. Valdivia, and S. Falkow, FACS-optimized mutants of the green 
fluorescent protein (GFP). Gene, 1996. 173(1 Spec No): p. 33-8. 
204. Yang, T.T., L. Cheng, and S.R. Kain, Optimized codon usage and chromophore 
mutations provide enhanced sensitivity with the green fluorescent protein. Nucleic 
Acids Res, 1996. 24(22): p. 4592-3. 
205. Zhang, G., V. Gurtu, and S.R. Kain, An enhanced green fluorescent protein allows 
sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res 
Commun, 1996. 227(3): p. 707-11. 
206. Heim, R. and R.Y. Tsien, Engineering green fluorescent protein for improved 
brightness, longer wavelengths and fluorescence resonance energy transfer. Curr 
Biol, 1996. 6(2): p. 178-82. 
207. Miyawaki, A., et al., Fluorescent indicators for Ca2+ based on green fluorescent 
proteins and calmodulin. Nature, 1997. 388(6645): p. 882-7. 
208. Nagai, T., et al., A variant of yellow fluorescent protein with fast and efficient maturation 
for cell-biological applications. Nat Biotechnol, 2002. 20(1): p. 87-90. 
209. Griesbeck, O., et al., Reducing the environmental sensitivity of yellow fluorescent 
protein. Mechanism and applications. J Biol Chem, 2001. 276(31): p. 29188-94. 
210. Rizzo, M.A., et al., An improved cyan fluorescent protein variant useful for FRET. Nat 
Biotechnol, 2004. 22(4): p. 445-9. 
211. Mena, M.A., et al., Blue fluorescent proteins with enhanced brightness and 
photostability from a structurally targeted library. Nat Biotechnol, 2006. 24(12): p. 
1569-71. 
212. Matz, M.V., et al., Fluorescent proteins from nonbioluminescent Anthozoa species. Nat 
Biotechnol, 1999. 17(10): p. 969-73. 
213. Bevis, B.J. and B.S. Glick, Rapidly maturing variants of the Discosoma red fluorescent 
protein (DsRed). Nat Biotechnol, 2002. 20(1): p. 83-7. 
214. Campbell, R.E., et al., A monomeric red fluorescent protein. Proc Natl Acad Sci U S A, 
2002. 99(12): p. 7877-82. 
  
107 
215. Shaner, N.C., et al., Improved monomeric red, orange and yellow fluorescent proteins 
derived from Discosoma sp. red fluorescent protein. Nat Biotechnol, 2004. 22(12): p. 
1567-72. 
216. Wang, L., et al., Evolution of new nonantibody proteins via iterative somatic 
hypermutation. Proc Natl Acad Sci U S A, 2004. 101(48): p. 16745-9. 
217. Chudakov, D.M., S. Lukyanov, and K.A. Lukyanov, Fluorescent proteins as a toolkit for 
in vivo imaging. Trends Biotechnol, 2005. 23(12): p. 605-13. 
218. Shaner, N.C., P.A. Steinbach, and R.Y. Tsien, A guide to choosing fluorescent proteins. 
Nat Methods, 2005. 2(12): p. 905-9. 
219. Shah, K., et al., Bimodal viral vectors and in vivo imaging reveal the fate of human 
neural stem cells in experimental glioma model. J Neurosci, 2008. 28(17): p. 4406-13. 
220. Aoyagi, Y., et al., Energy cost of whole-body protein synthesis measured in vivo in 
chicks. Comp Biochem Physiol A, 1988. 91(4): p. 765-8. 
221. Alwine, J.C., et al., Detection of specific RNAs or specific fragments of DNA by 
fractionation in gels and transfer to diazobenzyloxymethyl paper. Methods Enzymol, 
1979. 68: p. 220-42. 
222. Bassell, G.J., et al., Single mRNAs visualized by ultrastructural in situ hybridization are 
principally localized at actin filament intersections in fibroblasts. J Cell Biol, 1994. 
126(4): p. 863-76. 
223. Volpi, E.V. and J.M. Bridger, FISH glossary: an overview of the fluorescence in situ 
hybridization technique. Biotechniques, 2008. 45(4): p. 385-6, 388, 390 passim. 
224. Femino, A.M., et al., Visualization of single RNA transcripts in situ. Science, 1998. 
280(5363): p. 585-90. 
225. Guzowski, J.F., et al., Imaging neural activity with temporal and cellular resolution 
using FISH. Curr Opin Neurobiol, 2001. 11(5): p. 579-84. 
226. Molenaar, C., et al., Poly(A)+ RNAs roam the cell nucleus and pass through speckle 
domains in transcriptionally active and inactive cells. J Cell Biol, 2004. 165(2): p. 
191-202. 
227. Molenaar, C., et al., Linear 2' O-Methyl RNA probes for the visualization of RNA in 
living cells. Nucleic Acids Res, 2001. 29(17): p. E89-9. 
228. Tsuji, A., et al., Direct observation of specific messenger RNA in a single living cell 
under a fluorescence microscope. Biophys J, 2000. 78(6): p. 3260-74. 
  
108 
229. Glotzer, J.B., et al., Cytoplasmic flows localize injected oskar RNA in Drosophila 
oocytes. Curr Biol, 1997. 7(5): p. 326-37. 
230. Jacobson, M.R. and T. Pederson, Localization of signal recognition particle RNA in the 
nucleolus of mammalian cells. Proc Natl Acad Sci U S A, 1998. 95(14): p. 7981-6. 
231. Bonnet, G., O. Krichevsky, and A. Libchaber, Kinetics of conformational fluctuations in 
DNA hairpin-loops. Proc Natl Acad Sci U S A, 1998. 95(15): p. 8602-6. 
232. Bonnet, G., et al., Thermodynamic basis of the enhanced specificity of structured DNA 
probes. Proc Natl Acad Sci U S A, 1999. 96(11): p. 6171-6. 
233. Roberts, R.W. and D.M. Crothers, Specificity and stringency in DNA triplex formation. 
Proc Natl Acad Sci U S A, 1991. 88(21): p. 9397-401. 
234. Tsourkas, A., et al., Hybridization kinetics and thermodynamics of molecular beacons. 
Nucleic Acids Res, 2003. 31(4): p. 1319-30. 
235. Tyagi, S. and F.R. Kramer, Molecular beacons: probes that fluoresce upon 
hybridization. Nat Biotechnol, 1996. 14(3): p. 303-8. 
236. Leonetti, J.P., et al., Intracellular distribution of microinjected antisense 
oligonucleotides. Proc Natl Acad Sci U S A, 1991. 88(7): p. 2702-6. 
237. Mechti, N., et al., Nuclear location of synthetic oligonucleotides microinjected somatic 
cells: its implication in an antisense strategy. Nucleic Acids Symp Ser, 1991(24): p. 
147-50. 
238. Nitin, N., et al., Peptide-linked molecular beacons for efficient delivery and rapid mRNA 
detection in living cells. Nucleic Acids Res, 2004. 32(6): p. e58. 
239. Tyagi, S. and O. Alsmadi, Imaging native beta-actin mRNA in motile fibroblasts. 
Biophys J, 2004. 87(6): p. 4153-62. 
240. Santangelo, P.J., Molecular beacons and related probes for intracellular RNA imaging. 
Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2010. 2(1): p. 11-9. 
241. Wansink, D.G., et al., Fluorescent labeling of nascent RNA reveals transcription by 
RNA polymerase II in domains scattered throughout the nucleus. J Cell Biol, 1993. 
122(2): p. 283-93. 
242. Bertrand, E., et al., Localization of ASH1 mRNA particles in living yeast. Mol Cell, 1998. 
2(4): p. 437-45. 
243. Forrest, K.M. and E.R. Gavis, Live imaging of endogenous RNA reveals a diffusion and 
entrapment mechanism for nanos mRNA localization in Drosophila. Curr Biol, 2003. 
13(14): p. 1159-68. 
  
109 
244. Haim, L., et al., A genomic integration method to visualize localization of endogenous 
mRNAs in living yeast. Nat Methods, 2007. 4(5): p. 409-12. 
245. Magliery, T.J., et al., Detecting protein-protein interactions with a green fluorescent 
protein fragment reassembly trap: scope and mechanism. J Am Chem Soc, 2005. 
127(1): p. 146-57. 
246. DiMasi, J.A., The value of improving the productivity of the drug development process: 
faster times and better decisions. Pharmacoeconomics, 2002. 20 Suppl 3: p. 1-10. 
247. DiMasi, J.A., R.W. Hansen, and H.G. Grabowski, The price of innovation: new 
estimates of drug development costs. J Health Econ, 2003. 22(2): p. 151-85. 
248. Adams, C.P. and V.V. Brantner, Estimating the cost of new drug development: is it 
really 802 million dollars? Health Aff (Millwood), 2006. 25(2): p. 420-8. 
249. Simon, S.M. and M. Schindler, Cell biological mechanisms of multidrug resistance in 
tumors. Proc Natl Acad Sci U S A, 1994. 91(9): p. 3497-504. 
250. Russell, A.D., Mechanisms of bacterial resistance to antibiotics and biocides. Prog Med 
Chem, 1998. 35: p. 133-97. 
251. Neu, H.C., Penicillin-binding proteins and role of amdinocillin in causing bacterial cell 
death. Am J Med, 1983. 75(2A): p. 9-20. 
252. Eady, E.A., et al., Distribution of genes encoding erythromycin ribosomal methylases 
and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci. 
J Antimicrob Chemother, 1993. 31(2): p. 211-7. 
253. Swedberg, G., S. Ringertz, and O. Skold, Sulfonamide resistance in Streptococcus 
pyogenes is associated with differences in the amino acid sequence of its 
chromosomal dihydropteroate synthase. Antimicrob Agents Chemother, 1998. 42(5): 
p. 1062-7. 
254. Li, X.Z. and H. Nikaido, Efflux-mediated drug resistance in bacteria: an update. Drugs, 
2009. 69(12): p. 1555-623. 
255. Li, X.Z., L. Zhang, and H. Nikaido, Efflux pump-mediated intrinsic drug resistance in 
Mycobacterium smegmatis. Antimicrob Agents Chemother, 2004. 48(7): p. 2415-23. 
256. Cannon, R.D., et al., Efflux-mediated antifungal drug resistance. Clin Microbiol Rev, 
2009. 22(2): p. 291-321, Table of Contents. 
257. Gottesman, M.M., Mechanisms of cancer drug resistance. Annu Rev Med, 2002. 53: p. 
615-27. 
  
110 
258. Pages, J.M., M. Masi, and J. Barbe, Inhibitors of efflux pumps in Gram-negative 
bacteria. Trends Mol Med, 2005. 11(8): p. 382-9. 
259. Poole, K., Efflux pumps as antimicrobial resistance mechanisms. Ann Med, 2007. 39(3): 
p. 162-76. 
260. Webber, M.A. and L.J. Piddock, The importance of efflux pumps in bacterial antibiotic 
resistance. J Antimicrob Chemother, 2003. 51(1): p. 9-11. 
261. Rosenberg, E.Y., D. Ma, and H. Nikaido, AcrD of Escherichia coli is an aminoglycoside 
efflux pump. J Bacteriol, 2000. 182(6): p. 1754-6. 
262. Paulsen, I.T., M.H. Brown, and R.A. Skurray, Proton-dependent multidrug efflux 
systems. Microbiol Rev, 1996. 60(4): p. 575-608. 
263. Alguel, Y., et al., Crystal structures of multidrug binding protein TtgR in complex with 
antibiotics and plant antimicrobials. J Mol Biol, 2007. 369(3): p. 829-40. 
264. Schumacher, M.A., M.C. Miller, and R.G. Brennan, Structural mechanism of the 
simultaneous binding of two drugs to a multidrug-binding protein. Embo J, 2004. 
23(15): p. 2923-30. 
265. Lomovskaya, O. and K. Lewis, Emr, an Escherichia coli locus for multidrug resistance. 
Proc Natl Acad Sci U S A, 1992. 89(19): p. 8938-42. 
266. DeMarco, C.E., et al., Efflux-related resistance to norfloxacin, dyes, and biocides in 
bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother, 2007. 
51(9): p. 3235-9. 
267. Davidson, A.L., et al., Structure, function, and evolution of bacterial ATP-binding 
cassette systems. Microbiol Mol Biol Rev, 2008. 72(2): p. 317-64, table of contents. 
268. Ambudkar, S.V., et al., P-glycoprotein: from genomics to mechanism. Oncogene, 2003. 
22(47): p. 7468-85. 
269. Lubelski, J., W.N. Konings, and A.J. Driessen, Distribution and physiology of ABC-type 
transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev, 
2007. 71(3): p. 463-76. 
270. van Veen, H.W., C.F. Higgins, and W.N. Konings, Multidrug transport by ATP binding 
cassette transporters: a proposed two-cylinder engine mechanism. Res Microbiol, 
2001. 152(3-4): p. 365-74. 
271. Chami, M., et al., Three-dimensional structure by cryo-electron microscopy of YvcC, an 
homodimeric ATP-binding cassette transporter from Bacillus subtilis. J Mol Biol, 2002. 
315(5): p. 1075-85. 
  
111 
272. Dawson, R.J. and K.P. Locher, Structure of a bacterial multidrug ABC transporter. 
Nature, 2006. 443(7108): p. 180-5. 
273. Kobayashi, N., K. Nishino, and A. Yamaguchi, Novel macrolide-specific ABC-type 
efflux transporter in Escherichia coli. J Bacteriol, 2001. 183(19): p. 5639-44. 
274. Schuldiner, S., et al., Small is mighty: EmrE, a multidrug transporter as an experimental 
paradigm. News Physiol Sci, 2001. 16: p. 130-4. 
275. Paulsen, I.T., et al., A family of gram-negative bacterial outer membrane factors that 
function in the export of proteins, carbohydrates, drugs and heavy metals from gram-
negative bacteria. FEMS Microbiol Lett, 1997. 156(1): p. 1-8. 
276. Dinh, T., I.T. Paulsen, and M.H. Saier, Jr., A family of extracytoplasmic proteins that 
allow transport of large molecules across the outer membranes of gram-negative 
bacteria. J Bacteriol, 1994. 176(13): p. 3825-31. 
277. Nikaido, H., Multidrug efflux pumps of gram-negative bacteria. J Bacteriol, 1996. 
178(20): p. 5853-9. 
278. Vaara, M., Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella 
typhimurium. Antimicrob Agents Chemother, 1993. 37(11): p. 2255-60. 
279. Nikaido, H., et al., Multidrug efflux pump AcrAB of Salmonella typhimurium excretes 
only those beta-lactam antibiotics containing lipophilic side chains. J Bacteriol, 1998. 
180(17): p. 4686-92. 
280. Mao, W., et al., On the mechanism of substrate specificity by resistance nodulation 
division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD 
from Pseudomonas aeruginosa are involved in substrate recognition. Mol Microbiol, 
2002. 46(3): p. 889-901. 
281. Lee, A., et al., Interplay between efflux pumps may provide either additive or 
multiplicative effects on drug resistance. J Bacteriol, 2000. 182(11): p. 3142-50. 
282. Koronakis, V., et al., Crystal structure of the bacterial membrane protein TolC central to 
multidrug efflux and protein export. Nature, 2000. 405(6789): p. 914-9. 
283. Murakami, S., et al., Crystal structure of bacterial multidrug efflux transporter AcrB. 
Nature, 2002. 419(6907): p. 587-93. 
284. Yu, E.W., et al., Structural basis of multiple drug-binding capacity of the AcrB multidrug 
efflux pump. Science, 2003. 300(5621): p. 976-80. 
285. Su, C.C., et al., Conformation of the AcrB multidrug efflux pump in mutants of the 
putative proton relay pathway. J Bacteriol, 2006. 188(20): p. 7290-6. 
  
112 
286. Seeger, M.A., et al., Structural asymmetry of AcrB trimer suggests a peristaltic pump 
mechanism. Science, 2006. 313(5791): p. 1295-8. 
287. Aires, J.R. and H. Nikaido, Aminoglycosides are captured from both periplasm and 
cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli. J Bacteriol, 
2005. 187(6): p. 1923-9. 
288. Ziha-Zarifi, I., et al., In vivo emergence of multidrug-resistant mutants of Pseudomonas 
aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob 
Agents Chemother, 1999. 43(2): p. 287-91. 
289. El'Garch, F., et al., Cumulative effects of several nonenzymatic mechanisms on the 
resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents 
Chemother, 2007. 51(3): p. 1016-21. 
290. Poole, K., Efflux-mediated antimicrobial resistance. J Antimicrob Chemother, 2005. 
56(1): p. 20-51. 
291. Mazzariol, A., et al., High-level fluoroquinolone-resistant clinical isolates of Escherichia 
coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother, 2000. 
44(12): p. 3441-3. 
292. Aiello, A.E., E.L. Larson, and S.B. Levy, Consumer antibacterial soaps: effective or just 
risky? Clin Infect Dis, 2007. 45 Suppl 2: p. S137-47. 
293. Morita, Y., et al., NorM of vibrio parahaemolyticus is an Na(+)-driven multidrug efflux 
pump. J Bacteriol, 2000. 182(23): p. 6694-7. 
294. Miyamae, S., et al., A MATE family multidrug efflux transporter pumps out 
fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother, 
2001. 45(12): p. 3341-6. 
295. Morita, Y., et al., NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus 
and its homolog in Escherichia coli. Antimicrob Agents Chemother, 1998. 42(7): p. 
1778-82. 
296. Neyfakh, A.A., Natural functions of bacterial multidrug transporters. Trends Microbiol, 
1997. 5(8): p. 309-13. 
297. Zgurskaya, H.I. and H. Nikaido, Bypassing the periplasm: reconstitution of the AcrAB 
multidrug efflux pump of Escherichia coli. Proc Natl Acad Sci U S A, 1999. 96(13): p. 
7190-5. 
298. Ramos, J.L., et al., Mechanisms of solvent tolerance in gram-negative bacteria. Annu 
Rev Microbiol, 2002. 56: p. 743-68. 
  
113 
299. Barnett, M.J., et al., Nucleotide sequence and predicted functions of the entire 
Sinorhizobium meliloti pSymA megaplasmid. Proc Natl Acad Sci U S A, 2001. 98(17): 
p. 9883-8. 
300. Cox, J.S., et al., Complex lipid determines tissue-specific replication of Mycobacterium 
tuberculosis in mice. Nature, 1999. 402(6757): p. 79-83. 
301. Domenech, P., et al., The role of MmpL8 in sulfatide biogenesis and virulence of 
Mycobacterium tuberculosis. J Biol Chem, 2004. 279(20): p. 21257-65. 
302. Kruh, G.D. and M.G. Belinsky, The MRP family of drug efflux pumps. Oncogene, 2003. 
22(47): p. 7537-52. 
303. Suvannasankha, A., et al., Breast cancer resistance protein (BCRP/MXR/ABCG2) in 
acute myeloid leukemia: discordance between expression and function. Leukemia, 
2004. 18(7): p. 1252-7. 
304. Riordan, J.R. and V. Ling, Purification of P-glycoprotein from plasma membrane 
vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. 
J Biol Chem, 1979. 254(24): p. 12701-5. 
305. Shen, D.W., et al., Human multidrug-resistant cell lines: increased mdr1 expression 
can precede gene amplification. Science, 1986. 232(4750): p. 643-5. 
306. Kartner, N., J.R. Riordan, and V. Ling, Cell surface P-glycoprotein associated with 
multidrug resistance in mammalian cell lines. Science, 1983. 221(4617): p. 1285-8. 
307. Kartner, N., et al., Detection of P-glycoprotein in multidrug-resistant cell lines by 
monoclonal antibodies. Nature, 1985. 316(6031): p. 820-3. 
308. Chan, H.S., et al., A sensitive method for immunocytochemical detection of P-
glycoprotein in multidrug-resistant human ovarian carcinoma cell lines. Lab Invest, 
1988. 59(6): p. 870-5. 
309. Litman, T., et al., From MDR to MXR: new understanding of multidrug resistance 
systems, their properties and clinical significance. Cell Mol Life Sci, 2001. 58(7): p. 
931-59. 
310. Lage, H., ABC-transporters: implications on drug resistance from microorganisms to 
human cancers. Int J Antimicrob Agents, 2003. 22(3): p. 188-99. 
311. Gottesman, M.M. and V. Ling, The molecular basis of multidrug resistance in cancer: 
the early years of P-glycoprotein research. FEBS Lett, 2006. 580(4): p. 998-1009. 
  
114 
312. Surowiak, P., et al., ABCC2 (MRP2, cMOAT) can be localized in the nuclear 
membrane of ovarian carcinomas and correlates with resistance to cisplatin and 
clinical outcome. Clin Cancer Res, 2006. 12(23): p. 7149-58. 
313. Dietel, M., et al., Membrane vesicle formation due to acquired mitoxantrone resistance 
in human gastric carcinoma cell line EPG85-257. Cancer Res, 1990. 50(18): p. 6100-
6. 
314. Chen, C., J. Zhou, and C. Ji, Quercetin: a potential drug to reverse multidrug resistance. 
Life Sci, 2010. 87(11-12): p. 333-8. 
315. Walker, J.E., et al., Distantly related sequences in the alpha- and beta-subunits of ATP 
synthase, myosin, kinases and other ATP-requiring enzymes and a common 
nucleotide binding fold. Embo J, 1982. 1(8): p. 945-51. 
316. Hyde, S.C., et al., Structural model of ATP-binding proteins associated with cystic 
fibrosis, multidrug resistance and bacterial transport. Nature, 1990. 346(6282): p. 
362-5. 
317. Fojo, A.T., et al., Expression of a multidrug-resistance gene in human tumors and 
tissues. Proc Natl Acad Sci U S A, 1987. 84(1): p. 265-9. 
318. Goldstein, L.J., et al., Expression of a multidrug resistance gene in human cancers. J 
Natl Cancer Inst, 1989. 81(2): p. 116-24. 
319. Cole, S.P., et al., Overexpression of a transporter gene in a multidrug-resistant human 
lung cancer cell line. Science, 1992. 258(5088): p. 1650-4. 
320. Haimeur, A., et al., The MRP-related and BCRP/ABCG2 multidrug resistance proteins: 
biology, substrate specificity and regulation. Curr Drug Metab, 2004. 5(1): p. 21-53. 
321. Nooter, K., et al., The prognostic significance of expression of the multidrug resistance-
associated protein (MRP) in primary breast cancer. Br J Cancer, 1997. 76(4): p. 486-
93. 
322. Arts, H.J., et al., Drug resistance-associated markers P-glycoprotein, multidrug 
resistance-associated protein 1, multidrug resistance-associated protein 2, and lung 
resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res, 1999. 
5(10): p. 2798-805. 
323. Taniguchi, K., et al., A human canalicular multispecific organic anion transporter 
(cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with 
decreased drug accumulation. Cancer Res, 1996. 56(18): p. 4124-9. 
  
115 
324. Burger, H., et al., RNA expression of breast cancer resistance protein, lung resistance-
related protein, multidrug resistance-associated proteins 1 and 2, and multidrug 
resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin 
Cancer Res, 2003. 9(2): p. 827-36. 
325. Materna, V., et al., RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, 
and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic 
response. Gynecol Oncol, 2004. 94(1): p. 152-60. 
326. Borst, P., C. de Wolf, and K. van de Wetering, Multidrug resistance-associated proteins 
3, 4, and 5. Pflugers Arch, 2007. 453(5): p. 661-73. 
327. Konig, J., et al., Characterization of the human multidrug resistance protein isoform 
MRP3 localized to the basolateral hepatocyte membrane. Hepatology, 1999. 29(4): p. 
1156-63. 
328. Faneyte, I.F., P.M. Kristel, and M.J. van de Vijver, Multidrug resistance associated 
genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. 
Anticancer Res, 2004. 24(5A): p. 2931-9. 
329. Ohishi, Y., et al., ATP-binding cassette superfamily transporter gene expression in 
human primary ovarian carcinoma. Clin Cancer Res, 2002. 8(12): p. 3767-75. 
330. Konig, J., et al., Expression and localization of human multidrug resistance protein 
(ABCC) family members in pancreatic carcinoma. Int J Cancer, 2005. 115(3): p. 359-
67. 
331. Calatozzolo, C., et al., Expression of drug resistance proteins Pgp, MRP1, MRP3, 
MRP5 and GST-pi in human glioma. J Neurooncol, 2005. 74(2): p. 113-21. 
332. Kruh, G.D., et al., ABCC10, ABCC11, and ABCC12. Pflugers Arch, 2007. 453(5): p. 
675-84. 
333. Oguri, T., et al., MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol 
Cancer Ther, 2007. 6(1): p. 122-7. 
334. Nies, A.T., et al., Immunolocalization of multidrug resistance protein 5 in the human 
genitourinary system. J Urol, 2002. 167(5): p. 2271-5. 
335. Belinsky, M.G., et al., Characterization of the drug resistance and transport properties 
of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res, 2002. 62(21): p. 
6172-7. 
336. Matsuzaki, Y., et al., Tissue-specific expression of the ABCC6 gene. J Invest Dermatol, 
2005. 125(5): p. 900-5. 
  
116 
337. Scheffer, G.L., et al., MRP6 (ABCC6) detection in normal human tissues and tumors. 
Lab Invest, 2002. 82(4): p. 515-8. 
338. Hopper-Borge, E., et al., Analysis of the drug resistance profile of multidrug resistance 
protein 7 (ABCC10): resistance to docetaxel. Cancer Res, 2004. 64(14): p. 4927-30. 
339. Doyle, L.A., et al., A multidrug resistance transporter from human MCF-7 breast cancer 
cells. Proc Natl Acad Sci U S A, 1998. 95(26): p. 15665-70. 
340. Allikmets, R., et al., A human placenta-specific ATP-binding cassette gene (ABCP) on 
chromosome 4q22 that is involved in multidrug resistance. Cancer Res, 1998. 58(23): 
p. 5337-9. 
341. Miyake, K., et al., Molecular cloning of cDNAs which are highly overexpressed in 
mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. 
Cancer Res, 1999. 59(1): p. 8-13. 
342. Lage, H. and M. Dietel, Effect of the breast-cancer resistance protein on atypical 
multidrug resistance. Lancet Oncol, 2000. 1: p. 169-75. 
343. Maliepaard, M., et al., Subcellular localization and distribution of the breast cancer 
resistance protein transporter in normal human tissues. Cancer Res, 2001. 61(8): p. 
3458-64. 
344. Fetsch, P.A., et al., Localization of the ABCG2 mitoxantrone resistance-associated 
protein in normal tissues. Cancer Lett, 2006. 235(1): p. 84-92. 
345. Jonker, J.W., et al., The breast cancer resistance protein BCRP (ABCG2) concentrates 
drugs and carcinogenic xenotoxins into milk. Nat Med, 2005. 11(2): p. 127-9. 
346. van der Kolk, D.M., et al., Expression and activity of breast cancer resistance protein 
(BCRP) in de novo and relapsed acute myeloid leukemia. Blood, 2002. 99(10): p. 
3763-70. 
347. Ross, D.D., et al., Expression of breast cancer resistance protein in blast cells from 
patients with acute leukemia. Blood, 2000. 96(1): p. 365-8. 
348. Laing, N.M., et al., Amplification of the ATP-binding cassette 2 transporter gene is 
functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. 
Cancer Res, 1998. 58(7): p. 1332-7. 
349. Steinbach, D., et al., ABCA3 as a possible cause of drug resistance in childhood acute 
myeloid leukemia. Clin Cancer Res, 2006. 12(14 Pt 1): p. 4357-63. 
350. Izquierdo, M.A., et al., Overexpression of the ABC transporter TAP in multidrug-
resistant human cancer cell lines. Br J Cancer, 1996. 74(12): p. 1961-7. 
  
117 
351. Lage, H., et al., Enhanced expression of human ABC-transporter tap is associated with 
cellular resistance to mitoxantrone. FEBS Lett, 2001. 503(2-3): p. 179-84. 
352. Ruetz, S. and P. Gros, Phosphatidylcholine translocase: a physiological role for the 
mdr2 gene. Cell, 1994. 77(7): p. 1071-81. 
353. Childs, S., et al., Taxol resistance mediated by transfection of the liver-specific sister 
gene of P-glycoprotein. Cancer Res, 1998. 58(18): p. 4160-7. 
354. Gerloff, T., et al., The sister of P-glycoprotein represents the canalicular bile salt export 
pump of mammalian liver. J Biol Chem, 1998. 273(16): p. 10046-50. 
355. Yasui, K., et al., Alteration in copy numbers of genes as a mechanism for acquired drug 
resistance. Cancer Res, 2004. 64(4): p. 1403-10. 
356. Paterson, J.K., et al., Human ABCB6 localizes to both the outer mitochondrial 
membrane and the plasma membrane. Biochemistry, 2007. 46(33): p. 9443-52. 
357. Frank, N.Y., et al., ABCB5-mediated doxorubicin transport and chemoresistance in 
human malignant melanoma. Cancer Res, 2005. 65(10): p. 4320-33. 
358. Schatton, T., et al., Identification of cells initiating human melanomas. Nature, 2008. 
451(7176): p. 345-9. 
359. Nieth, C. and H. Lage, Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl 
(Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following 
exposure to mitoxantrone. J Chemother, 2005. 17(2): p. 215-23. 
360. Gillet, J.P., et al., Microarray-based detection of multidrug resistance in human tumor 
cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res, 
2004. 64(24): p. 8987-93. 
361. Szakacs, G., et al., Predicting drug sensitivity and resistance: profiling ABC transporter 
genes in cancer cells. Cancer Cell, 2004. 6(2): p. 129-37. 
362. Efferth, T., et al., Expression profiling of ATP-binding cassette transporters in childhood 
T-cell acute lymphoblastic leukemia. Mol Cancer Ther, 2006. 5(8): p. 1986-94. 
363. Awasthi, S., et al., Transport of glutathione conjugates and chemotherapeutic drugs by 
RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and 
drug resistance. Int J Cancer, 2003. 106(5): p. 635-46. 
364. Awasthi, Y.C., et al., The non-ABC drug transporter RLIP76 (RALBP-1) plays a major 
role in the mechanisms of drug resistance. Curr Drug Metab, 2007. 8(4): p. 315-23. 
  
118 
365. Hudson, M.E., et al., Identification of differentially expressed proteins in ovarian cancer 
using high-density protein microarrays. Proc Natl Acad Sci U S A, 2007. 104(44): p. 
17494-9. 
366. Hosoi, E., et al., Effect of MDR antagonists on the cidal activity of vincristine for cells 
expressing MDR-1 is superior to those expressing MRP. Int J Oncol, 1998. 13(2): p. 
343-8. 
367. Ambudkar, S.V., et al., Biochemical, cellular, and pharmacological aspects of the 
multidrug transporter. Annu Rev Pharmacol Toxicol, 1999. 39: p. 361-98. 
368. Krishna, R. and L.D. Mayer, Multidrug resistance (MDR) in cancer. Mechanisms, 
reversal using modulators of MDR and the role of MDR modulators in influencing the 
pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 2000. 11(4): p. 265-83. 
369. Germann, U.A., et al., Cellular and biochemical characterization of VX-710 as a 
chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. 
Anticancer Drugs, 1997. 8(2): p. 125-40. 
370. te Boekhorst, P.A., et al., Reversal of typical multidrug resistance by cyclosporin and its 
non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells 
expressing the mdr1 phenotype. Cancer Chemother Pharmacol, 1992. 30(3): p. 238-
42. 
371. Wandel, C., et al., P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of 
inhibitory potencies. Cancer Res, 1999. 59(16): p. 3944-8. 
372. Bates, S., et al., A Phase I study of infusional vinblastine in combination with the P-
glycoprotein antagonist PSC 833 (valspodar). Cancer, 2001. 92(6): p. 1577-90. 
373. Martin, C., et al., The molecular interaction of the high affinity reversal agent XR9576 
with P-glycoprotein. Br J Pharmacol, 1999. 128(2): p. 403-11. 
374. Starling, J.J., et al., Pharmacological characterization of LY335979: a potent 
cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul, 1997. 
37: p. 335-47. 
375. van Zuylen, L., et al., Development of multidrug-resistance convertors: sense or 
nonsense? Invest New Drugs, 2000. 18(3): p. 205-20. 
376. Stewart, A., et al., Phase I trial of XR9576 in healthy volunteers demonstrates 
modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous 
administration. Clin Cancer Res, 2000. 6(11): p. 4186-91. 
  
119 
377. Erlund, I., et al., Plasma concentrations of the flavonoids hesperetin, naringenin and 
quercetin in human subjects following their habitual diets, and diets high or low in 
fruit and vegetables. Eur J Clin Nutr, 2002. 56(9): p. 891-8. 
378. Nguyen, H., S. Zhang, and M.E. Morris, Effect of flavonoids on MRP1-mediated 
transport in Panc-1 cells. J Pharm Sci, 2003. 92(2): p. 250-7. 
379. Taur, J.S. and R. Rodriguez-Proteau, Effects of dietary flavonoids on the transport of 
cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell 
models. Xenobiotica, 2008. 38(12): p. 1536-50. 
380. Cooray, H.C., et al., Interaction of the breast cancer resistance protein with plant 
polyphenols. Biochem Biophys Res Commun, 2004. 317(1): p. 269-75. 
381. Yoshimura, S., et al., Inhibitory effect of flavonoids on the efflux of N-acetyl 5-
aminosalicylic acid intracellularly formed in Caco-2 cells. J Biomed Biotechnol, 2009. 
2009: p. 467489. 
382. Shapiro, A.B. and V. Ling, Extraction of Hoechst 33342 from the cytoplasmic leaflet of 
the plasma membrane by P-glycoprotein. Eur J Biochem, 1997. 250(1): p. 122-9. 
383. Conseil, G., et al., Flavonoids: a class of modulators with bifunctional interactions at 
vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci 
U S A, 1998. 95(17): p. 9831-6. 
384. Stavri, M., L.J. Piddock, and S. Gibbons, Bacterial efflux pump inhibitors from natural 
sources. J Antimicrob Chemother, 2007. 59(6): p. 1247-60. 
385. Stermitz, F.R., et al., Synergy in a medicinal plant: antimicrobial action of berberine 
potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad 
Sci U S A, 2000. 97(4): p. 1433-7. 
386. Ball, A.R., et al., Conjugating berberine to a multidrug efflux pump inhibitor creates an 
effective antimicrobial. ACS Chem Biol, 2006. 1(9): p. 594-600. 
387. Samosorn, S., et al., Antibacterial activity of berberine-NorA pump inhibitor hybrids with 
a methylene ether linking group. Bioorg Med Chem, 2009. 17(11): p. 3866-72. 
388. Lomovskaya, O., et al., Identification and characterization of inhibitors of multidrug 
resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination 
therapy. Antimicrob Agents Chemother, 2001. 45(1): p. 105-16. 
389. Nakayama, K., et al., MexAB-OprM-specific efflux pump inhibitors in Pseudomonas 
aeruginosa. Part 1: discovery and early strategies for lead optimization. Bioorg Med 
Chem Lett, 2003. 13(23): p. 4201-4. 
  
120 
390. Thorarensen, A., et al., 3-Arylpiperidines as potentiators of existing antibacterial agents. 
Bioorg Med Chem Lett, 2001. 11(14): p. 1903-6. 
391. Bohnert, J.A. and W.V. Kern, Selected arylpiperazines are capable of reversing 
multidrug resistance in Escherichia coli overexpressing RND efflux pumps. 
Antimicrob Agents Chemother, 2005. 49(2): p. 849-52. 
392. Nelson, M.L. and S.B. Levy, Reversal of tetracycline resistance mediated by different 
bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport 
protein. Antimicrob Agents Chemother, 1999. 43(7): p. 1719-24. 
393. Meier, A., et al., Genetic alterations in streptomycin-resistant Mycobacterium 
tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents 
Chemother, 1994. 38(2): p. 228-33. 
394. Gill, A.E. and S.G. Amyes, The contribution of a novel ribosomal S12 mutation to 
aminoglycoside resistance of Escherichia coli mutants. J Chemother, 2004. 16(4): p. 
347-9. 
395. Unge, J., et al., The crystal structure of ribosomal protein L22 from Thermus 
thermophilus: insights into the mechanism of erythromycin resistance. Structure, 
1998. 6(12): p. 1577-86. 
396. Thompson, J., P.A. Skeggs, and E. Cundliffe, Methylation of 16S ribosomal RNA and 
resistance to the aminoglycoside antibiotics gentamicin and kanamycin determined 
by DNA from the gentamicin-producer, Micromonospora purpurea. Mol Gen Genet, 
1985. 201(2): p. 168-73. 
397. Beauclerk, A.A. and E. Cundliffe, Sites of action of two ribosomal RNA methylases 
responsible for resistance to aminoglycosides. J Mol Biol, 1987. 193(4): p. 661-71. 
398. Doi, Y. and Y. Arakawa, 16S ribosomal RNA methylation: emerging resistance 
mechanism against aminoglycosides. Clin Infect Dis, 2007. 45(1): p. 88-94. 
399. Jana, S. and J.K. Deb, Molecular targets for design of novel inhibitors to circumvent 
aminoglycoside resistance. Curr Drug Targets, 2005. 6(3): p. 353-61. 
400. Mingeot-Leclercq, M.P., Y. Glupczynski, and P.M. Tulkens, Aminoglycosides: activity 
and resistance. Antimicrob Agents Chemother, 1999. 43(4): p. 727-37. 
401. Karlowsky, J.A., et al., Altered denA and anr gene expression in aminoglycoside 
adaptive resistance in Pseudomonas aeruginosa. J Antimicrob Chemother, 1997. 
40(3): p. 371-6. 
  
121 
402. Daigle, D.M., D.W. Hughes, and G.D. Wright, Prodigious substrate specificity of 
AAC(6')-APH(2"), an aminoglycoside antibiotic resistance determinant in enterococci 
and staphylococci. Chem Biol, 1999. 6(2): p. 99-110. 
403. Azucena, E. and S. Mobashery, Aminoglycoside-modifying enzymes: mechanisms of 
catalytic processes and inhibition. Drug Resist Updat, 2001. 4(2): p. 106-17. 
404. Kim, C., et al., Characterization of the bifunctional aminoglycoside-modifying enzyme 
ANT(3'')-Ii/AAC(6')-IId from Serratia marcescens. Biochemistry, 2006. 45(27): p. 
8368-77. 
405. Pedersen, L.C., M.M. Benning, and H.M. Holden, Structural investigation of the 
antibiotic and ATP-binding sites in kanamycin nucleotidyltransferase. Biochemistry, 
1995. 34(41): p. 13305-11. 
406. Hon, W.C., et al., Structure of an enzyme required for aminoglycoside antibiotic 
resistance reveals homology to eukaryotic protein kinases. Cell, 1997. 89: p. 887-
895. 
407. Sakon, J., et al., Molecular structure of kanamycin nucleotidyltransferase determined to 
3.0-A resolution. Biochemistry, 1993. 32(45): p. 11977-84. 
408. Wright, G.D., A.M. Berghuis, and S. Mobashery, Aminoglycoside antibiotics. Structures, 
functions, and resistance. Adv Exp Med Biol, 1998. 456: p. 27-69. 
409. McKay, G.A., et al., Recognition of aminoglycoside antibiotics by enterococcal-
staphylococcal aminoglycoside 3'-phosphotransferase type IIIa: role of substrate 
amino groups. Antimicrob Agents Chemother, 1996. 40(11): p. 2648-50. 
410. Miller, G.H., et al., The most frequent aminoglycoside resistance mechanisms--
changes with time and geographic area: a reflection of aminoglycoside usage 
patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis, 1997. 24 Suppl 
1: p. S46-62. 
411. Gates, C.A. and D.B. Northrop, Substrate specificities and structure-activity 
relationships for the nucleotidylation of antibiotics catalyzed by aminoglycoside 
nucleotidyltransferase 2''-I. Biochemistry, 1988. 27(10): p. 3820-5. 
412. Gates, C.A. and D.B. Northrop, Determination of the rate-limiting segment of 
aminoglycoside nucleotidyltransferase 2''-I by pH and viscosity-dependent kinetics. 
Biochemistry, 1988. 27(10): p. 3834-42. 
  
122 
413. Perdersen, L.C., M.M. Benning, and H.M. Holden, Structural investigation of the 
antibiotic and ATP-binding sites in kanamycin nucleotidyltransferase. Biochemistry, 
1995. 34: p. 13305-13311. 
414. Van Pelt, J.E., R. Iyengar, and P.A. Frey, Gentamicin nucleotidyltransferase. 
Stereochemical inversion at phosphorus in enzymatic 2'-deoxyadenylyl transfer to 
tobramycin. J Biol Chem, 1986. 261(34): p. 15995-9. 
415. Holm, L. and C. Sander, DNA polymerase beta belongs to an ancient 
nucleotidyltransferase superfamily. Trends Biochem Sci, 1995. 20(9): p. 345-7. 
416. Aravind, L. and E.V. Koonin, DNA polymerase beta-like nucleotidyltransferase 
superfamily: identification of three new families, classification and evolutionary 
history. Nucleic Acids Res, 1999. 27(7): p. 1609-18. 
417. Kotra, L.P., J. Haddad, and S. Mobashery, Aminoglycosides: perspectives on 
mechanisms of action and resistance and strategies to counter resistance. 
Antimicrob Agents Chemother, 2000. 44(12): p. 3249-56. 
418. Ferretti, J.J., K.S. Gilmore, and P. Courvalin, Nucleotide sequence analysis of the gene 
specifying the bifunctional 6'-aminoglycoside acetyltransferase 2"-aminoglycoside 
phosphotransferase enzyme in Streptococcus faecalis and identification and cloning 
of gene regions specifying the two activities. J Bacteriol, 1986. 167(2): p. 631-8. 
419. Costa, Y., et al., Characterization of the chromosomal aac(6')-Ii gene specific for 
Enterococcus faecium. Antimicrob Agents Chemother, 1993. 37(9): p. 1896-903. 
420. DiGiammarino, E.L., et al., Solution studies of isepamicin and conformational 
comparisons between isepamicin and butirosin A when bound to an aminoglycoside 
6'-N-acetyltransferase determined by NMR spectroscopy. Biochemistry, 1998. 37(11): 
p. 3638-44. 
421. Bhatnagar, R.S., et al., Structure of N-myristoyltransferase with bound myristoylCoA 
and peptide substrate analogs. Nat Struct Biol, 1998. 5(12): p. 1091-7. 
422. Weston, S.A., et al., Crystal structure of the anti-fungal target N-myristoyl transferase. 
Nat Struct Biol, 1998. 5(3): p. 213-21. 
423. Dutnall, R.N., et al., Structure of the histone acetyltransferase Hat1: a paradigm for the 
GCN5-related N-acetyltransferase superfamily. Cell, 1998. 94(4): p. 427-38. 
424. Taylor, S.S., et al., Structural framework for the protein kinase family. Annu Rev Cell 
Biol, 1992. 8: p. 429-62. 
  
123 
425. Rao, V.D., et al., Structure of type IIbeta phosphatidylinositol phosphate kinase: a 
protein kinase fold flattened for interfacial phosphorylation. Cell, 1998. 94(6): p. 829-
39. 
426. Daigle, D.M., G.A. McKay, and G.D. Wright, Inhibition of aminoglycoside antibiotic 
resistance enzymes by protein kinase inhibitors. J Biol Chem, 1997. 272(40): p. 
24755-8. 
427. Edson, R.S. and C.L. Terrell, The aminoglycosides: streptomycin, kanamycin, 
gentamicin, tobramycin, amikacin, netilmicin, and sisomicin. Mayo Clin Proc, 1987. 
62(10): p. 916-20. 
428. King, J.W., et al., Alterations in the microbial flora and in the incidence of bacteremia at 
a university hospital after adoption of amikacin as the sole formulary aminoglycoside. 
Clin Infect Dis, 1992. 14(4): p. 908-15. 
429. Mitchison, D.A., The diagnosis and therapy of tuberculosis during the past 100 years. 
Am J Respir Crit Care Med, 2005. 171(7): p. 699-706. 
430. Wongsrichanalai, C., et al., Extensive drug resistance in malaria and tuberculosis. 
Emerg Infect Dis, 2010. 16(7): p. 1063-7. 
431. Wilton, P., et al., Strategies to contain the emergence of antimicrobial resistance: a 
systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy, 
2002. 7(2): p. 111-7. 
432. Quigley, E.M., Probiotics in functional gastrointestinal disorders: what are the facts? 
Curr Opin Pharmacol, 2008. 8(6): p. 704-8. 
433. Sayamov, R.M., Treatment and prophylaxis of cholera with bacteriophage. Bull World 
Health Organ, 1963. 28(3): p. 361-7. 
434. Hyman, P. and S.T. Abedon, Bacteriophage host range and bacterial resistance. Adv 
Appl Microbiol, 2010. 70: p. 217-48. 
435. Sette, A. and R. Rappuoli, Reverse vaccinology: developing vaccines in the era of 
genomics. Immunity, 2010. 33(4): p. 530-41. 
436. Igaz, P., [Antimicrobial peptides: a new way to treat bacterial infections]. Orv Hetil, 
2001. 142(4): p. 169-71. 
437. Ghadiri, M.R., et al., Self-assembling organic nanotubes based on a cyclic peptide 
architecture. Nature, 1993. 366(6453): p. 324-7. 
438. Fernandez-Lopez, S., et al., Antibacterial agents based on the cyclic D,L-alpha-peptide 
architecture. Nature, 2001. 412(6845): p. 452-5. 
  
124 
439. Fourmy, D., M.I. Recht, and J.D. Puglisi, Binding of neomycin-class aminoglycoside 
antibiotics to the A-site of 16 S rRNA. J Mol Biol, 1998. 277(2): p. 347-62. 
440. Haddad, J., et al., Design of novel antibiotics that bind to the ribosomal acyltransfer site. 
J Am Chem Soc, 2002. 124(13): p. 3229-37. 
441. Venot, A., et al., Disaccharide mimetics of the aminoglycoside antibiotic neamine. 
Chembiochem, 2004. 5(9): p. 1228-36. 
442. Moazed, D. and H.F. Noller, Interaction of antibiotics with functional sites in 16S 
ribosomal RNA. Nature, 1987. 327: p. 389-394. 
443. Wong, C.H., et al., Specificity of aminoglycoside antibiotics for the A-site of the 
decoding region of ribosomal RNA. Chem Biol, 1998. 5(7): p. 397-406. 
444. Fourmy, D., S. Yoshizawa, and J.D. Puglisi, Paromomycin binding induces a local 
conformational change in the A-site of 16S rRNA. J Mol Biol, 1998. 277: p. 333-345. 
445. Karimi, R. and M. Ehrenberg, Dissociation rate of cognate peptidyl-tRNA from the A-
site of hyper-accurate and error-prone ribosomes. Eur J Biochem, 1994. 226: p. 355-
360. 
446. Cabanas, M.J., D. Vazquez, and J. Modolell, Inhibition of ribosomal translocation by 
aminoglycoside antibiotics. Biochem. Biophys. Res. Commun., 1978. 83: p. 991-997. 
447. Davies, J., L. Gorini, and B.D. Davis, Misreading of RNA codewords induced by 
aminoglycoside antibiotics. Mol Pharmacol, 1965. 1: p. 93-106. 
448. Green, R. and H.F. Noller, Ribosomes and translation. Annu Rev Biochem, 1997. 66: p. 
679-716. 
449. Mehta, R. and W.S. Champney, Neomycin and paromomycin inhibit 30S ribosomal 
subunit assembly in Staphylococcus aureus. Curr Microbiol, 2003. 47(3): p. 237-43. 
450. Hermann, T., Strategies for the Design of Drugs Targeting RNA and RNA-Protein 
Complexes. Angew Chem Int Ed Engl, 2000. 39(11): p. 1890-1904. 
451. Tok, J.B.H., J. Cho, and R.R. Rando, Aminoglycoside hybrids as potent RNA 
antagonists. Tetrahedron, 1999. 55(18): p. 5741-5758. 
452. Michael, K., H. Wang, and Y. Tor, Enhanced RNA binding of dimerized 
aminoglycosides. Bioorg Med Chem, 1999. 7(7): p. 1361-71. 
453. Tok, J.B. and G.R. Huffman, Enhanced binding of aminoglycoside dimers to a 
"dimerized" A-site 16S rRNA construct. Bioorg Med Chem Lett, 2000. 10(14): p. 
1593-5. 
  
125 
454. Litovchick, A., A.G. Evdokimov, and A. Lapidot, Aminoglycoside-arginine conjugates 
that bind TAR RNA: synthesis, characterization, and antiviral activity. Biochemistry, 
2000. 39(11): p. 2838-52. 
455. Lee, J., et al., An approach to enhance specificity against RNA targets using 
heteroconjugates of aminoglycosides and chloramphenicol (or linezolid). J Am Chem 
Soc, 2004. 126(7): p. 1956-7. 
456. Riguet, E., et al., Neamine dimers targeting the HIV-1 TAR RNA. Bioorg Med Chem 
Lett, 2005. 15(21): p. 4651-5. 
457. Ellington, A.D., RNA ligands: out of shape but fir for recognition. Curr Biol, 1993. 3(6): p. 
375-7. 
458. Wilson, D.S. and J.W. Szostak, In vitro selection of functional nucleic acids. Annu Rev 
Biochem, 1999. 68: p. 611-47. 
459. Chow, C.S. and F.M. Bogdan, A Structural Basis for RNAminus signLigand Interactions. 
Chem Rev, 1997. 97(5): p. 1489-1514. 
460. Walter, F., Q. Vicens, and E. Westhof, Aminoglycoside-RNA interactions. Curr Opin 
Chem Biol, 1999. 3(6): p. 694-704. 
461. Zapp, M.L., S. Stern, and M.R. Green, Small molecules that selectively block RNA 
binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell, 1993. 
74(6): p. 969-78. 
462. Wang, S., et al., Binding of neomycin to the TAR element of HIV-1 RNA induces 
dissociation of Tat protein by an allosteric mechanism. Biochemistry, 1998. 37(16): p. 
5549-57. 
463. Hermann, T. and E. Westhof, RNA-binding Antibiotics. 1999, European Molecular 
Biology Organization. 
464. Mei, H.Y., et al., Inhibition of an HIV-1 Tat-derived peptide binding to TAR RNA by 
aminoglycoside antibiotics. Bioorg Med Chem Lett, 1995. 5: p. 2755-2760. 
465. Faber, C., et al., Structural rearrangements of HIV-1 Tat-responsive RNA upon binding 
of neomycin B. J Biol Chem, 2000. 275(27): p. 20660-6. 
466. Tok, J.B., J. Cho, and R.R. Rando, Aminoglycoside antibiotics are able to specifically 
bind the 5'-untranslated region of thymidylate synthase messenger RNA. 
Biochemistry, 1999. 38(1): p. 199-206. 
467. von Ahsen, U., J. Davies, and R. Schroeder, Antibiotic inhibition of group I ribozyme 
function. Nature, 1991. 353: p. 368-370. 
  
126 
468. von Ahsen, U., J. Davies, and R. Schroeder, Non-competitive inhibition of group I intron 
RNA self-splicing by aminoglycoside antibiotics. J Mol Biol, 1992. 226: p. 935-941. 
469. Mikkelsen, N.E., et al., Inhibition of RNase P RNA cleavage by aminoglycosides. Proc 
Natl Acad Sci USA, 1999. 96: p. 6155-6160. 
470. Mikkelsen, N.E., et al., Aminoglycoside binding displaces a divalent metal ion in a 
tRNA-neomycin B complex. Nat Struct Biol, 2001. 8(6): p. 510-4. 
471. Huang, L., A. Serganov, and D.J. Patel, Structural insights into ligand recognition by a 
sensing domain of the cooperative glycine riboswitch. Mol Cell, 2010. 40(5): p. 774-
86. 
472. Garst, A.D., et al., Crystal structure of the lysine riboswitch regulatory mRNA element. J 
Biol Chem, 2008. 283(33): p. 22347-51. 
473. Edwards, A.L., et al., Structural basis for recognition of S-adenosylhomocysteine by 
riboswitches. RNA, 2010. 16(11): p. 2144-55. 
474. Batey, R.T., S.D. Gilbert, and R.K. Montange, Structure of a natural guanine-
responsive riboswitch complexed with the metabolite hypoxanthine. Nature, 2004. 
432(7015): p. 411-5. 
475. Serganov, A., et al., Structural basis for discriminative regulation of gene expression by 
adenine- and guanine-sensing mRNAs. Chem Biol, 2004. 11(12): p. 1729-41. 
476. Jenkins, J.L., et al., Comparison of a preQ1 riboswitch aptamer in metabolite-bound 
and free states with implications for gene regulation. J Biol Chem, 2011. 286(28): p. 
24626-37. 
477. Klein, D.J., T.E. Edwards, and A.R. Ferre-D'Amare, Cocrystal structure of a class I 
preQ1 riboswitch reveals a pseudoknot recognizing an essential hypermodified 
nucleobase. Nat Struct Mol Biol, 2009. 16(3): p. 343-4. 
478. Smith, K.D., et al., Structural and biochemical determinants of ligand binding by the c-
di-GMP riboswitch. Biochemistry, 2010. 49(34): p. 7351-9. 
479. Montange, R.K. and R.T. Batey, Structure of the S-adenosylmethionine riboswitch 
regulatory mRNA element. Nature, 2006. 441(7097): p. 1172-5. 
480. Stoddard, C.D., et al., Free state conformational sampling of the SAM-I riboswitch 
aptamer domain. Structure, 2010. 18(7): p. 787-97. 
481. Lu, C., et al., SAM recognition and conformational switching mechanism in the Bacillus 
subtilis yitJ S box/SAM-I riboswitch. J Mol Biol, 2010. 404(5): p. 803-18. 
  
127 
482. Gilbert, S.D., et al., Structure of the SAM-II riboswitch bound to S-adenosylmethionine. 
Nat Struct Mol Biol, 2008. 15(2): p. 177-82. 
483. Lu, C., et al., Crystal structures of the SAM-III/S(MK) riboswitch reveal the SAM-
dependent translation inhibition mechanism. Nat Struct Mol Biol, 2008. 15(10): p. 
1076-83. 
484. Serganov, A., L. Huang, and D.J. Patel, Coenzyme recognition and gene regulation by 
a flavin mononucleotide riboswitch. Nature, 2009. 458(7235): p. 233-7. 
485. Thore, S., M. Leibundgut, and N. Ban, Structure of the eukaryotic thiamine 
pyrophosphate riboswitch with its regulatory ligand. Science, 2006. 312(5777): p. 
1208-11. 
486. Serganov, A., et al., Structural basis for gene regulation by a thiamine pyrophosphate-
sensing riboswitch. Nature, 2006. 441(7097): p. 1167-71. 
487. Klein, D.J., et al., Requirement of helix P2.2 and nucleotide G1 for positioning the 
cleavage site and cofactor of the glmS ribozyme. J Mol Biol, 2007. 373(1): p. 178-89. 
488. Dann, C.E., 3rd, et al., Structure and mechanism of a metal-sensing regulatory RNA. 
Cell, 2007. 130(5): p. 878-92. 
489. Duchardt-Ferner, E., et al., Highly modular structure and ligand binding by 
conformational capture in a minimalistic riboswitch. Angew Chem Int Ed Engl, 2010. 
49(35): p. 6216-9. 
 
 
  
128 
 
CHAPTER 3 
FACTORS THAT INFLUENCE SELECTIVITY OF THE NEOMYCIN-B 
RNA APTAMER 
 
A paper to be submitted to Nucleic Acid Research 
 
 
Muslum Ilgu, Ragothaman M Yennamalli$, Megan M. Kleckler, Monica H. Lamm, 
Taner Z. Sen and Marit Nilsen-Hamilton* 
 
 
$Current address: 440 Henry Mall, University of Wisconsin-Madison, Madison WI 53706 
 
*Corresponding author 
  
129 
 
ABSTRACT 
Nucleic acid aptamers are frequently characterized as highly specific for their ligands, 
which implies precise molecular recognition between interacting groups on the aptamer and 
ligand.  However, as short oligonucleotides, aptamers are likely to be structurally flexible, 
which suggests they might readily adjust to alternative ligands and therefore have low 
specificity.  To understand the role of aptamer structure in establishing ligand specificity, we 
examined the neomycin-B aptamer, which has been reported as highly selective for 
neomycin-B over other aminoglycosides.  Experimental values for ligand specificity 
correlated well, for almost all aminoglycosides, with the relative affinity scores from docking 
analysis with the aptamer considered rigid.  However, the aptamer specificity was much less 
constrained than previously reported.  Consistent with this finding, the molecular dynamics 
simulations predicted a very flexible binding pocket and pentaloop of the unoccupied 
aptamer and that the A16 in the pentaloop of the aptamer interact with the ligand as shown 
previously by NMR. To understand how the flexible pocket and A16 could collaborate to 
define ligand specificity, we examined the effect of ionic environment with aptamer variants 
containing replacement bases or a deletion at position 16, with 2-aminopurine substituted 
aptamer analogs and with NMR spectrometry.  The configuration of A16 in the aptamer was 
found to be ligand dependent and strongly affected by the ionic environment.  Contrary to 
what was predicted by previous NMR spectroscopy results, the presence of A16 in the 
pentaloop had no impact on the aptamer’s affinity for neomycin-B.  However, the A in this 
position appears to be responsible for the broader ligand specificity and large differences in 
affinity and ligand specificities between buffer conditions.  The results of this study 
demonstrate that to understand the structural contributions of an aptamer to its affinity and 
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specificity for ligands requires investigation of the structural dynamics in a variety of ionic 
environments. 
INTRODUCTION 
Nucleic acids, especially RNAs, have diverse functions in living organisms that 
frequently involve conformational rearrangements during ligand binding and signaling, co-
transcriptional folding, catalysis in ribozymes and the assembly of ribonucleoproteins (Al-
Hashimi and Walter 2008; Nick Taylor et al. 2008; Forster et al. 2012).  Alternatively, 
interaction between RNAs and inhibitory molecules can shift the RNA conformation to 
become nonfunctional as for the interaction between ribosomal RNA and aminoglycosides. 
Aminoglycosides are an important class of broad-spectrum antibiotics that target the 
A-site of the ribosome where mRNA and tRNA come to close proximity for the amino acid 
transfer of prokaryotic ribosomes and interfere with protein synthesis (Dahlberg 1989).  As a 
result of this binding, the helix-44 constituting the A-site is distorted and the genetic code is 
misread leading to ceasing of translation and death of bacteria (Moazed and Noller 1987).  
However, aminoglycosides also interact with a variety of other natural RNAs including Rev-
responsive element (RRE) (Zapp et al. 1993; Wang et al. 1997) and trans-activating region 
(TAR) of HIV-1 (Wang et al. 1998), the hepatitis delta virus (HDV) ribozyme (Rogers et al. 
1996; Chia et al. 1997), hammerhead (HH) ribozyme (Stage et al. 1995; Tor et al. 1998), 
RNase P (Mikkelsen et al. 1999), iron response element (IRE) (Lee et al. 2004), the site 1 
mRNA of thymidylate synthase (TS) (Tok et al. 1999), group 1 self-splicing introns (von 
Ahsen et al. 1991; von Ahsen et al. 1992) and tRNAPhe (Mikkelsen et al. 2001).  Some of 
these interactions cause their toxicity and so limit the usefulness of these otherwise very 
effective antibiotics. 
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To understand the interaction between RNA and aminoglycosides, RNA aptamers 
were selected for neomycin-B (Wallis et al. 1995), tobramycin (Wang et al. 1996; Werstuck 
and Green 1998), kanamycin-A (Lato et al. 1995; Werstuck and Green 1998) and 
kanamycin-B (Kwon et al. 2001).  Among these and the naturally occurring RNAs, a 23mer 
RNA aptamer selected against neomycin-B is the smallest RNA motif reported to have high 
affinity and specificity for neomycin-B over paromomycin (Wallis and Schroeder 1997; 
Cowan et al. 2000; de-los-Santos-Alvarez et al. 2007; Stampfl et al. 2007; de-los-Santos-
Alvarez et al. 2009).  Other aminoglycoside-binding RNA aptamers have been reported with 
different specificities than for their original targets, such as the lividomycin aptamer that 
recognizes neomycin-B and paromomycin equally well (Lato et al. 1995), the W13 RNA that 
binds tobramycin and neomycin-B with equal affinity (Wang and Rando 1995) and the 
kanamycin-B aptamer that recognizes aminoglycosides in the order tobramycin>kanamycin-
B>neomycin-B (Kwon et al. 2001).   
In this study, we have examined the structural basis of the specificity of the 23mer 
neomycin-B aptamer by an integrated experimental and computational approach.  Although 
an NMR-derived structure is available for the aptamer in complex with neomycin-B, there is 
no equivalent structure for the aptamer in the absence of ligand.  Therefore, we simulated 
the unoccupied aptamer structure using molecular dynamics (MD) software.  In these 
simulations adenosine (A16) in the pentaloop that is found in the NMR structure flipped over 
the binding pocket with hydrogen bonds to the fourth sugar ring of neomycin-B was found to 
be very mobile.  Contrary to the NMR results, the MD simulation and molecular docking 
analysis predicted that A16 interacts with the nonpolar face of the sugar moiety rather than 
through hydrogen bonds.  Experimental analysis of a 2-aminopurine substituted aptamer by 
fluorescence and isothermal titration calorimetry (ITC) were consistent with these predictions 
for the interaction with paromomycin and with the likelihood that A16 exists in a stacked 
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condition in the pentaloop of the unoccupied aptamer.  Experimental studies of aptamers 
with various bases in position 16 demonstrated a variable dependence on the nature of the 
base or its absence for affinity to different aminoglycosides.  In these studies, the aptamer 
also demonstrated a different profile of specificity for neomycin-B versus paromomycin 
compared with that previously reported (Wallis et al. 1995).  Follow-up studies with a series 
of 10 aminoglycosides indicated that the aptamer can recognize a variety of 
aminoglycosides with similar binding affinities.  These measured affinities were well-
correlated with the computationally determined molecular docking scores.  Further studies to 
examine the question of why the current studies showed a broad aminoglycoside specificity 
compared with previous studies of others that demonstrated a narrow specificity for 
neomycin-B revealed the significant impact of buffer constituents.  Thus, our results 
demonstrate that the interaction of this short RNA with aminoglycosides is influenced by its 
ionic environment, depends variably on different structural motifs. 
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MATERIALS AND METHODS 
Chemicals and RNAs 
Neomycin-B, paromomycin, ribostamycin, tobramycin, kanamycin-A, kanamycin-B, 
sisomicin, geneticin, netilmicin and amikacin were obtained as their sulfate salts from 
Sigma-Aldrich (St. Louis, MO). All RNA oligos were purchased from Integrated DNA 
Technologies Inc. (Coralville, IA) and they were kept at -20oC in ddH2O until used in the 
isothermal titration calorimetry (ITC) or in 2AP fluorescence experiments. Sodium 
cacodylate was purchased from Sigma-Aldrich (St. Louis, MO) and cacodylic acid was from 
Amresco (Solon, OH).  All other chemicals used to prepare the buffers were obtained from 
Fisher Scientific (Pittsburgh, PA). 
Isothermal titration calorimetry (ITC) 
ITC experiments were performed on a Microcal VP-ITC microcalorimeter 
(Northampton, MA), which was calibrated using the built-in electrical calibration check.  They 
were conducted in buffer A (13.5mM NaCl, 150mM KCl, 20mM HEPES, 0.22mM Na2HPO4, 
0.44mM KH2PO4, 120µM MgCl2, 120nM CaCl2, 100µM MgSO4 in ddH2O at pH 7.3 at 25°C), 
buffer B (10 mM Na2HPO4 at pH 6.1), buffer C (10 mM Na2HPO4 at pH 7.3), buffer D (10 
mM Na2HPO4, 5mM MgCl2 at pH 7.3), or buffer E (5 mM MgCl2, 200 mM NH4CI, 80 mM KCl, 
80 mM Na-cacodylate at pH 7.4).  For an individual experiments, both the RNAs in the 
reaction cell and the aminoglycosides (neomycin-B, paromomycin, ribostamycin, tobramycin, 
kanamycin-A, kanamycin-B, sisomicin, geneticin, netilmicin and amikacin) in the syringe 
were prepared in the same buffer.  All solutions were degassed at room temperature 
immediately prior to use in the experiment.  Following thermal equilibrium at 25°C, an initial 
60 second delay and a single 1.0 µL titrant injection, 30 serial injections of 10 µL 
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aminoglycoside was added at an interval of 150 seconds into the stirred sample cell (1.4 mL) 
containing the RNA oligos at a stirring rate of 310 rpm at 25°C.  The heat associated with 
each titration peak was integrated and plotted against the respective molar ratio of 
aminoglycoside and RNA.  To correct for heats of dilution from titrants, control experiments 
were performed by making identical injections of the titrant solution into a cell containing 
only the respective buffer and these values were subtracted from the titration of the titrant 
solution into the reaction cell.  Data were analyzed using nonlinear least-squares curve 
fitting in Origin7.0 (OriginLab Corp., Northampton, MA) using the standard one-binding site 
or two-binding site models supplied with Origin7.0 
Molecular docking of aminoglycosides to the neomycin RNA aptamer via DOCK 
Preparation of the RNA 
The RNA aptamer structure was obtained from Protein Data Bank (REF: PMID: 
10592235) (PDB, pdb id: 1nem (REF: PMID: 10425683)). After visualizing all the models in 
the pdb file the coordinates of the 5th model of NMR was used in this study.  The Dock Prep 
module of Chimera v 1.5.2 (Pettersen et al. 2004) was used to prepare the aptamer for 
docking.  The steps include removing water molecules, addition of hydrogen atoms, 
assigning partial charges (using AMBER parm99 partial charges) and saving the receptor in 
two formats; pdb and Tripos Mol2.  
Preparation of aminoglycoside antibiotics  
Ten aminoglycosides were selected for this study; amikacin, geneticin, kanamycin-A, 
kanamycin-B, neomycin-B, netilmicin, paromomycin, ribostamycin, sisomicin, and 
tobramycin.  A relative docking score for each aminoglycoside was established against that 
of neomycin-B.  Preparation of the ligands for docking involved the addition of hydrogens 
and assigning partial Gasteiger charges using BABEL v 1.6 (CCL.NET).  
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Active site identification and molecular docking 
The ligand (neomycin-B) in complex with the RNA as given in the pdb file was used 
to define the active site.  Atoms within a radius of 10 Å from neomycin-B were defined as the 
binding site (or active site) using the module SPHGEN of DOCK v6.2 (Kuntz et al. 1982). 
Molecular docking was performed using DOCK v6.2 (Kuntz et al. 1982), in which the 
first step is to construct a three-dimensional grid around the active site with a spacing of 
0.3Å.  The grid helps in the next steps of docking that includes but not limited to calculating 
the binding energies, avoiding steric clashes, etc.  The incremental construction method of 
“anchor-and-grow” was used to identify the most probable conformation of the ligand.  In this 
method, the largest substructure of the ligand (for example an aromatic ring) is first identified 
and placed in the active site as the so-called “anchors”.  The flexible elements (for example 
linking regions between aromatic rings) are then incrementally added, and each increment is 
evaluated for the lowest binding energy and minimal steric clash.  At this stage the anchors 
are held rigid and various orientations of flexible parts are allowed to “grow”.  Through such 
an “anchor-and-grow” method the entire conformational search space of the aminoglycoside 
is explored.  The parameters used in the molecular docking are given in Appendix S1. For 
each ligand, 1000 orientations were considered and the highly ranked conformation of the 
ligand along with the DOCK score is given as output. 
Post-docking analysis : Use of Ligplot to map the RNA-aminoglycoside interactions  
Ligplot v4.5.3 (Wallace et al. 1995) was used to map the interactions between the 
aptamer and the aminoglycosides and to validate the docking predictions.  Specifically, 
Ligplot plots the hydrogen bonds and hydrophobic contacts between the receptor and ligand 
from a given pdb.  It also gives a flattened 2D plot of the various residues of the receptor 
interacting with the ligand. 
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Measurement of 2-aminopurine (2AP) fluorescence intensity 
To determine the effect of aminoglycoside binding on the pentaloop structure of the 
neomycin aptamer, 2AP was introduced to replace adenosine at position 16.  For binding 
assays 1.0 µM of the neomycin aptamer was mixed with various concentrations of 
neomycin-B (0 – 10 µM), paromomycin (0 – 40 µM), or ribostamycin (0 – 10 µM) in buffer A, 
B, C, D and E.  The binding of aminoglycosides was monitored by 2AP fluorescence using a 
Cary Eclipse spectrofluorometer (Varian, Palo Alto, CA).  RNA alone in the buffer was 
subtracted from the raw data.  Quartz cells with 1 cm path lengths were used for excitation 
and emission spectra that were acquired from 255 nm to 350 nm and 320 nm to 500 nm, 
respectively to establish the maximum excitation and emission wavelengths for further 
studies. 	  For all further measurements the excitation wavelength (λex) was 307 nm and the 
emission wavelength (λem) was 370 nm and the emission slit was 5 nm. The effects of 
aminoglycosides binding to the aptamer on 2AP fluorescence were fit to the following 
equation by a nonlinear regression function using CoStat (CoHort software, Monterey, CA):  
ΔF/ΔFmax=a*[aminoglycoside]/(Kd+ [aminoglycoside]); where, ΔF is the fluorescence 
change of F370 (for 2AP), ΔFmax is the maximal 2AP fluorescence change of the bound 
compared to the free state. [aminoglycoside] is the concentration of aminoglycoside, “Kd” is 
the dissociation constant for the neomycin aptamer aminoglycoside interaction and “a” is a 
constant. 
Molecular dynamics simulations using GROMACS 
Coordinates of the neomycin-B RNA aptamer were taken from model 5 of the 
experimental NMR structure (Protein Data Bank (PDB) code: 1nem) (Jiang et al. 1999).  
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Preparing Neomycin-B for MD simulations 
Force field parameters for neomycin-B were obtained from SwissParam (Zoete et al. 
2011), which provides topology and parameters for small organic molecules compatible with 
both the CHARMM22 all atom force field and GROMACS.  The data was derived from the 
Merck Molecular ForceField (MMFF) and the dihedral angle terms were taken, as is, where 
the harmonic part of the bond, angle and improper terms were retained.  Van der Waals 
parameters were taken from the closest atom type in CHARMM22 and the charges were 
obtained from MMFF.  Generally, these estimated charges are not accurate enough to use 
in MD simulations.  Therefore, the partial charges were calculated with GAMESS (General 
Atomic and Molecular Electronic Structure System) by fitting the electrostatic potentials 
obtained from the quantum mechanical ab initio calculations at the HF/6-31G* level 
(Spackman 1996). 
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RESULTS 
Broad aminoglycoside specificity of the neomycin-B aptamer 
With the goal of utilizing the 23mer neomycin-B aptamer in an intracellular 
environment, under which conditions it has been previously applied, we tested the affinity 
and specificity of this aptamer using buffer conditions that resemble those inside the cell 
(Buffer A).  To our surprise, the relative dissociation constants (Kds) of this aptamer for 
neomycin-B and paromomycin were quite different from those previously reported (Wallis et 
al. 1995; Wallis and Schroeder 1997).  Whereas it had previously been found that the 
aptamer is highly specific for neomycin-B, binding paromomycin with more than 100-fold 
lower affinity, we observed only a 5-fold difference in Kd between paromomycin and 
neomycin-B in buffer A.  The Kd for paromomycin was 1.4 + 0.19 (N=5 independent 
estimates) compared with 0.29 + 0.06 (N=8) for neomycin-B.  To further examine the 
aptamer specificity, eight more ligands were tested from both neomycin– and kanamycin-
family aminoglycosides (Fig. 1A) with the result that the aptamer can recognize both family 
members of the aminoglycosides (Table S1).   
Molecular docking and MD simulations predict a hydrophobic interaction between 
A16 and the sugar and a flexible pentaloop 
To develop a better understanding of the interaction of the neomycin-B aptamer (Fig. 
1B) and aminoglycosides, we explored the use of molecular docking analysis in which the 
RNA was considered as a rigid body and the aminoglycosides as explicitly-protonated with 
rotational freedom.  The results of this analysis showed a correlation between the 
experimental results and the docking scores for 9 of the 10 aminoglycosides tested with an 
R2 of 0.71 (Fig. 1C, Table S2).  The exception was ribostamycin, for which the results 
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significantly deviated from the derived linear fit (Fig. 1C, gray triangle).  Unlike other 
neomycin-family aminoglycoside tested in this study, ribostamycin is missing the fourth ring 
(Fig. 1A).  The very similar binding affinity between ribostamycin and neomycin-B 
determined by ITC suggests that ring IV plays a minor role in RNA binding, consistent with 
observations from the NMR study (Jiang et al. 1999). 
When the NMR and molecular docking results were compared, a significant 
difference between them was how the adenosine at position 16 (A16) in the pentaloop 
interacts with the aminoglycoside.  Whereas the NMR spectra showed hydrogen bonding 
between the base and neomycin-B, a Ligplot analysis of the aptamer-aminoglycoside 
predicted the A16 to make hydrophobic contacts with the aminoglycosides (Fig. S3).  To 
investigate further this interaction between the aptamer and aminoglycosides, we used MD 
simulation with force fields for the neomycin-B inserted (Wallis and Schroeder 1997).  As for 
the docking analysis, the A16 was also predicted by MD to interact with the nonpolar face of 
the sugar ring rather than by hydrogen bonding as shown by NMR. 
The unoccupied aptamer was also simulated by MD after removing the neomycin-B 
coordinates.  A comparison of the simulations of the occupied and unoccupied aptamers 
showed a flexible binding pocket and a large RMSD for A16 in the pentaloop reflecting a 
relatively wide dynamic range for this base in the unoccupied aptamer that is restricted 
when neomycin-B is in the binding pocket (Fig. 2). 
Experimental analysis of an aptamer with 2-aminopurine in position 16 identifies a 
shift in the environment of A16 with ligand binding 
To test the predictions made by the Ligplot and MD analysis that A16 is very mobile 
and interacts with the aminoglycoside on the nonpolar face of the fourth ring, we created an 
aptamer with the A16 replaced by 2-aminopurine (2AP).   A mobile base that interacts by 
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hydrophobic forces with the aminoglycoside is expected to increase in fluorescence upon 
ligand binding.  A large increase in 2AP fluorescence was observed with the binding of 
neomycin-B and other aminoglycosides.  Using this fluorescent response, we determined 
the Kds for neomycin-B, paromomycin and ribostomycin (Fig. 3A).  Although the Kds 
determined for neomycin-B and paromomycin matched well with the ITC results, the value 
obtained for ribostamycin did not (Fig. 3B, Table S1 and S5).  However, the Kd determined 
by 2AP fluorescence moved the calculated ∆G for ribostamycin more in line with the other 
aminoglycosides in relation to the docking scores (Fig. 3C). 
Effects of buffer components on the aptamer-aminoglycoside specificity 
Neither the DOCK analysis nor the MD simulations explained why the originally 
reported aminoglycoside specificity of this neomycin-B RNA aptamer was so different from 
that observed here.  Consequently, we explored the possibility that the buffer constituents 
might affect specificity and used the 2AP16 aptamer to test the binding of aminoglycosides 
the buffers used in previous studies (Fig. 4).  High specificity for neomycin-B over 
paromomycin and ribostamycin was confirmed in cacodylate buffer (E) as previously 
reported (Wallis et al. 1995).  However, in the phosphate buffer (B) used for NMR structural 
determination (Jiang et al. 1999) the aptamer was less specific for neomycin-B over 
paromomycin as found in the buffer (A) used for our study.  The pH does not seem a factor 
in the specificity difference for aminoglycoside as the aptamer showed similar lack of 
specificity in the NMR buffer composition at pH 6.1 and 7.3 (Fig. 4 compare buffers B and C).  
The possibility of a pH effect on aptamer binding was also tested with ITC (Fig. 5A).  
Here it was found that the ITC titrations displayed a nonhyperbolic profile with a large heat 
release in the early portion of the titration up to a molar ratio of 1, after which a normal 
titration curve was observed.  Such nonhyperbolic titration profiles suggest the possibility of 
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a significant structural change in the aptamer prior to binding to the aminoglycoside and 
therefore a considerable entropic component to the binding interaction.   
Magnesium ions have been shown to promote folding by lowering the entropic cost 
(Fiore et al. 2012).  Therefore, we tested the effect of 5mM MgCl2 at pH 7.3 (buffer D) on 
aptamer binding to neomycin-B, paromomycin and ribostamycin (Fig. 6B).  For each 
aminoglycoside, the presence of MgCl2 shifted the titration curve toward a hyperbolic profile. 
These results suggest that the interaction of aptamer with aminoglycosides includes a large 
entropic cost that is minimized by the presence of MgCl2. 
The role of the A16 in establishing specificity of aminoglycoside binding 
The prominent position of A16 in the NMR structure, being flipped over neomycin-B, 
suggests that it might be important for establishing affinity and perhaps specificity of 
aminoglycoside binding.  We tested this hypothesis by comparing the abilities of four 
aptamer variants in this position to bind aminoglycosides.  Binding to neomycin-B and 
paromomycin was largely unaffected by changing the base in position 16.  Even deleting the 
base did not decrease affinity of the aptamer for neomycin-B although it decreased the 
affinity for paromomycin by 5-fold (Fig. 6, Table S4).  By contrast, changing the base 
decreased the affinity for ribostamycin by 5-fold (A16G) and 7-fold (A16U and A16C) and 
deleting the base dramatically decreased the affinity for ribostamycin by 40-fold (Fig. 6, 
Table S4).    
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DISCUSSION  
Our study of the 23mer neomycin-B RNA aptamer showed the expected high affinity 
binding with neomycin-B, but also identified an unexpectedly broad aminoglycoside 
specificity.  Previous NMR studies of the structure of the aptamer occupied by neomycin-B 
demonstrated that binding to aminoglycosides by this aptamer is largely determined by the 
neamine core (ring I and II), which sits deep in the major groove and has both electrostatic 
and hydrogen bonding interactions.   
The aminoglycoside-aptamer interactions were also predicted computationally with 
the NMR-derived aptamer structure as a rigid body to dock each of 9 aminoglycosides.  
Although most available docking software programs have been developed for protein-ligand 
systems, use of the docking software DOCK for a nucleic acid-ligand system was validated 
with a set of available RNA-small complexes previously solved by X-ray crystallography. 
After some modification of the algorithms and parameters, 70% of the small molecules with 
fewer than seven rotatable bonds and 26% of the small molecules with fewer than 13 
rotatable bonds could be successfully recreated (Lang et al. 2009).  Here, the experimental 
results from ITC analysis of aminoglycoside binding correlated well with the molecular 
docking scores (R2 = 0.71), which suggests that the NMR structure determined with 
neomycin-B in the aptamer pocket (Jiang et al. 1999) is similar to that which interacts with 
other aminoglycosides.   One exception was ribostamycin. 
By comparison with the reported high specificity of the neomycin aptamer for 
neomycin-B, we found a broader specificity for a number of aminoglycosides.  To 
understand the molecular basis for the specificity, we simulated the occupied and 
unoccupied aptamer using MD simulations.  The simulated occupied aptamer was within 3 Ǻ 
RMSD of the initial NMR structure and so appeared essentially the same as the NMR 
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structure.  With the neomycin-B removed from the NMR coordinates, the aptamer retained 
essentially the same structure but the adenosine at position 16 of the pentaloop was 
extremely mobile.  This base was predicted by the MD simulation of the occupied aptamer 
to interact with the nonpolar face of the fourth neomycin-B ring.   A similar result was 
predicted computationally by Ligplot. 
We tested the predictions of the MD simulations regarding the interaction of A16 with 
aminoglycosides by replacing A16 with 2-aminopurine.  The resulting aptamer (2AP16) 
demonstrated an increase in fluorescence on binding to aminoglycosides, which is expected 
if the interaction changes the position of A16 to a more solvent accessible location.  This 
result confirmed the Ligplot showing the hydrophobic interaction and MD predictions where 
we found it flexible as it transits from bound to unbound form.  We then calculated the Kds 
for neomycin-B, paramomycin and ribostamycin using the 2AP fluorescence change as 
monitor of binding.  The results from these studies matched the estimated Kds obtained by 
ITC for neomycin-B and paromomycin but the results for ribostamycin were quite different.  
As ribostamycin was the only aminoglycoside for which the correlation was very poor 
between ITC and DOCK scores, it was of interest to note that the ∆G determined for 
ribostamycin based on the 2AP titration was much more in line with the other 
aminoglycosides.  These results suggest that the interaction between the aptamer and 
ribostamycin might involve a larger entropic component than for the other aminoglycosides, 
which appear to be mainly enthalpy-driven resulting from electrostatic and hydrogen 
bonding interactions as evidenced by the negative ΔH and ΔS determined by ITC. 
We explored the basis for the very different reported specificities of the neomycin-B 
aptamer and discovered that the interaction of this aptamer with aminoglycosides is very 
dependent on the buffer constituents.  The buffer in which all of our earlier experiments were 
performed contained a mixture of salts at the concentration expected inside the average 
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mammalian cell with an appropriate intracellular pH.  In this buffer, and in the phosphate 
buffer used for obtaining the NMR structure, the aptamer shows a broad specificity with less 
preference for neomycin-B over paromomycin than it does in the cacocylate-based buffer 
used in previous studies (Wallis et al. 1995).  These results were obtained using the 
fluorescent output of the 2AP16 aptamer.  When similar results were sought by ITC, it was 
found that the titration in the presence of the NMR buffer demonstrated evidence of a 
structural change in the form of a significant increase in heat release in the initial phase of 
the titration followed by a standard titration profile.  We examined the possibility that this dip 
in the ITC titration was related to the pH or lack of divalent cation content of the buffer and 
identified the latter as the reason.  When magnesium was included in the buffer, the initial 
dip in the titration profile was largely eliminated.  Magnesium ions are known to stabilize 
RNA tertiary structure (Misra and Draper 1998).  Although previously thought to promote 
RNA folding by shielding the electrostatic repulsion between the RNA backbone charges, a 
recent analysis suggests that the role of magnesium is to facilitate counterion uptake, 
decreasing its entropic penalty and thereby reducing disorder of the ensemble (Fiore et al. 
2012).  
Our results suggest that the presence of magnesium increases the adoption of a 
structure compatible with high affinity aminoglycoside binding, but it does not affect the 
specificity of the aptamer for aminoglycosides.  This is evident when the relative affinities for 
the aminoglycosides are compared in 10 mM phosphate buffer in the presence and absence 
of 5 mM MgCl2 and also in the more complex buffer A that mimics intracellular conditions.  
On the other hand, cacodylate buffer (E) that contains NaCl, KCl and NH4Cl has a dramatic 
effect on aptamer specificity. 
We also examined the role of adenosine 16 in the pentaloop and discovered that this 
base does not contribute to binding of neomycin-B and can be deleted without changing the 
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affinity of the aptamer for this aminoglycoside.  This result was surprising because the 
reported NMR structure shows the base lying over the sugar and interacting by hydrogen 
bonding.  Unlike for neomycin-B, the aptamer affinity for ribostamycin was very sensitive to 
both the presence and nature of the base in position 16.  Another profile was observed for 
the binding of paromomycin for which the nature of the base did not seem to be critical, but 
removing it decreased the binding affinity by 5-fold.  Thus, the nature of the interaction with 
the neomycin-B aptamer varies with the aminoglycoside and the specificity for 
aminoglycoside can be significantly altered by the buffer components in the environment 
and the change or removal of a single base.  
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FIGURE LEGENDS 
Figure 1. Chemical structures of neomycin and kanamycin-class aminoglycosides 
used in docking with 23mer neomycin-B RNA aptamer and comparison of docking 
scores with experimental results. A) The neomycin-class aminoglycoside antibiotics have 
a 2-deoxystreptamine (2-DOS, ring II), disubstituted at positions 4 and 5 positions while the 
kanamycin-class has substitutions at positions 4 and 6.  The substitutions at the R positions 
are indicated for neomycin-class aminoglycoides. For kanamycin-class aminoglycosides, the 
main substations (R1 and R2) are located on the ring I. Sisosmicin and netilmicin differ with 
only a single substitution at the R position on 2-DOS (ring II).  The structure of geneticin 
differ from the rest of the aminoglycosides such that it has an extra methyl attached to C6 on 
the ring I, and the other two attached to ring III one on the amino at 3rd position and the other 
at 4th position.  B) Predicted secondary structure of the 23mer Neomycin-B RNA 
Aptamer. The secondary structure of the neomycin-B RNA aptamer was predicted by 
RNAstructure4.6 (Matthews et al. 2004). In order to be consistent with the previous NMR 
study, we kept the same numbering used in Jiang et al. (1999) in which the first base is 
labeled as position 4.  C) Comparison of the predicted docking scores obtained from 
DOCK6.2 with the experimentally (ITC)-calculated binding free energies (ΔG) of 
aminoglycosides binding to the neomycin-B RNA aptamer Isothermal titration calorimetry 
experiments determined the binding free energies (kcal/mol) for aminoglycosides as follows: 
neomycin-B < ribostamycin < kanamycin-B < paromomycin < tobramycin < sisomicin < 
gentamicin < geneticin < kanamycin-A.  This is the order of binding from the strongest to the 
weakest binder of the aptamer.  Also, docking predicted the order of aminoglycoside binding 
with 71% correlation with ITC experiments if ribostamycin were not included.  With 
ribostamycin (gray triangle) included in the calculation the correlation was 36%. 
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Figure 2. Comparison of RMSDs from molecular dynamics (MD) simulations. 
Comparison of the RMSDs between the occupied (black) and unoccupied (gray) MD 
simulations showed the A16 as the most flexible segment and with the largest difference 
between occupied and unoccupied forms in the region of A14 to A16.  In the occupied 
aptamer the A16 is found over the neomycin-B.  The corresponding atom numbers for the 
residue A16 are located between 395 and 427, where the highest difference in RMSD is 
observed between the occupied and unoccupied RNA simulations. 
Figure 3.  Aptamer affinity monitored by 2AP fluorescence and compared with ITC. A) 
The 2AP16 aptamer was titrated with neomycin-B (black squares), paromomycin (gray 
circles) and ribostamycin (white triangles) and the titration curves were fitted for 2AP 
fluorescence using a hyperbolic model.  B) The Ka’s were determined by ITC (black bars) 
and 2AP fluorescence (gray bars).  Neomycin-B and paromomycin binding affinities are 
similar when calculated using either method (fluorescence or ITC); however, the 
ribostamycin binding affinity differed depending on the method. C) When the Ka for 
ribostamycin from 2AP fluorescence (Fl) was included in figure 1C, the ribostamycin point is 
closer to the correlation fit line obtained from the comparison of ITC and docking scores.  
Figure 4.  Effect of buffer on aminoglycoside binding to the neomycin-B aptamer. A 
comparison of 2AP fluorescence changes upon neomycin-B (black squares), paromomycin 
(gray circles) and ribostamycin (white triangles) binding in the presence of different ionic 
conditions. Buffer B: NMR buffer at pH 6.1, Buffer C: NMR buffer at pH 7.3, Buffer D: 
NMR buffer with 5mM MgCl2 at pH 7.3 and Buffer E: in cacodylate-based binding buffer 
used by Wallis et al. In buffer E, the binding of paromomycin and ribostamycin is 
significantly lower than in other buffers, whereas the binding of neomycin-B is not affected.  
The fluorescence measurements were taken at 370 nm after exciting at 307 nm in a 
spectrofluorometer.  
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Figure 5.  Comparison of heat releases upon aminoglycoside binding to neomycin 
RNA aptamer in buffers with varying pH or Mg.  A) The effect of pH on heat release upon 
neomycin-B and paromomycin binding at pH 6.1 (gray) and at pH 7.3 (black). The binding 
modes for neomycin-B and paromomycin were the same at different pHs.  However, the 
observed heat releases were larger at pH 7.3 for both titrations. B) The heat releases from 
neomycin-B, paromomycin and ribostamycin binding with (gray) and without magnesium 
ions (black). With the inclusion of magnesium the initial dip in the heat release was not 
observed. 
Figure 6.  The effect of adenine on aminoglycoside binding and selectivity of the 
neomycin-B RNA aptamer.  Replacing the adenine with other nucleotide bases (cytosine-
A16C, guanine-A16G and uracil-A16C) or removing (ΔA16) changes the behavior of the 
neomycin-B RNA aptamer in terms of its selectivity and ligand binding ability in buffer A.  
The data represent the average association constants (Kas) obtained from a minimum of two 
replicate ITC experiments.  Refer to the supplemental Table 4 for the Kd values for each 
variant.   
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SUPPORTING INFORMATION 
Table S1.  Comparison of binding affinities of the neomycin-B RNA aptamer to a 
variety of aminoglycosides 
 Kd, µM (Replicates) 
Neomycin-B 0.29 ± 0.05 (8) 
Ribostamycin 0.49 ± 0.08 (5) 
Kanamycin-B 0.75 ± 0.26 (5) 
Paromomycin 1.4 ± 0.19 (5) 
Tobramycin 4.8 ± 0.95 (3) 
Sisomicin 8.4 ± 2.9 (3) 
Geneticin 26 ± 9.3 (5) 
Kanamycin-A 43 ± 3.6 (3) 
Amikacin 90 (4, 1*) 
Netilmicin 99 (5, 1*) 
 
Dissociation constants of aminoglycosides were determined via isothermal titration 
calorimetry (ITC) experiments as described in materials and methods section and their 
respective average Kd values are represented. *For amikacin and netilmicin, the value 
represent a single successful ITC result with a good fit out of 4 and 5 respective 
experiments, the rest indicated no observable interaction with the neomycin-B RNA aptamer. 
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Table S2.  Docking scores for the aminoglycosides 
Ligand name 
DOCK score 
(kcal/mol) for 
explicitly protonated 
Neomycin-B -171.678558 
Paromomycin -156.995514 
Kanamycin-B -147.330307 
Tobramycin -141.835739 
Sisomicin -139.940292 
Netilmicin -138.805573 
Amikacin -135.783234 
Kanamycin-A -130.461761 
Geneticin -129.358246 
Ribostamycin -126.219162 
 
Docking scores obtained from DOCK6.2 and the scores are placed from the best binder to 
the least. 
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Figure S3.  Predicted interaction between the neomycin RNA aptamer and neomycin-
B via docking 
 
A16 was found to have hydrophobic interactions instead of hydrogen bonding as seen in 
NMR.  Also, C7, U8, G9, G18, and U21 were found to have hydrogen bonding interactions 
with neomycin-B. 
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Table S4.   Comparison of binding affinities of the neomycin-B RNA aptamer variants 
to neomycin-B, ribostamycin and paromomycin. 
 
  Dissociation Constants (µM) 
 A16 A16C A16U A16G    ΔA16 
Neomycin-B 0.29 ± 0.05 0.17 ± 0.09 0.32 ± 0.1 0.24 ± 0.04 0.26 ± 0.06 
Ribostamycin 0.49 ± 0.08 2.8 ± 0.85 2.8 ± 0.19 1.85 ± 0.21 13.3 ± 3.89 
Paromomycin 1.4 ± 0.19 0.93 ± 0.08 1.48 ± 0.23 2.52 ± 0.45  7.5 ± 0.85 
 
Dissociation constants of aminoglycosides were determined via ITC experiments as 
described in materials and methods section with buffer A and their respective average Kd 
values are represented. 
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Table S5.  Dissociation constants of aminoglycosides to the neomycin aptamer in 
different buffers. 
Dissociation Constants (µM) 
 Buffer A Buffer B Buffer C Buffer D Buffer E 
Neomycin-B 0.53 ± 0.09 0.39 ± 0.08 0.39 ± 0.06 1.69 ± 0.20 0.79 ± 0.23 
Ribostamycin 2.51 ± 0.34 0.45 ± 0.08 0.39 ± 0.06 24.9 ± 8.51 1.06 ± 0.38 
Paromomycin 1.17 ± 0.25 1.21 ± 0.25 19.9 ± 8.1 23.7 ± 11.3 0.59 ± 0.11 
 
Comparison of the Kds for neomycin-B, paromomycin and ribostamycin binding under 
different buffer conditions calculated from the 2AP study.  Aminoglycoside binding in buffer 
A, B, C, D and E.  The fluorescence measurements are taken at 370nm after exciting at 
307nm in a spectrofluorometer. 
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ABSTRACT 
One of the most challenging requirements in cancer treatment is maintaining 
sufficiently high intracellular drug concentration due to the upregulation of multi-drug 
transporters by cancer cells.  Modern drug synthesis research has attempted to address this 
problem by many approaches that are mainly based on “push” mechanisms.  However, the 
extent to which the extracellular drug concentration can be increased is limited.  Therefore, 
we have tested a different approach based on a “pull” mechanism by expressing molecules 
that can bind drugs inside the cells.  These expressed molecules are aptamers, single 
stranded nucleic acids selected for tight and specific binding to their targets.  The action of 
mobile aptamers with specificity for a particular drug was predicted by a prior mathematical 
model to increase the intracellular drug concentration.  To test this hypothesis, the E. coli 
BL21 strain was transformed with plasmids from which aptamers were expressed and the 
effect was observed over a 12h period on the toxicity of a variety of aminoglycosides as 
compared to the E. coli without aptamers.  In this study, we observed a decrease in the IC50 
values by 2 to 5 fold for several aminoglycoside antibiotics with several aminoglycoside-
binding aptamers.  This study points to a completely new approach to increase the efficacy 
of drugs via intracellular expression of RNA aptamers or other small mobile drug receptors. 
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INTRODUCTION 
The entry of unnatural chemicals or toxins into cells is limited by the lipid bilayer 
membrane that surrounds cells and serves as a protective layer.  Most drugs used to treat 
diseases must penetrate this barrier to reach their targets without the benefit of transporters 
that are used by cells to import natural products for metabolism.  Cells have mechanisms to 
increase their survival rates in the presence of toxins.  Cancer cell populations evolve to 
upregulate the drug transporters or increase expression of the target protein of the drug and 
thereby become drug resistant.  In either case, the drug cannot accumulate to a sufficiently 
high concentration inside the cells, which as a consequence are more likely to survive and 
proliferate.  Cancer cells that survive a drug treatment frequently have elevated levels of the 
drug pumps called Pgp (P-glycoprotein) or MDR (multi drug resistance protein) [1, 2].  These 
efflux pumps help the cells in which they are elevated to survive, with the result that the 
cancer cell population tends to become increasingly drug resistant with continued drug 
treatment.   Cells can also become resistant to a drug by increasing the intracellular 
concentration of the drug’s target protein.  The excess target protein soaks up the drug, 
leaving some of the target protein still active and thus these cells survive.   
Many approaches have been taken to combat drug resistance [3].  These 
approaches involve either directly targeting the pumps with drugs or antibodies, or 
decreasing the pump mRNA levels by antisense DNAs or RNAi, or decreasing pump mRNA 
production by targeting the relevant transcriptional regulators.  Computational approaches 
can also be used to design anti-pump drugs and recently high-resolution 3D structures of 
specific protein pumps supported these approaches.  One of these strategies may 
eventually lead to the development of small molecule drugs to solve the problem of multi 
drug resistance; however, none of them have so far been very successful in combating multi 
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drug resistance a new approach to combating the resistant condition would have useful 
medical applications.   
By mathematical modeling it was proposed that the intracellular concentration of 
drug might be increased by the presence of a receptor for that drug inside a mammalian cell 
[4].  In that study, the receptor was proposed to be a small RNA aptamer that can bind to a 
drug.  Aptamers were also utilized as intramers in several other studies and successfully 
shown to be effective in inhibiting their targets [5, 6] or controlling gene expression [7].  
Here, we tested, in a bacterial system, the effects of expressed the RNA aptamers that 
could bind to aminoglycosides on the IC50 values of the aminoglycosides.  Our hypothesis 
was that aminoglycoside-RNA-binders, when expressed in bacteria, will increase the 
sensitivity of the bacteria to the aminoglycoside to which the aptamer bound.  We used both 
natural RNAs and in vitro selected aptamers that bind aminoglycosides.  The complete 
binding affinities of a group of aminoglycosides to these RNAs were determined. The RNAs 
were cloned for bacterial expression and tested for their effects on bacterial growth in the 
presence and absence of aminoglycosides over a 12h period.  The results showed that 
expression of several aminoglycoside-binding aptamers lowered the IC50 values by 2 to 5 
fold for the aptamer aminoglycoside ligands.   
Currently, we are testing the other predictions from the mathematical model [4].  One 
prediction was that expressing aptamers would increase the intracellular concentration of 
the target drug.  Therefore, we are developing a method to measure the intracellular 
concentration of aminoglycosides.  Another prediction to test is the mobility of the aptamers, 
which was shown to be critical for the aptamer effect on drug concentration.  To test this, 
aptamers will be cloned into a larger mRNA cassette and the effect of these longer RNAs 
compared with shorter single unit aptamers.  
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Mechanism of action of the aminoglycosides 
Aminoglycoside antibiotics are produced as secondary metabolites and secreted by 
Streptomyces and Actinomyces spp. to have advantage over its neighboring species.  
These natural compounds were isolated from their fungal sources and have been 
successfully used as antibiotics for many years.  In addition, there are semi-synthetic 
aminoglycosides like amikacin, dibekacin, sisomicin and netilmicin.  Chemically, 
aminoglycosides can be divided into two main categories; streptomycin and 2-
deoxystreptamine-containing ones.  The latter is further divided into neomycin-class or 4,5-
disubstituted (e.g., neomycin-B, ribostamycin and paromomycin) and kanamycin-class or 
4,6-disubstituted deoxystreptamine (e.g., tobramycin, kanamycin-A and –B) [8].  Both 
classes are composed of amino sugars linked to its basic building block, 2-
deoxystreptamine with common functional groups on rings I and II, which form the neamine 
core (Fig.1A).  
Aminoglycosides interact directly with the conserved regions of the ribosomal RNA 
A-site (aminoacyl-tRNA site or decoding region) in the bacterial ribosomes as their primary 
target and exert their biological effects [9-12].  Aminoglycoside binding shifts the position of 
the two adenines A1492 and A1493 in the 16S rRNA and decreases the dissociation rate of 
tRNAs from the A-site, thereby inducing misreading of the genetic code and inhibiting 
translation, which in turn results in bacterial cell death [13, 14].  In addition, 
aminoglycosides’ preferential targeting capability to prokaryotic ribosomes over eukaryotic 
ribosomes makes their clinical use more successful [15] and they have been used to treat 
Gram-negative and Gram-positive bacterial infections for over half a century [8]. 
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Possible RNAs to use as DRAGINs that interact with aminoglycosides 
A variety of small RNAs have been shown to interact with aminoglycosides over the 
past thirty years [16-18].  These RNAs include mainly non-coding RNAs whose function and 
activity can be biologically significant but are interfered with by the binding of 
aminoglycosides.  
In addition to the A-site, other RNAs involved in a variety of biochemical pathways 
have been recognized as aminoglycoside targets.  For example, aminoglycosides are also 
known to interact with viral mRNAs; Rev-responsive element (RRE) [19-21] and trans-
activating region (TAR) of HIV-1 [22, 23], ribozymes; the hammerhead [24, 25], hairpin [26] 
and human hepatitis delta virus (HDV) [27, 28].  Furthermore, yeast tRNAPhe [29] and 
tRNAAsp [30], iron responsive element (IRE) [31], the T-box antiterminator RNA [32], the 5' 
untranslated region of thymidylate synthase mRNA [33], transfer messenger RNA (tmRNA) 
[34], RNase P [35], group I self-splicing intron [36-38] and the tau exon 10 splicing 
regulatory element [39] can also be targeted by aminoglycosides.  In addition to these 
natural RNAs, some aminoglycoside-specific RNA aptamers have been in vitro selected 
against neomycin-B [40, 41], tobramycin [7, 42], kanamycin-A [7] and kanamycin-B [43] 
using SELEX.  Studies of the interaction of these functional domains of RNAs with 
aminoglycosides have validated the potential use of aminoglycosides as successful drugs. 
 Aminoglycoside-RNA binding is mediated through hydrogen bonding between 
amino and hydroxyl groups of aminoglycosides and RNA bases [42] as well as mutual 
electrostatic interactions between the positively charged amino groups of the 
aminoglycosides and negatively charged phosphate backbone of the RNA [44].  As a result, 
aminoglycosides can bind to the bulge regions of the RNAs listed above with affinities in the 
low µM range.  We utilized the smallest aminoglycoside-binding RNAs including the 23mer 
neomycin, 25mer kanamycin and 27mer tobramycin aptamers as well as 27mer A-site, 
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30mer RRE of HIV-1 and 33mer thymidylate synthase mRNA region in our ITC studies and 
observed their effects on decreasing bacterial growth as predicted by the previous 
mathematical model. 
MATERIALS AND METHODS 
Bacterial growth curves were determined in a Synergy2  plate-reader (Biotek).  Non-
tissue culture treated, flat bottom 96-well polystyrene microtest plates were purchased from 
Falcon (originally from Becton-Dickinson Labware).  96-well plate sealing membranes were 
regular strength breathe-easy sealing membranes from Research Products International 
Corp.  Micropipettes were Eppendorf purchased from Reference and Pipetmen were from 
Gilson.   Test tubes were 14ml Polystyrene Round-Bottom Tubes from Falcon.  The 
incubator was a Max-Q 4000 (Branstead Lab Inc.). 
Aminoglycoside antibiotics used in the experiments were neomycin-B, paromomycin, 
tobramycin, kanamycin-A and -B that were obtained as their sulfate salts from Sigma-Aldrich 
(St. Louis, MO).  E. coli BL21(DE3)star was obtained from Invitrogen (Eugene, OR) as 
chemically competent.  
The list of plasmids is as follows.  
pMU159 (empty plasmid used as a control); kanamycin aptamer; 1mer, 3mer, 7mer, 
12mer, 14mer and 28mer, tobramycin aptamer; 1mer, 5mer, 7mer, 8mer, 10mer, 12mer, 
neomycin aptamer; 1mer, 3mer, 8mer, 15mer, 16mer, 24mer, 32mer. A-site mimic/decoding 
region; 1mer and 3mer, thymidylate synthase mRNA region; 1mer and 3mer and Rev-
responsive element (RRE); 1mer and 2mer.   
All RNA oligonucleotides were obtained from Integrated DNA Technologies Inc. 
(Coralville, IA) and they were kept at -20oC in ddH2O until used in the isothermal titration 
calorimetry (ITC) assays. 
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Bacterial growth analysis 
Transformed BL21 cultures were primarily grown for about 16h at 37oC in Luria-
Bertani (LB) broth with 100 µg/mL ampicillin.  Then, the cultures were diluted about 100 
times and induced with 1 mM IPTG for 1h at 37oC with shaking 250 rpm.  Following the 
induction, aminoglycosides (neomycin-B, paromomycin, tobramycin, and kanamycin-A and -
B) were added and the cultures were grown for 12h at 37oC in a plate reader (Biotek, model: 
Synergy HT). The OD600 values were recorded at designated time points (every 15 or 30 
min or every hour) and the resulting growth curves were analyzed by Microsoft Excel 
software. 
Analysis of binding interaction by isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry (ITC) experiments were performed on a Microcal VP-
ITC microcalorimeter (Northampton, MA), which was calibrated using the built-in electrical 
calibration check.  All ITC experiments were conducted in buffer A (13.5 mM NaCl, 150 mM 
KCl, 20 mM HEPES, 0.22 mM Na2HPO4, 0.44 mM KH2PO4, 120 µM MgCl2, 120 nM CaCl2, 
100 µM MgSO4 in ddH2O at pH 7.3 and 25°C), which was constituted to resemble 
intracellular conditions.  Both the RNAs in the reaction cell and the aminoglycosides 
(neomycin-B, paromomycin, tobramycin, and kanamycin-A and –B) were prepared in buffer 
A.  All solutions were degassed at room temperature immediately prior to use.  Titrant 
solution (10 µL) of each aminoglycoside was added from a 300 µL microsyringe at an 
interval of 150 sec into the stirred sample cell (1.4288 mL) containing the RNA 
oligonucleotides at a stirring rate of 310 rpm at 25°C.  To correct for heats of dilution 
resulting from the ligands, control experiments were performed by making the identical 
injections of the titrant solution into a cell containing only buffer and then these values were 
subtracted from the titration of the titrant solution into the reaction cell.  Data were analyzed 
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using nonlinear least-squares curve fitting in Origin7.0 (Origin Lab Corp., Northampton, MA) 
using the standard one and two binding site models supplied within Origin7.0.  
Determination of IC50 values for aminoglycosides 
 We determined the IC50 values for neomycin-B, paromomycin, tobramycin, 
kanamycin-A and –B by varying the concentrations of the aminoglycosides and determining 
their growth curves under each condition.  The IC50 values were calculated from the OD600 
measurements representing the cell densities at stationary phase at 16h.  Table 1 
summarizes the calculated IC50s.  
Cloning of aptamer sequences 
For cloning the 1mer and 3mer aptamers, we used double-stranded synthetic DNA 
oligos obtained from ISU DNA Facility that were inserted in the multiple cloning site and 
ligated with T4 DNA ligase.  The multimers were cut from the pZERO carrier plasmid, 
inserted in the multiple cloning site and ligated with T4 DNA ligase.  All clones were 
confirmed to be correct by sequencing done at ISU DNA Facility. 
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RESULTS AND DISCUSSION 
Decrease in IC50 for several different aminoglycosides was observed in cells 
expressing aptamers compared with controls 
To test the hypothesis that the expression of aptamers will increase the intracellular 
concentration of a drug, we used the aminoglycosides and took advantage of the 
susceptibility of E. coli to inhibition of growth by this drug and used a simple experimental 
design that monitored the effect of aptamer expression on cell growth (Fig. 1).  If the 
expression of aptamers increases the intracellular concentration of the aminoglycosides as 
suggested by the mathematical modeling then the IC50 for suppressing bacterial growth by 
aminoglycosides should be decreased in bacteria that express the aptamers.  RNA 
aptamers that interact with the aminoglycosides (Fig. 2B) were tested.  The results showed 
that the lag phase was extended and the density of cultures at stationary phase was 
decreased in cells that expressed the aptamers (Fig. 3).  Similar results were found with 
cells that express aptamers previously selected to recognize the aminoglycosides 
neomycin-B, tobramycin, paromomycin and kanamycins A and B.  With expressing single 
unit neomycin aptamer, we were able to decrease the final bacterial densities with lower 
neomycin-B concentrations, decreasing the IC50 by about 2-fold (Fig. 4).  The enhancement 
in affective concentration of neomycin-B is about 2 to 3 µM for the cell densities at 1h and 
6h time points. 
 To assess the significance of the finding that expression of aptamers 
increases the sensitivity of cells to the aptamer targets, we first evaluated the effect of 
aptamers alone on the bacterial growth.  Our results suggest that aptamer expression has 
no effect on bacterial growth (Figure 5A-F).   
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Mathematical prediction I: Increase in drug concentration 
In the mathematical model, as the drug receptor, an aptamer was used and its 
presence with the appropriate kinetic parameters and its capability to move through the cell 
cytoplasm was found to be essential to draw its target drug into the cell.  As a result, it was 
predicted that, with the aptamer, a higher intracellular free drug concentration would be 
achieved than in the absence of the aptamer (Fig. 6, from Levine, H. A.; Boushaba, K.; 
Nilsen-Hamilton, M. Math Bioscience, 2009, 220, 131).  Here we showed that bacteria 
growth decreases with the aptamer expression as predicted.  Also, the binding affinities of 
RNAs for the aminoglycosides determined by ITC (Table 2) fit within the range of affinities 
predicted to be effective for drawing in the drug in the mathematical model. 
Although the initial results are reported here are consistent with the model, the effect 
of aptamer expression on the intracellular aminoglycoside concentration has not yet been 
determined.  Measuring the aminoglycoside concentrations is a challenge because they do 
not have an intrinsic chemical or physical property that we can be utilized for detection.  
Therefore, the intracellular concentrations of aminoglycosides will be measured 
commercially available 3H-labeled aminoglycosides.  These will be used in place of the 
unlabeled drugs and the radioactive counts from two cultures measured: one with the 
aptamer expressed and the other with control RNA expressed.  This study will provide us 
with a comparison of the aptamer expressing cells and the cells without aptamers.  
Measure extracellular drug concentrations 
An assumption that is made in these studies and in the math modeling is that the 
extracellular concentration of aminoglycoside remains constant. This will be tested using the 
2AP labeled 23mer neomycin RNA aptamer and monitor the increase in its fluorescence 
upon aminoglycoside binding.  An alternate way to determine the extracellular concentration 
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of aminoglycosides will be to use the quantitative ninhydrin assay, which is generally 
sensitive to amino acids, amino sugars and primary, secondary, and tertiary amines and can 
be used to quantify aminoglycosides that contain both primary and secondary amines.  
Although the method is quite low in its sensitivity (~100 µM LOD) it will be necessary to 
partially purify and concentrate the aminoglycoside from the culture medium. This will be 
done using a cation exchange column.   
Mathematical Prediction II: Mobility affects the aptamer action  
In the mathematical model, it was shown that, without diffusion of the aptamer, there 
was no effect on the inhibitor efficacy.  However, when the aptamer was made diffusible, 
within limits that depend upon the aptamer inhibitor binding affinities (Kas), the efficacy of the 
inhibitor was increased (Fig. 7, from Levine, H. A.; Boushaba, K.; Nilsen-Hamilton, M. Math 
Bioscience, 2009, 220, 131).   
Because larger RNAs are less mobile, we can test the effect of mobility of the 
aptamer by comparing the effect of a single aptamer in a smaller or larger RNA transcript.  If 
the mathematical prediction is accurate, then we should observe a decrease in 
aminoglycoside efficacy with aptamers in longer transcripts.  Current data in which we have 
compared transcripts with single aptamers and those with multiple aptamers (larger 
transcripts) suggest that this prediction is likely to be true because the aptamers are less 
effective in increasing aminoglycoside efficacy when they are expressed as multimers 
compared to single unit of neomycin-B aptamer (Fig. 8). However, in these experiments 
there are two experimental design variables, which are the length of RNA and number of 
aptamers. 
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FIGURE LEGENDS 
Figure 1.  DRAGINs bacterial expression system and experimental set-up. The 
RNA aptamers were cloned downstream of a T7 RNA polymerase promoter with termination 
signal at the end.  Neomycin-B (Neo), kanamycin (Kan), tobramycin (Tob) aptamers, Rev-
response element (RRE), thymidylate synthase (TS) mRNA region, and 16S rRNA A site 
were cloned after the T7 RNA polymerase promoter with a termination signal at the end of 
the encoded RNA. This expression system depends on the presence of T7 RNA polymerase 
in the bacterial strain used, BL21(DE3)star. 
Figure 2.  Chemical structures of neomycin and kanamycin-class 
aminoglycosides, RNA aptamers used in this study and the working model for the 
DRAGINs.  A) Neomycin-class aminoglycoside antibiotics have a 2-deoxystreptamine (ring 
II), disubstituted at positions 4 (ring I) and 5 (rings III and IV) while kanamycin-class has 
substitutions at positions 4 (ring I) and 6 (ring III).  B) Predicted secondary structure of the 
RNA Aptamers. The secondary structures of the aptamers were predicted by 
RNAstructure4.6 (Matthews et al. 2004). C) Model for the DRAGINs in bacteria. 
Figure 3.  Comparison of bacterial growth with and without expressed 
aptamers. These results show that the aptamer expression decreases the growth of 
bacteria with 7.5 µM paromomycin.  A) single unit thymidylate synthase mRNA region 
(closed circle) and B) 3mer 16S A-site minimal unit (closed circle). In both, the control cells 
with no aptamer is shown with closed squares, C) Two units of RRE (closed circle) and B) 
single unit thymidylate synthase mRNA region (closed circle) expression decreased the 
growth of bacteria with 5uM kanamycin-B.  In both the control cells with no aptamer is 
shown with closed squares.  
Figure 4.  Comparison of bacterial growth with single unit of neomycin 
aptamer.  These results indicate that the aptamer decreases the level of bacterial density 
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with lower concentration of neomycin-B  Final cell densities after normalized to no drug 
control sample for one unit of neomycin aptamer (closed circle) and control cells with no 
aptamer at A) 1h time point  and at B) 6h time point with varying concentrations of 
neomycin-B. 
Figure 5.  Comparison of bacterial growth with and without the aptamer 
expression.  Our results show that the growth of bacteria is not affected by the expression 
of aptamers.  E. coli BL21 cells with no aptamer containing cells (closed square) are 
compared with A) kanamycin aptamer B) tobramycin aptamer C) neomycin aptamer D) 
thymidylate synthase mRNA region E) Rev-response element F) 16S A-site RNA expressing 
cells. The coefficient of variation is between 5 to 15% in these experiments, the average of 
minimum of three samples represented here. 
Figure 6.  Comparison of the mean total inhibitor concentration with and 
without the aptamer as a function of time. This figure is taken from Boushaba et al. [4].  
Here it is predicted that aptamer can concentrate the drug by more than 10 fold. 
Figure 7.  Sensitivity of the mean efficiency to the aptamer-inhibitor off rate 
and the mobility of the aptamer and the target.  A) if the aptamer diffuses and the drug 
target does not diffuse.  B) Drug target diffuses at twice the rate of the aptamer.  As seen 
the effect of aptamer is negligible since drug target can move around the cell and can 
interact with the drug before it is pumped out by the efflux pumps. 
Figure 8.  Comparison of bacterial growth with single and multiaptamers.  
These results indicate that the aptamer number of aptamers affect the growth of bacteria 
differently with 2.5uM kanamycin-B.  A) One unit of neomycin aptamer (closed circle) and B) 
16mer of neomycin aptamers (closed circle). In both the control cells with no aptamer is 
shown with closed squares.  16mer expressing cells rescued the effect of aptamers 
observed with kanamycin-B. 
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Table 1.	  	  IC50 values for neomycin– and kanamycin-class aminoglycosides. 
 IC50 (µM) 
 Lag Phase Log Phase Stationary Phase 
Neomycin-B 1.7 4.8 6.3 
Paromomycin 1.9 13 17.7 
Kanamycin-B 1.8 6.4 6.2 
Kanamycin-A 2.9 9.4 9.9 
Tobramycin 1.8 5.7 6.4 
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Table 2.  Dissociation constants of RNAs used in the DRAGINs. 
 
 
 Dissociation Constants (µM) 
 
Neomycin-B 
Aptamer 
Tobramycin 
Aptamer 
Kanamycin 
Aptamer 
Rev-
Response 
Element 
Thymidylate 
Synthase 
mRNA region 
16S rRNA 
Decoding 
region 
Neomycin-B 0.29 ± 0.06 2.2 ± 0.5 6.3 ± 0.65 3.54 ± 0.68 0.88 ± 0.11 1.93 ± 0.58 
Paromomycin 1.4 ± 0.19 17.2 ± 1.96 9.1 ± 1.0 27 ± 4.95 6.29 ± 3.49 5.31 ± 1.85 
Kanamycin-B 0.75 ± 0.26 2.43 ± 1.37 5.26 ± 0.39 8.13 ± 1.41 6.5 ± 3.2 8.9 ± 3.54 
Kanamycin-A 43 ± 3.6 73.8 ± 3.96 14.4 ± 2.77 32.2 ± 3.39 10.3 ± 6.65 37.1± 4.38 
Tobramycin 4.8 ± 0.95 0.17 ± 0.03 7.0 ± 0.53 4.98 ± 0.75 5.75 ± 1.87 10.3 ± 3.87 
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CHAPTER 5. GENERAL CONCLUSIONS 
THE SPECIFICITY OF AN RNA APTAMER IS HIGHLY DEPENDENT ON THE IONIC 
ENVIRONMENT 
Aptamers are nucleic acid molecules specifically selected for a target of interest, 
which can be a small molecule or a whole cell.  In general, the family of aptamers obtained 
through SELEX specifically bind to that target with very strong affinity in the range of pM to 
mM.  However, our results have shown that specificity of the RNA aptamer selected for 
neomycin-B is highly dependent on the buffer components used in binding assays.  The first 
report for the selection of the 23mer neomycin-B RNA aptamer showed that, in a pH 7.4 
buffer containing potassium cacodylate, magnesium chloride and ammonium chloride, the 
aptamer binds to neomycin-B with >100-fold better affinity than a very closely related analog, 
paromomycin [1].  By contrast, in our binding assays, we used a pH 7.3 buffer containing 
HEPES, NaCl, KCl, MgCl2 and CaCl2 and found that the aptamer has only a 5-fold better 
binding affinity to neomycin-B than paromomycin, which was similarly observed in 
phosphate-saline buffer.  This indicated that the binding ability of the aptamer changes with 
its surroundings.  We further characterized the binding of ten aminoglycosides to the 
aptamer under identical buffer conditions (HEPES, NaCl, KCl, MgCl2 and CaCl2, pH 7.3) by 
ITC.  These results showed that both neomycin– and kanamycin-family aminoglycosides 
bound the aptamer.  In parallel studies, the order of binding was captured with very high 
accuracy by molecular docking analysis with the single exception of ribostamycin.  These 
initial binding studies identified the importance of the first two rings for RNA recognition that 
make specific contacts within the binding pocket of the neomycin-B RNA aptamer.  Because 
the RNA was considered rigid in the docking analysis, we performed molecular dynamics 
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(MD) simulations, which have been recently used to study the dynamics of nucleic acids and 
aptamer-target interactions.  The proper use of MD simulations yields results in good 
agreement with experimental data and our aim with MD simulation was to extend structural 
and dynamical information beyond the limitations of current experimental techniques.  In MD 
simulations, we observed that the 16th adenine residue was highly flexible in the absence of 
the ligand, which is probably the transition from bound to unbound state.  This simulation 
enabled us to provide a simulated 3D-structure of unoccupied neomycin-B RNA aptamer 
with experimental validations.  By replacing A16 with 2-aminopurine (2AP) and detecting the 
increase in its fluorescence, we confirmed the change in A16 position upon ligand binding.  
This result indicated that A16 was changing its position from a stacked position, where its 
fluorescence is quenched to a more solvent accessible position, where it can emit more of 
its fluorescence [2].  However, the difference in the level of increase in 2AP fluorescence 
with neomycin-B, ribostamycin and paromomycin is suggest that interactions with these 
ligands or differential effects of the ligands on aptamer structure also contribute to the 
fluorescence change. 
In conclusion, we have characterized the binding of ten aminoglycosides to the 
23mer neomycin-B RNA aptamer by ITC and molecular docking.  These studies were 
complemented with MD simulations and 2AP fluorescence studies with further analyses to 
show that the ionic conditions were important for both aminoglycoside binding and selectivity 
of the aptamer.  In this study, we have combined computational and experimental 
approaches to understand the details of aminoglycoside RNA interactions.  Our results show 
that the specificity and affinity of this RNA for its ligands differ with the ionic environment and 
suggest that other aptamers should be carefully examined for similar effects of their 
environment. 
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APTAMER-TARGET INTERACTIONS CAN BE UTILIZED FOR IN VIVO APPLICATIONS 
Although aptamers are selected in vitro, they can be integrated into expression 
platforms for intracellular use.  In our study, we have shown that aptamers can be 
successfully utilized for in vivo applications.  As recently shown by Paige et al., RNA 
aptamers once expressed inside the cell can be utilized to detect cellular metabolites 
including S-adenosyl methionine and ADP [3], in our studies we utilized RNA aptamers in 
IMAGEtags to detect gene expression in real time and in DRAGINs to increase the number 
of drug molecules inside cells to enhance drug efficacy.  Thus, our results have shown proof 
of principle in yeast and bacterial cells for two new methods that utilize intracellular 
transcribed aptamers that recognize the aminoglycosides, neomycin-B, tobramycin and 
PDC.  The next phase of the IMAGEtags project will be to develop the capability of detecting 
gene expression in mammalian cells.  For DRAGINs, the next phase will be to determine if 
the same principle of increasing intracellular drug levels 2 to 5-fold holds in mammalian cells.   
MATHEMATICAL MODELING OF APTAMER EXPRESSION MAY CHALLENGE US TO 
IMPROVE THE DRAGINS SYSTEM 
In 2009, our research group in collaboration with mathematicians in the Department 
of Mathematics at Iowa State University mathematically predicted the utility of aptamers to 
concentrate drugs inside mammalian cells [4].  With DRAGINs, we have demonstrated the 
utilization of aptamers inside bacterial cells to increase drug concentrations.  Our data 
showed that the aptamer expression system works as predicted by the previous 
mathematical model.   We believe that further mathematical modeling of DRAGINs system 
may challenge us to answer other critical basic questions and may help us improve our 
system.  We are collaborating with Drs. Howard Levine and YeonJung Seo to better 
understand the DRAGINs system by mathematical modeling, this time with a compartment 
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model for prokaryotes.  Once completed, the predictions of the model will be tested by wet-
lab experiments. 
UNDERSTANDING RNA-AMINOGLYCOSIDE INTERACTIONS MAY HELP TO DEVELOP 
BETTER ANTIBIOTICS 
 Aminoglycosides have been on the market for the last several decades.  
However, the emergence of resistant bacterial strains may eventually make these antibiotics 
useless.  Understanding the interaction of aminoglycosides with their target RNAs can help 
resolve this problem. We have characterized the neomycin-B RNA aptamer aminoglycoside 
interactions; however, there are other natural and synthetic RNAs that can interact with the 
aminoglycosides.  These nonspecific interactions may increase the chance of side effects 
through aminoglycoside use.  Pinpointing the details of aminoglycoside-RNA interactions, 
might lead to the development of more potent aminoglycoside-based antibiotics.  The results 
of these studies may allow researchers to design more specific drugs to the bacterial target 
sites with less nonspecific binding.  Using structural information in designing new drugs may 
significantly decrease the amount of trial-error period spent in the lab for a new compound 
that may take years to appear in the market.  Indeed, 3D structures of some of these RNAs 
in complex with aminoglycosides are already available for use in molecular docking and MD 
simulations to design more potent antibiotics.  However, structural data for some of these 
RNAs are not available and to fill this gap, recent 3D prediction programs like MC-Sym [5], 
might help to get necessary data and push development of the RNA and pharmaceutical 
fields one step further. 
RNA-AMINOGLYCOSIDE INTERACTIONS MAY HELP US DEVELOP RIBOSWITCHES 
Natural riboswitches generally bind to small metabolites and control gene expression.  
They play critical roles as check points in gene expression pathways and limit the amount of 
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ATP spent that would be otherwise wasted on unnecessary translation.  In addition to the 
natural riboswitches, recently, artificial riboswitches have been designed to control gene 
expression by external stimuli [6].  In this study, several neomycin-B riboswitches were 
identified for designing specific gene expression platforms that are regulated by neomycin-B.  
These systems can be improved with a better understanding of RNA-aminoglycoside 
interactions.  Experimental and computational approaches can also be applied here to 
develop more responsive or better riboswitches. 
FUTURE PERSPECTIVE 
It has been more than two decades since two groups [7, 8] invented the aptamer 
selection procedure independently.  Many studies have demonstrated aptamer applications 
in medicine and Macugen, approved by FDA (Food and Drug Administration) by the end of 
2004, is the first aptamer drug.  It is a polyethyleneglycol (PEG)-modified anti-VEGF 
aptamer that is used to treat age-related macular degeneration.  In addition to their potential 
applications in medicine, aptamers also serve as good biosensors in vitro.  Recently, 
aptamer selection has been done through robotics and with the addition of high-throughput 
sequencing, it is now less time consuming to obtain an aptamer than previously.  This high 
throughput and highly efficient selection technology should soon meet the high demand of 
aptamers that recognize various biologically significant targets both in vitro and in vivo.  
Once available in sufficient numbers, aptamers have the potential to replace most of the 
antibodies used in diagnosis. 
As aptamers have been selected in vitro, they have also been identified in nature.  
The first natural riboswitch to be reported regulates genes involved in riboflavin synthesis in 
bacteria [9].  Following these studies, many riboswitches that contain aptamer domains have 
been identified by Breaker’s lab at Yale [10].  Riboswitches are RNA elements in upstream 
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regions of the coding mRNA that can specifically bind to metabolites with their aptamer 
domains and regulate gene expression both at the transcriptional and translational level.  
Perhaps, the identified riboswitches may be just small portion of the natural aptamers 
identified so far and genomes may be filled with aptamers.  I think bioinformatics will play an 
essential role to identify the remaining aptamers hidden in the genomes. 
Also, aptamers selected for aminoglycoside antibiotics have particular importance 
because these antibiotics have been used to fight against pathogenic Gram-negative 
bacteria.  A better understanding of aptamer aminoglycoside interactions, as has been 
developed in this study, can be utilized to design more effective aminoglycoside-based 
drugs, which may help to kill the newly arising antibiotic resistance bacterial strains. 
In addition to their applications to drug development, aminoglycoside-RNA 
interactions can be used as in vivo sensors in the form of riboswitches, in which 
aminoglycosides serve as external stimuli.  Therefore, a better understanding of RNA-
aminoglycoside interactions may also help researchers to in vitro select new riboswitches 
and/or aptamers, characterize them and apply these into different in vivo platforms.  One of 
the fields utilizing these platforms is “synthetic biology” for which designed expression 
systems or short metabolic circuits are frequently utilized.  Computational approaches may 
help to develop better riboswitches for these circuits.  Such improved RNA-aminoglycoside 
pairs might be applied to controlling different pathways used by synthetic biologists in their 
designed expression systems.   
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APPENDIX I. CONTRIBUTION TO THE DEVELOPMENT OF 
IMAGETAGS (INTRACELLULAR MULTIAPTAMER GENETIC TAGS) 
FOR DETECTING PROMOTER ACTIVITY IN LIVING CELLS 
In our research group, we have developed a novel way for imaging promoter activity 
in real time in vivo.  In this method, we have utilized strings of RNA aptamers as in vivo RNA 
tags called IMAGEtags (Intracellular MultiAptamer GEnetic tags).  This system can be 
expressed from a promoter of choice.  The tobramycin, neomycin-B and PDC RNA 
aptamers have been utilized for this system and expressed in yeast from the GAL1 promoter.  
I have used the neomycin-B RNA aptamers, for which paromomcyin is a ligand, in this 
project to construct neomycin-B IMAGEtags.  For imaging, we used yeast cells that 
expressed the neomycin-B IMAGEtags or a control RNA to test our system.  These cells 
were incubated with a mixture of two paromomycin derivatives conjugated with the FRET 
pairs, Cy3 and Cy5, respectively.  With these constructs, the transcribed aptamers can be 
imaged after activation of the promoter by galactose.  This work has been submitted to 
Nature Methods. 
In this project, I also cloned kanamycin aptamers as IMAGEtags in a carrier plasmid 
called pZERO (as shown in Table 1); but, the binding affinity of kanamycin-B to its cognate 
aptamer was not high enough for in vivo studies.  However, if we can find another Cy3 and 
Cy5-labeled ligand that can bind to the kanamycin aptamer with better affinity, we can also 
utilize these constructs as IMAGEtags. 
In this project, I utilized neomycin-B aptamer; however, I had to use paromomycin-
Cy3 and paromomycin-Cy5 as the FRET pairs to detect the promoter activity in living yeast 
cells.  This was due to chemical limitations in labeling neomycin-B at a single position, with 
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the consistent result being two products of the conjugation reaction between neomycin-B 
and either Cy3 or Cy5-succinimidyl ester (data not shown).  Because it has only single 
active primary amino group, paromomycin could be labeled with Cy3 or Cy5 at a single 
position.  So, I tested if the neomycin-B RNA aptamer could bind to paromomycin and 
determined the dissociation constant as ~ 1.5 µM.  This was a good enough affinity to test 
the neomycin-B IMAGEtags in cell studies.  The binding affinities were determined via ITC 
using buffer A (chapter 2), which is designed to have similar concentrations of free mono- 
and divalent cations as the cell cytoplasm.  I calculated the dissociation constants for Cy3-
paromomycin as ~ 4 µM, shown in figure 2 and for paromomycin-Cy5 as ~ about 3 µM, 
shown in figure 3. 
FRET Image Acquisition 
I detected the initial FRET with paromomycin-Cy3 and paromomycin-Cy5 and 
observed that the 24mer neomycin-B IMAGEtags gave a higher FRET signal than the 
control cells (0mer) shown in figure 1.  The cells were observed using an inverted Nikon 
Eclipse 200 fluorescence microscope with a 63X objective and immersion oil. Cells were 
excited by a 568 nm Argon/Krypton laser to measure sensitized emission using emission 
filters for FRET of 700-750nm.  However, this microscope had the limitation that it could not 
also be used to obtain bright field images, which would have allowed the identification of all 
yeast cells in each field. To obtain bright field images I then used the Leica SP5X laser 
scanning confocal microscope with a 63X objective and immersion oil.  This microscope has 
the capability to obtain the bright field images as well as individual fluorescence signals 
either from Cy3 or Cy5.  Cells were excited by a 550 nm white light laser (WLL) and FRET 
images were taken to measure sensitized emission using emission filters for FRET of 660-
710 nm. 
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Test to check the stability of IMAGEtags 
It is well known that E. coli tend to eliminate repeated sequences from its genome or from 
plasmids that they carry [1-3].  To determine the stability of the IMAGEtags, I transformed E. 
coli with plasmids containing IMAGEtags, and picked up three colonies from each 
transformation.  Then, I performed two tests on the plasmids isolated from each colony; 
agarose gel electrophoresis and with sequencing.  In both of the assays, the results showed 
that the number of repeated aptamers stayed the same in both kanamycin and neomycin-B 
IMAGEtags with a single exception being a 15mer obtained from originally 16mer neomycin-
B IMAGEtag (Table 2)  
  
199 
TABLES AND FIGURES 
Table 1. Results from the cloned inserts with multiaptamers. 
Repeated Sequence Source and number 
of initial repeats  
Number of 
repeats after one 
round  
Oligonucleotides (6) 6, 8* Neomycin-B aptamer  
(GGACUGGGCGAGAAGUUUAGUCC) 
 
Vector (8) 16, 23*, 24, 32 
Oligonucleotides (7) 7 Kanamycin aptamer  
(GCGCAGUGGGCAUAGAACCAUGCGC) Vector (7) 9*, 12*, 14, 26, 28, 
56 
 
Cloning of neomycin-B and kanamycin aptamers was performed to obtain multiaptamers 
that were used in IMAGEtags.  The initial sequence repeats were inserted as annealed 
oligonucleotides or were in a vector from a previous round. We obtained 8, 16, 23, and 24 
repeats and 9, 12, 14, 26, 28, 56 units from the neomycin-B and kanamycin aptamer 
clonings, respectively.  Each aptamer repeat was separated by a four adenine nucleotides 
used as a linker and the asterisk indicates that the number of repeats obtained was not 
expected from the components used during cloning.  
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Table 2. Stability of cloned repeated sequences. 
 
Plasmids containing a variety of repeated sequences were tested for their stability in E. coli.  
They were isolated from randomly selected clones of transformed bacteria and tested for the 
number of sequence repeats by either sequencing or restriction digestion followed by gel 
electrophoresis of the released insert to determine its size. 
Number of repeats Repeated sequence 
Original Selected colonies 
Vector Analysis Type 
8 8 (3) pTrc Sequencing 
16 15 (1); 16 (2) pTrc Sequencing 
24 24 (3) pTrc Sequencing 
24 24 (4) pZX-2 Gel electrophoresis 
Neomycin-B aptamer 
32 32 (3) pTrc Sequencing 
3 3 (3) pTrc Sequencing 
7 7 (3) pTrc Sequencing 
12 12 (3) pTrc Sequencing 
14 14 (3) pTrc Sequencing 
Kanamycin aptamer 
28 28 (3) pTrc Sequencing 
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FIGURE LEGENDS 
Figure 1. Comparison of FRET images from 24mer IMAGEtags and 0mer control 
samples.  The yeast cells with 24mer or with empty plasmid were grown overnight.  Then, 
10uL of the cells were taken from each culture and spun down.  The medium was changed 
to induction medium containing 5 µM of Cy3- and Cy5-paromomycin and the cells were 
incubated for 15 min at 30oC.  After this, the cells were spun down and washed 3 times with 
TBS to remove the excess dyes.  Finally, the cells were re-suspended in TBS and placed in  
the 3.5 cm glass-bottom dishes and the images were taken with either 63 X-oil objective (for 
all 24mer images) or 63 X-oil (bottom middle images) and 20X air objectives for the 0mer 
control samples. A 550 nm white light laser (WLL) was used to excite the Cy3-paromoycin 
and FRET images were taken to measure the sensitized emission using emission filters for 
Cy5 of 660-710 nm.  
Figure 2. ITC thermogram from the titration of the neomycin-B RNA aptamer into Cy3-
paromomycin.  The thermodynamic parameters are shown in the squared box and the 
calculated dissociation constant (Kd) was about 4 µM. 
Figure 3. ITC thermogram from the titration of the neomycin-B RNA aptamer in Cy5-
paromomycin.  The thermodynamic parameters are shown in the square box and the 
calculated dissociation constant (Kd) was about 3 µM. 
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APPENDIX II. NUCLEAR MAGNETIC RESONANCE (NMR) STUDY 
OF THE NEOMYCIN-B RNA APTAMER TO DETERMINE THE 
CONFORMATION OF A16 UPON AMINOGLYCOSIDE BINDING 
As I have detailed in the study of the neomycin-B RNA aptamer in chapter 3, the 16th 
adenine (A16) residue was observed as a flexible residue in the MD simulations and results 
from a study of the 2AP-modified aptamer suggest that this base changes its position from a 
stacked to a less constrained conformation upon aminoglycoside binding.  The fluorescence 
emission of the 2AP16 is expected to increase upon its release from the stacked position in 
the loop.  To experimentally determine the positioning of A16 in the bound and unbound 
conformations, we have performed 1H, NOESY and TOCSY NMR experiments.  The 1D and 
2D assignments for the RNA residues are still in progress and this work will be completed in 
collaboration with the NMR facility manager, Bruce Fulton at Iowa State University. 
NMR Protocol: Bruker Avance 700 spectrometer equipped with a 5 mm HCN-Z gradient 
cryoprobe was used to collect the 1H NMR spectra of all samples.  Spectra were acquired at 
sample temperatures of 25° C and 5° C.  All 1D 1H NMR spectra were acquired using a 
WATERGATE pulse sequence with water flipback (Bruker sequence p3919fpgp) to 
minimize solvent saturation transfer.  The 1D spectra are the averages of 64 transients. The 
spectral width was 18182 Hz (25 ppm).  The TOCSY spectra were acquired using MLEV17 
isotropic mixing and WATERGATE solvent suppression (Bruker sequence mlevgpph19). 
NOESY spectra were acquired with WATERGATE and water flipback solvent suppression 
(Bruker sequence noesyfpgpphrs19).  Mixing times of 75 ms and 200ms were used for 
TOCSY and NOESY spectra, respectively.  The samples were prepared as 500 µM 
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neomycin-B RNA aptamer alone for unbound and with 500 µM neomycin-B for the bound 
conformations in 10 mM Na2HPO4 at pH 7.3, 95% H2O/5 % D2O. 
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FIGURE LEGENDS 
Figure 1. Representative NMR spectra of neomycin-B RNA aptamer samples.  Each 
panel shows a region of the 1D 1H spectrum and the corresponding region of the 200 ms 
NOESY spectrum.  All spectra were recorded in 95% H2O/5 % D2O buffer at 25° C.  A) 
Base-pair hydrogen bond region of neomycin-B RNA aptamer alone, B) base to 1’ region of 
neomycin-B RNA aptamer alone, C) base-pair hydrogen bond region of ligand-bound 
neomycin-B RNA aptamer, D) base to 1’ region of ligand-bound neomycin-B RNA aptamer.
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APPENDIX III. EQUILIBRIUM BINDING ANALYSIS OF 
RIBOSWITCHES THAT BIND TO NEOMYCIN-B 
One of the few-engineered riboswitches for neomycin-B was obtained by an in vivo 
screening method developed in yeast [1].  In this study, several riboswitches were identified 
by which neomycin-B can regulate the expression of green fluorescent protein (GFP).  The 
binding affinities for for neomycin-B of these riboswitches were reported to be in the low nM.  
However, based on my previous observations that aminoglycoside-binding RNAs have the 
capability to interact with more than one type of aminoglycoside, I decided to test the binding 
of these neomycin-B riboswitches with ten aminoglycosides by ITC.  The riboswitches with 
the best regulatory capability were chosen for study.  My binding studies indicated that these 
riboswitches behaved very similar to the other aptamers that I tested in that they bind to 
both neomycin and kanamycin-class aminoglycosides.  However, their selectivities were 
quite different from each other and in some cases neomycin-B was not the highest affinity 
ligand.  For example, 30NEO4A binds to paromomycin better than it binds to neomycin-B.  
This RNA is one of the best paromomycin binders amongst all the RNAs tested.   
 Figure 1 shows the predicted secondary structures of the riboswitches examined in 
this study.  These riboswitches share the structural features of having stem I, internal bulge, 
stem II and loop.  These structural features are also observed in most other RNAs that 
interact with aminoglycosides.  Aminoglycosides in general bind to the major-grooves of 
RNA duplexes and as the internal bulge has a widened major groove, the internal bulge is 
the most probable binding site in these riboswitches.  Figure 2 shows the mechanism of 
riboswitch action with the presence of neomycin-B inhibiting the initiation of translation.  
Figure 3 shows the association constants for these three riboswitches with ten different 
aminoglycosides.  The buffer used in these ITC assays was buffer A (chapter 2), which is 
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designed to have concentrations of mono- and divalent cations as the cell cytoplasm.  
These studies were done in preparation for a comparison of riboswitch function in yeast 
cells  
 
FIGURE LEGENDS 
Figure 1. Predicted secondary structures of the neomycin-B riboswitches.  The 
secondary structures were predicted by using the RNAStructure5.2 software.  The free 
energies were also obtained using the same program and are represented for all RNAs.  
The nomenclature for the RNAs is as follows: 25, 31 and 30 are the lengths, NEO is the 
abbreviation for neomycin-B as the original ligand and 2A, 3A, 4A identify individual 
aptamers (or riboswitches). 
Figure 2. Schematic representation of aptamer-mediated inhibition of translational initiation. 
The aptamer is placed upstream of the start codon of GFP.  Left: without neomycin the 
aptamer does not interfere with ribosomal scanning and GFP can be expressed.  Right: 
when neomycin binds to the aptamer, this complex inhibits the small ribosomal subunit and 
leads to decreased gene expression. 
Figure 3. Association constants (Kas) of the neomycin-B riboswitches for ten different 
aminoglycosides.  The affinities were determined by ITC in buffer A (13.5mM NaCl, 150mM 
KCl, 20mM HEPES, 0.22mM Na2HPO4, 0.44mM KH2PO4, 120µM MgCl2, 120nM CaCl2, 
100µM MgSO4 in ddH2O at pH 7.3 at 25°C) and the calculated Kds (dissociation constant = 
1/Ka) range from ~30 nM to 100 µM for these aminoglycoside ligands. 
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